{"title": "PDF", "author": "PDF", "url": "https://seq.es/wp-content/uploads/2016/09/seq_0214-3429_29_6_completo.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "REVISTA ESPA\u00d1OLA DEREVISTA ESPA\u00d1OLA DEQuimioterapiaQuimioterapia\nISSN: 0214-3429\nVolumen 29N\u00famero 6Diciembre 2016P\u00e1ginas: 288-344SPANISH JOURNAL\nOF CHEMOTHERAPY\nImagen portada: Mar\u00eda Teresa CorcueraPublicaci\u00f3n Oficial\nde la Sociedad Espa\u00f1olade QuimioterapiaQuimioterapiaREVISTA ESPA\u00d1OLA DE\nRevista Espa\u00f1ola de \nQuimioterapia tiene un car\u00e1cter multidisciplinar y est\u00e1 dirigida a todos aquellos profesionales involucrados en la epidemiolog\u00eda, diagn\u00f3stico, cl\u00ednica y tratamiento de las enfermedades infecciosas\nFundada en 1988 por la Sociedad \nEspa\u00f1ola de Quimioterapia\nIndexada en\nScience Citation IndexExpanded (SCI),Index Medicus (MEDLINE), Excerpta Medica/EMBASE,\u00cdndice M\u00e9dico Espa\u00f1ol (IME), \u00cdndice Bibliogr\u00e1\ufb01co en Ciencias de la Salud (IBECS)\nSecretar\u00eda t\u00e9cnica \nDpto. de Microbiolog\u00edaFacultad de MedicinaAvda. Complutense, s/n28040 Madridrevista@seq.esDisponible en Internet:www.seq.esPublicidad y SuscripcionesSociedad Espa\u00f1ola de QuimioterapiaDpto. de Microbiolog\u00edaFacultad de MedicinaAvda. Complutense, s/n28040 Madrid\nAtenci\u00f3n al cliente\nTel\u00e9fono 91 394 15 12Correo electr\u00f3nicoinfo@seq.es\nConsulte nuestra p\u00e1gina web\nwww.seq.esPublicaci\u00f3n que cumple los requisitos desoporte v\u00e1lido\nISSN\n0214-3429\ne-ISSN \n1988-9518\nDep\u00f3sito Legal\nM-32320-2012\nMaquetaci\u00f3n\nacomm\nImagen portada:\nMar\u00eda Teresa Corcuera\nImpresi\u00f3n\nEspa\u00f1a\nE\nsta publicaci\u00f3n se imprime en papel no \u00e1cido. \nThis publication is printed in acid free paper.\nLOPD\nInformamos a los lectores que, seg\u00fan la Ley 15/1999 de 13 de diciembre, sus datos personales forman parte de la base de datos de la Sociedad Espa\u00f1ola de Quimioterapia (si es usted socio)\nSi desea realizar cualquier recti\ufb01caci\u00f3n o \ncancelaci\u00f3n de los mismos, deber\u00e1 enviar una solicitud por escrito bien a la Sociedad Espa\u00f1ola de Quimioterapia\u00a9 Copyright 2016Sociedad Espa\u00f1ola deQuimioterapia\nReservados todos los derechos.\nQueda rigurosamente prohibida,sin la autorizaci\u00f3n escrita deleditor, la reproducci\u00f3n parcialo total de esta publicaci\u00f3npor cualquier medio oprocedimiento, comprendidos lareprograf\u00eda y el tratamientoinform\u00e1tico, y la distribuci\u00f3n deejemplares mediante alquiler opr\u00e9stamo p\u00fablicos, bajo lassanciones establecidas por la leySociedad Espa\u00f1ola de QuimioterapiaQuimioterapiaREVISTA ESPA\u00d1OLA DE\nDirector\nJ. Barber\u00e1n L\u00f3pez\nComit\u00e9 Editorial\nF. \u00c1lvarez Lerma (Barcelona)\nF. Baquero Mochales (Madrid)\nE. Bouza Santiago (Madrid)\nJ. A. Garc\u00eda Rodr\u00edguez (Salamanca)\nM. Gobernado Serrano (Valencia)\nConsejo Editorial\nG. Acu\u00f1a (Chile)\nJ. M. Aguado (Madrid)L. Aguilar (Madrid)J. I. Al\u00f3s (Madrid)J. R. Azanza (Pamplona)J. Arag\u00f3n (Las Palmas de Gran Canaria) A. Artero (Valencia)J. Campos (Madrid)F.J. Candel (Madrid)E. Cant\u00f3n (Valencia)R. Cant\u00f3n (Madrid)J. A. Capdevila Morell (Barcelona)E. Carreras (Barcelona)M. Casal (C\u00f3rdoba)J. Castillo (Zaragoza) J. J. Cast\u00f3n (Ciudad Real)R. Cisterna (Bilbao)J. Cobo Reinoso (Madrid)J. Cordero (Madrid)M. C\u00f3rdoba (Madrid)P. Courvalin (Francia)J. L. del Pozo (Navarra)R. De la C\u00e1mara (Madrid)J. De la Torre (C\u00f3rdoba)A. Delgado (Bilbao)A. Dom\u00ednguez-Gil Hurl\u00e9(Salamanca)J. Eiros (Valladolid)C. P\u00e9rez Giraldo (Badajoz)J. L P\u00e9rez-Arellano (Las Palmas)B. P\u00e9rez-Gorricho (Madrid)A. Ramos (Madrid)C. Ram\u00edrez Ronda (Estados Unidos)J. Reina (Palma de Mallorca)M. A. Ripoll (\u00c1vila)J. Sabbaj (Guatemala)M. Sabri\u00e1 (Barcelona)M. Salavert (Valencia)B. S\u00e1nchez Artola (Madrid)J. I. Santos (M\u00e9xico)M. A. Sanz (Valencia)M. Segovia (Murcia)R. Serrano (Madrid)P. M. Shah (Alemania)D. Sevillano (Madrid)A. Soriano (Barcelona)A. Su\u00e1rez (Madrid)A. Tomasz (Estados Unidos)J. R. Toral Revuelta (Madrid)J. Tuells (Alicante)C. Vallejo (Oviedo)K. Ueno (Jap\u00f3n)J. Vila (Barcelona)J. Yuste (Madrid)J. Li\u00f1ares (Barcelona)P. Llinares (La Coru\u00f1a)J. E. Losa Garcia (Madrid)J. R. Maestre Vera (Madrid)A. M. Mart\u00edn S\u00e1nchez (Las Palmas)I. Mart\u00ednez Gil (Madrid)L. Mart\u00ednez Mart\u00ednez (Santander)E. Maseda (Madrid)T. Mazzei (Italia)M. A. Men\u00e9ndez (Madrid)R. Men\u00e9ndez (Valencia)P. Merino (Madrid))R. Meyer (Estados Unidos)P. Mu\u00f1oz (Madrid)J. L. Mu\u00f1oz Bellido (Salamanca)A. Navarro (Madrid)V. Navarro (Alicante)R. Negroni (Argentina)C. E. Nord (Suecia)A. Novelli (Italia)V. Olmo (Las Palmas)A. Orero (Madrid)R. Ortiz de Lejarazu (Valladolid)J. A. Oteo (Logro\u00f1o)E. Palencia Herrej\u00f3n (Madrid) J. Parra (Granada)A. Pascual Hern\u00e1ndez (Sevilla)J. Pasquau (Sevilla)J. Pem\u00e1n (Valencia)P. Escribano (Madrid)M. C. Fari\u00f1as \u00c1lvarez (Santander)C. Fari\u00f1as (Santander)S. M. Finegold (Estados Unidos)J. Fort\u00fan (Madrid)X. Garau (Barcelona)E. Garc\u00eda S\u00e1nchez (Salamanca)I. Garc\u00eda Garc\u00eda (Salamanca)J. Garc\u00eda Rodr\u00edguez (Madrid)J. E. Garc\u00eda S\u00e1nchez (Salamanca)E. Garc\u00eda V\u00e1zquez  (Murcia)H. Giamarellou (Grecia)A. C. G\u00f3mez Garc\u00eda (Badajoz)J. G\u00f3mez G\u00f3mez (Murcia)M. L. G\u00f3mez-Lus (Madrid)J. Gonz\u00e1lez del Castillo (Madrid)F. Gonz\u00e1lez Romo (Madrid)E. Gotuzzo (Per\u00fa)J. J. Granizo (Madrid)S. Grau (Barcelona)J. Guinea (Madrid)X. Guirao (Barcelona)N. Gutierrez Zu\ufb01aurre (Salamanca)J. Hern\u00e1ndez Quero (Granada)J. P. Horcajada Gallego (Barcelona)B. Isidoro (Madrid)R. Isturiz (Venezuela)J. Kosmidis (Grecia)H. Lecour (Portugal)\nJ. Mensa Pueyo (Barcelona)\nJ. J. Picazo de la Garza (Madrid)\nJ. Prieto Prieto (Madrid)\nB. Regueiro Garc\u00eda (Santiago de Compostela)\nA. Torres Mart\u00ed (Barcelona)Secretario de Redacci\u00f3n\nLuis Alou CerveraSumario\nDeterminantes de resistencia a f\u00e1rmacos antiparasitarios en la filariasis 288\nlinf\u00e1tica humana\nFernando Cobo\nGripe estacional en octogenarios y nonagenarios ingresados en un hospital 296  \ngeneral: epidemiolog\u00eda, cl\u00ednica y factores pron\u00f3sticos\nJos\u00e9 M. Ramos, M. Mar Garc\u00eda-Navarro, M. Pilar Gonz\u00e1lez de la Aleja, Rosario S\u00e1nchez-Mart\u00ednez, \nAdelina Gimeno-Gasc\u00f3n, Sergio Reus, Esperanza Merino, Juan C. Rodr\u00edguez-D\u00edaz Joaqu\u00edn Portilla\nCaracter\u00edsticas cl\u00ednico-demogr\u00e1ficas de la poblaci\u00f3n del Sur de Gran Canaria 302  \ncon diagn\u00f3stico de enterobiasis: valoraci\u00f3n de la toma de muestras \nDeyanira Carrillo-Quintero, Laura del Otero Sanz, Sara Hern\u00e1ndez-Egido, Antonio Mart\u00edn S\u00e1nchez\nMonoterapia con darunavir/cobicistat. Experiencia en un hospital de tercer nivel 308\nLucia Yunquera-Romero, Roc\u00edo Asensi-D\u00edez, Juan Carlos del Rio-Valencia, Isabel Mu\u00f1oz-Castillo, Manuel \u00c1ngel Casta\u00f1o-Carracedo\nCuestiones claves en la atenci\u00f3n del paciente infectado en Urgencias 318\nFlavia Chiarella, Juan Gonz\u00e1lez-Del Castillo, Francisco Javier Candel, Eric Jorge Garc\u00eda- Lamberechts, Mar\u00eda Jos\u00e9 N\u00fa\u00f1ez-Orantos, Francisco Javier Mart\u00edn-S\u00e1nchez representing the Infectious Disease  Group of Spanish Emergency Medicine Society \nEvaluaci\u00f3n de un nuevo dispositivo para la recogida de la muestra, transporte 328 \ny detecci\u00f3n del estreptococo del grupo B en mujeres embarazadas\nAlberto Tenorio-Abreu, Jos\u00e9 Antonio G\u00f3mez-Fern\u00e1ndez, Luis Arroyo-Pedrero, Esmeralda Rodr\u00edguez-\nMolins\nTipificaci\u00f3n mediante secuencias multilocus de cepas humanas de 332 \nCampylobacter coli  en Granada (Espa\u00f1a)\nJos\u00e9 Antonio Carrillo-\u00c1vila, Antonio Sorl\u00f3zano-Puerto, Mercedes P\u00e9rez-Ruiz, Jos\u00e9 Guti\u00e9rrez-Fern\u00e1ndez\nControles interlaboratorio: algo m\u00e1s que un examen de conocimientos 336\nMarina Pe\u00f1uelas, Francisco Javier Candel, Avelina Su\u00e1rez Moya\nCoinfecci\u00f3n por Mycobacterium africanum  y Mycobacterium avium  en una 338 \npaciente con SIDA\nAna Garc\u00eda-Ca\u00f1as, Juana Cacho-Calvo, Gabriel Gaspar Alonso-Vega, F. Javier Esteban-Fern\u00e1ndez, Sergio Julio Rodriguez-\u00c1lvarez, Gloria P\u00e9rez-Caballero, Emilia Cond\u00e9s-Moreno\nCarga de enfermedad por neumon\u00eda 340\nMiguel L\u00f3pez Gobernado, Alberto P\u00e9rez-Rubio, Agust\u00edn Mayo, Jos\u00e9 M\u00aa Eiros\nVaricela z\u00f3ster con fallo multiorg\u00e1nico fulminante tras altas dosis de corticoides 342\nDolores Escudero, Santiago Mel\u00f3n, Raquel Rodr\u00edguez-Garc\u00eda, Luc\u00eda Vi\u00f1a, Iv\u00e1n Astola,  Fernando V\u00e1zquezRevisi\u00f3n\nCartas al DirectorOriginal breveOriginalesQuimioterapiaREVISTA ESPA\u00d1OLA DE\nVolumen 29\nN\u00famero 6Diciembre 2016Contents\nQuimioterapiaREVISTA ESPA\u00d1OLA DE\nVolume 29\nNumber 6December 2016\nDeterminants of parasite drug resistance in human lymphatic filariasis 288 \nFernando Cobo\nSeasonal influenza in octogenarians and nonagenarians admitted to a general 296 \nhospital: epidemiology, clinical presentation and prognostic factors\nJos\u00e9 M. Ramos, M. Mar Garc\u00eda-Navarro, M. Pilar Gonz\u00e1lez de la Aleja, Rosario S\u00e1nchez-Mart\u00ednez, \nAdelina Gimeno-Gasc\u00f3n, Sergio Reus, Esperanza Merino, Juan C. Rodr\u00edguez-D\u00edaz Joaqu\u00edn Portilla\nDemographic and clinical features of diagnosed individuals of enterobiasis in 302 \nthe southern Gran Canaria: sampling assessment\nDeyanira Carrillo-Quintero, Laura del Otero Sanz, Sara Hern\u00e1ndez-Egido, Antonio Mart\u00edn S\u00e1nchez\nDarunavir/cobicistat monotherapy. Experience in a tertiary hospital 308\nLucia Yunquera-Romero, Roc\u00edo Asensi-D\u00edez, Juan Carlos del Rio-Valencia, Isabel Mu\u00f1oz-Castillo, \nManuel \u00c1ngel Casta\u00f1o-Carracedo\nKey issues in the infected patient care in the Emergency Department 318\nFlavia Chiarella, Juan Gonz\u00e1lez-Del Castillo, Francisco Javier Candel, Eric Jorge Garc\u00eda-Lamberechts, Mar\u00eda Jos\u00e9 N\u00fa\u00f1ez-Orantos, Francisco Javier Mart\u00edn-S\u00e1nchez representing the Infectious Disease  Group of Spanish Emergency Medicine Society \nMultilocus Sequence Typing analysis of human Campylobacter coli  328\nin Granada (Spain)\nAlberto Tenorio-Abreu, Jos\u00e9 Antonio G\u00f3mez-Fern\u00e1ndez, Luis Arroyo-Pedrero, Esmeralda Rodr\u00edguez-Molins\nEvaluation of a new device for sample collection, transport and detection 332 \nof Group B Streptococcus  in pregnant women\nAlberto Tenorio-Abreu, Jos\u00e9 Antonio G\u00f3mez-Fern\u00e1ndez, Luis Arroyo-Pedrero, Esmeralda Rodr\u00edguez-Molins\nInterlaboratory controls: more than just a knowledge test 336\nMarina Pe\u00f1uelas, Francisco Javier Candel, Avelina Su\u00e1rez Moya\nMycobacterium africanum  and Mycobacterium avium  co-infection in an 338 \nAIDS patient\nAna Garc\u00eda-Ca\u00f1as, Juana Cacho-Calvo, Gabriel Gaspar Alonso-Vega, F. Javier Esteban-Fern\u00e1ndez, \nSergio Julio Rodriguez-\u00c1lvarez, Gloria P\u00e9rez-Caballero, Emilia Cond\u00e9s-Moreno\nPneumonia: burden of disease 340\nMiguel L\u00f3pez Gobernado, Alberto P\u00e9rez-Rubio, Agust\u00edn Mayo, Jos\u00e9 M\u00aa Eiros\nVaricella Zoster with fulminant multiorgan failure after high-dose  342\ncorticosteroids\nDolores Escudero, Santiago Mel\u00f3n, Raquel Rodr\u00edguez-Garc\u00eda, Luc\u00eda Vi\u00f1a, Iv\u00e1n Astola, \nFernando V\u00e1zquezReview\nLetters to \nthe editorBrief \nReportsOriginalsRev Esp Quimioter 2016;29(6): 288-295 288Determinantes de resistencia a f\u00e1rmacos \nantiparasitarios en la \ufb01lariasis linf\u00e1tica humana\nRESUMEN\nLa infecci\u00f3n por \ufb01larias sigue siendo end\u00e9mica en varios \npa\u00edses y algunas de estas infecciones pueden producir enfer -\nmedad grave. La eliminaci\u00f3n de la \ufb01lariasis linf\u00e1tica se basa en \nadministraci\u00f3n de f\u00e1rmacos, mediante la utilizaci\u00f3n de los tres medicamentos disponibles actualmente para su tratamiento: dietilcarbamazina, albendazol e ivermectina. Sin embargo, ha sido descrito el fen\u00f3meno de la resistencia a estos f\u00e1rmacos. La resistencia a antihelm\u00ednticos utilizados en seres humanos est\u00e1 adquiriendo una importancia cada vez mayor, desde que el programa global para eliminar la \ufb01lariasis linf\u00e1tica se ha ins -\ntaurado en grandes grupos de poblaci\u00f3n, y conforme la dura -\nci\u00f3n de ese programa va aumentando. Recientemente, ha sido publicada la resistencia a ivermectina en Ghana, y la amplia propagaci\u00f3n de resistencia a benzimidazoles (tal como alben -\ndazol) est\u00e1 presente debido a que las mutaciones espec\u00ed\ufb01cas en el gen que codi\ufb01ca la \u03b2-tubulina han sido asociadas con re-\nsistencia a f\u00e1rmacos. Adem\u00e1s, es ampliamente conocido que la sensibilidad a dietilcarbamazina no es del 100% para el trata-miento de la \ufb01lariasis linf\u00e1tica. Por ello, se hace necesaria una revisi\u00f3n de los mecanismos de resistencia a estos antihelm\u00ednti -\ncos, para una optimizaci\u00f3n del tratamiento frente a la \ufb01lariasis linf\u00e1tica humana. \nPALABRAS CLAVE: Filariasis, resistencia, administraci\u00f3n de f\u00e1rmacos en \nmasa, albendazol, ivermectina, dietilcarbamazina\nINTRODUCTION\nLymphatic \ufb01lariasis is a disease caused by infection with a \ngroup of \ufb01larial nematodes transmitted by mosquito vectors. \nThe World Health Organization (WHO) considers lymphatic \ufb01 -\nlariasis to be a neglected tropical disease affecting approxima -\ntely 120 million people in over 73 countries1. Wuchereria ban-ABSTRACT\nInfection with \ufb01larial nematodes remains endemic in \nseveral countries worldwide and some of these infections are commonly associated with severe disease. The elimination of lymphatic \ufb01lariasis relies on drug administration using the three drugs currently available for treatment: diethylcarba -\nmazine, albendazole, and ivermectin. However, development of drug resistance is a reported phenomenon. The issue of resistance to antihelminthics used in humans has become increasing importance since the global program to eliminate lymphatic \ufb01lariasis is implemented in larger population groups and the duration of the program is increasing. Recently, iver-mectin resistance has been reported in Ghana, and widespread of resistance to benzimidazole (such as albendazole) is pres -\nent because speci\ufb01c mutations in the gene encoding \u03b2-tubulin \nhave been associated with drug resistance. Moreover, it is well known that diethylcarbamazine susceptibility is not 100% for lymphatic \ufb01lariasis treatment. A review of the mechanisms of resistance to these antihelminthics is necessary in order to op-timize the treatment for human lymphatic \ufb01lariasis.\nKEY WORDS: Filariasis, resistance, mass drug administration, albendazole, \nivermectin, diethylcarbamazineDeterminants of parasite drug resistance in human \nlymphatic \ufb01lariasis \nDepartment of Microbiology and Parasitology. Hospital Universitario Virgen de las Nieves. Granada, SpainFernando Cobo \nCorrespondence:\nDr. Fernando CoboDepartment of Microbiology and ParasitologyHospital Universitario Virgen de las NievesAvda Fuerzas Armadas, 2 - 18014 Granada, SpainPhone: +34958020780 - Fax: +34958248562E-mail: fernando.cobo.sspa@juntadeandalucia.esReviewBacteriemia por S aureus de origen respiratorio y  mortalidad F. Cobo\nRev Esp Quimioter 2016;29(6): 288-295 28930 years, new treatment regimens and strategies to face with \nlymphatic \ufb01lariasis were established. Thus, in 1997 WHO clas -\nsi\ufb01ed lymphatic \ufb01lariasis as a potentially eradicable disease14. \nThe main objective of GPELF is to eliminate lymphatic \ufb01laria-sis as a public health problem, decreasing in transmission by reducing the micro\ufb01lariae load through the supply of a com -\nbination of two drugs that should be applied to entire popu -\nlations at risk by MDA\n4. The elimination strategy is based on \nstopping the spread of infection and in controlling morbidity. In order to apply this program, the \ufb01rst step consists on map-ping the geographical distribution of the disease. Once made, once-yearly administration of single doses of two drugs given together for at least 5 years is the recommended regimen for treatment (table 1). Coverage of at least 65% of the total at-risk population should be established to be effective. Finally, a surveillance phase after MDA should be established with trans -\nmission assessment surveys\n15. In areas where onchocerciasis \nis co-endemic, IVM (150 \u00b5g/kg) plus ALB (400 mg) is the re-commended treatment, while in areas where onchocerciasis is not endemic, DEC (8 mg/kg) plus ALB (400 mg) is the preferred treatment regimen. \nDuring the period 2000-2011, more than 3.9 billion doses \nof these drugs were administered to the endemic population. By the end of 2011, 53 of 73 endemic countries were already applying MDA\n16; twelve of these countries had already moved \nto the surveillance phase. The \ufb01nal objective is to apply MDA for 100% of endemic countries and move to the surveillance phase and for 70% of endemic countries to be veri\ufb01ed for no transmission by 2020\n17.\nMECHANIMS OF ACTION OF ANTIFILARIAL \nAGENTS\nDiethylcarbamazine (DEC)\nDEC is a piperazine derivate used as major chemothe -\nrapeutic agent to treat lymphatic \ufb01lariasis since 194718-19. \nAlthough the cause by which DEC leads to decrease the con -\ncentration of parasites in the peripheral circulation is still \nunknown, several mechanisms of action have been suggested (table 2). In vitro studies have demonstrated that alterations in parasite eicosanoid metabolism are present. Speci\ufb01cally, the effects on parasite eicosanoid production (block on the crofti is responsible for approximately 90% of the \ndisease worldwide, while the remaining cases are due to Brugia malayi and B. timori\n2. These \ufb01larial \nnematodes have important social and economic impact causing considerable morbidity and serious illnesses with resultant social stigmatization, mar -\nginalization, and loss of work in patients\n3.\nControl and treatment of lymphatic \ufb01lariasis is \ndif\ufb01cult for several reasons: limitation of effecti -\nve drugs, vector control programmes unsuccessful and no available vaccines. For that reason, in 2000 WHO launched The Global Programme to Eliminate Lymphatic Filariasis (GPELF) with the objective to eliminate this disease as a public health problem by 2020\n4. The elimination strategy is based on annual treatment \nof whole communities with combinations of drugs, known as mass drug administration (MDA). Currently MDA use the three drugs available for treatment at different regimens: ivermectin (IVM), albendazole (ALB), and diethylcarbamazine (DEC)\n5. The \npossibility of this global elimination strategy has been establis -\nhed due to the eradication some years ago of lymphatic \ufb01laria -\nsis in China and other countries using DEC alone.\nHowever, the issue of resistance to antihelminthics using \nfor treating human infections has become increasingly impor -\ntant6. Previously, it has been already reported the emergence \nof high levels of drug resistance in veterinary medicine due to the extensively use of benzimidazoles (BZ) and IVM\n7-8. In view \nof this fact, it stands to reason that the MDA in larger popu -\nlations groups for several years may perform a strong selec-tive pressure on parasites, leading also to the emergence of drug-resistant strains\n9. As population groups and the duration \nof the programme increase, the threat of treatment failure due to the emergence of resistance could be more visible. On the other hand, the genetic variation of \ufb01larial parasites can be an important factor that might in\ufb02uence the ef\ufb01cacy of the drug as well as the development and spread of drug resistance\n10.\nUntil now, it has been demonstrated the evidence of non -\nsusceptibility to DEC in \ufb01larial nematodes11, although detailed \nstudies of resistance are dif\ufb01cult due to a poor understanding of its mechanism of action. In 2004, resistance to IVM was reported in Onchocerca volvulus\n12, but no con\ufb01rmed reports of resistance \nin W. bancrofti have been provided. However, there is growing \nevidence of resistance to BZ in many nematode parasites13.\nDespite these \ufb01ndings, the importance and the mecha -\nnisms of resistance to these drugs remain still unclear. The objective of this review is to assess the magnitude of antihel -\nminthic resistance in lymphatic \ufb01lariasis as well as to explore the main determinants of parasite drug resistance in order to better understand the potential treatment failures with MDA and to improve the treatment strategies.\nANTIFILARIAL DRUGS FOR LYMPHATIC \nFILARIASIS: MASS DRUG ADMINISTRATION\nBecause of the \ufb01ndings on the research during the past Table 1  Recommended treatment strategies for mass drug \nadministration (MDA).\nSource: WHO. IVC: ivermectin; ALB: albendazole; DEC = diethylcarbamazine.Type of filarias Region Treatment strategy\nLymphatic filariasis Africa IVM and ALB for at least 5 years\nLymphatic filariasis Rest of the world DEC and ALB for at least 5 years\nOnchocerciasis Africa IVM every year for at least 15-17 years\nOnchocerciasis Rest of the world IVM twice every year until transmission\n  have been interruptedBacteriemia por S aureus de origen respiratorio y  mortalidad F. Cobo\nRev Esp Quimioter 2016;29(6): 288-295 290adults stages, leading to depletion of glycogen and reducing \nthe stores of adenosine triphosphate (ATP) leading to immobi -\nlization and death of the parasite26. However, the most impor-\ntant effect of ALB on W. bancrofti is the prolonged suppres-\nsion of reproduction by the adult parasites (approximately 9 months)\n27. Macro\ufb01laricidal effect has been demonstrated only \nwhen high and frequent doses are administrated (400 mg/day/21 days), but it is associated with high side effects and intolerability\n28.\nIvermectin (IVM)\nIVM was the \ufb01rst commercially available macrocyclic lac -\ntone endectocide and until now it is the only macrocyclic lac -\ntone used in parasites infecting humans. This drug was disco -\nvered in the mid-1970s and it was introduced as antiparasitic \nagent in 1981, showing activity against a wide variety of ne -\nmatodes29. The target of IVM is aimed at the micro\ufb01laria stage \nof several nematodes (e.g. O. volvulus) binding with high af\ufb01 -\nnity to glutamate (GABA)-gated chloride channels causing an increase in the permeability of the cell membrane to chloride ions with hyperpolarization of the nerve or muscle cell. Hyper -\npolarization results in paralysis and death of the parasite either directly or by lack of feeding in worms. GABA is an important inhibitory neurotransmitter in the nematode neuromuscular system, and some research found that GABA receptors could play a role in the mechanism of action of IVM\n30. \nIn nematodes, macrocyclic lactones could cause some \neffects such as paralysis/activation of body muscle, pharyn -\ngeal pumping and inhibition of reproduction31. Paralysis of \nthe pharyngeal muscle is unlikely to be important in \ufb01lariae. However, inhibition of reproduction could be the most impor -\ntant effect in these parasites. It is likely that IVM acts on mi -\ncro\ufb01lariae in vivo by increasing their sensitivity to the host im -\nmune system, although the true mechanism is still unknown.  cyclooxygenase pathway) and host endothelium can lead to \ndeath of micro\ufb01laria\n20. These changes may produce vasocons -\ntriction, ampli\ufb01ed endothelial adhesion, and cytotoxic activity and then can lead to immobilization of micro\ufb01larias. All these facts could produce activation of the innate and non-speci\ufb01c immune system\n21.\nOn the other hand, other studies have found evidences \nthat DEC induces micro\ufb01larial DNA break with subsequent apoptosis possibly related to an altered function of microtu -\nbules, although this process is not enough to eliminate micro -\n\ufb01larias, because in in vitro conditions the micro\ufb01lariae are still \nalive\n22.\nWith regard to macro\ufb01laricidal effect, the distinct results \nin the different studies are most likely due to different level of transmission in the areas where the study was performed. However, available data show that DEC could also eliminate the adult worms causing lymphatic \ufb01lariasis when adminis -\ntered in low doses in medicated table salt\n23, but this macro -\n\ufb01laricidal effect is limited. Studies that show higher rates of adulticidal effect have often been carried out in areas without new worm infections.\nAlbendazole (ALB)\nALB is a broad-spectrum anthelmintic belonging to benzi -\nmidazole group of antihelminthics that has been used widely \nto treat intestinal helminthic infections since the late 1980s and now also serves as treatment of lymphatic \ufb01lariasis\n24. Se-\nveral mechanisms of action were proposed for the BZs in the past, but currently it is well known that the BZ drugs perform their primary action selectively binding to the cytoskeletal pro -\ntein \u03b2-tubulin\n25. This binding inhibits the polymerization and \nblocks the formation of microtubule matrix which is essential to the functioning of cells. Finally, these facts lead to stop cell division. Moreover, ALB blocks glucose uptake in the larval and Table 2  Summary of the proposed mechanisms of action and parasite drug resistance for MDA \ndrugs.\nMDA: mass drug administration\nDEC: diethylcarbamazine; ALB: albendazole; IVM: ivermectinDrug Mechanism of action Effects Mechanism of resistance\nDEC Block on the cyclooxygenase pathway Immobilization of microfilarias Single nucleotide polymorphisms\n   Activation of innate and non-specific immune system\n Microfilarial DNA break Apoptosis\n Macrofilaricidal effect Death of the adult parasite\nALB Binding to \u03b2-tubulin and blocks the Stop cell division Unknown\n formation of microtubule matrix \n Blocks glucose uptake Immobilization and death of the parasite\n Macrofilaricidal effect Suppression of reproduction by the adult parasite\nIVM Affinity to glutamate-gated chloride channel Paralysis and death of the parasite  Changes in \u03b2-tubulin, protein 60 and acidic ribosomal \nprotein P-glycoprotein and ABC transporters dysfunction Polymorphisms of MDR1 and CYP3A genesBacteriemia por S aureus de origen respiratorio y  mortalidad F. Cobo\nRev Esp Quimioter 2016;29(6): 288-295 291ver, it was not until 2004 when it was reported resistance to \nIVM in the human parasite O. volvulus. In a study performed \nin patients living in northern Ghana, a suboptimal response to ivermectin treatment was demonstrated\n12, and more recently, \nresistance to IVM was found in other population-based study from Ghana\n38. Some studies have been performed by analysing \nchanges in \u03b2-tubulin, protein 60 and acidic ribosomal protein genes\n39. However, no clearly relationship has been established \nbetween these genes and the apparition of IVM resistance. \nOn the other hand, research has also focused on the study \nto other genes such as P glycoprotein and ABC transporter that could be associated with resistance to IVM\n40-43. Some works \nhave concluded that IVM treatment results in a homozygote de\ufb01cit of these genes in the treated population and changes in allele frequencies have been found after IVM administration. However, the signi\ufb01cance of these \ufb01ndings in the development of resistance to IVM remains unclear. \nOn the other hand, IVM is a known substrate for both the \nCYP3A4 and MDR1 genes and several studies have previously identi\ufb01ed genetic polymorphisms within the MDR1 gene re -\nlated with some effects on drug response\n44-45. In addition, the \nCYP3A gene and some subfamilies have been involved in the metabolism of some pharmaceutical drugs. It is well known that genetic polymorphisms may cause suboptimal response to some drugs due to a pharmacokinetic variability. Some authors have theorized about the relationship of the polymorphisms of both MDR1 and CYP3A genes and the presence of drug in -\nef\ufb01cacy\n46. \nIn 2010, a study exploring the in\ufb02uence of genetic varia -\ntions within MDR1, CYP3A4, and CYP3A5 genes on response to IVM treatment by examining genotype frequencies in respon -\nders and suboptimal responders was performed\n47. The authors \nfound both a signi\ufb01cantly higher MDR1 (3435T) variant allele frequency in suboptimal responders than in responders (21% vs. 12%) and also than in the control group (21% vs. 11%). With regard to genotypes, CYP3A5*1/CYP3A5*1 and CYP3A5*1/CYP3A5*3 genotypes were also found to be signi\ufb01cantly diffe -\nrent for responders and suboptimal responders. The haplotype *1/*1/*3/*1 was also found to be signi\ufb01cantly different for res -\nponders and suboptimal responders. Although this study only included a small population, a relationship between CYP3A4 and MDR1 variants and response to IVM treatment could be established based on host genetic differences. These distinct genetic variants can play an important role in the variable drug response to IVM. However, further studies including larger po -\npulations will be necessary in order to con\ufb01rm these results. \nMany studies have reported that drug pressures on pa -\nrasite populations leads to the development of drug resistan -\nce and reduces genetic variation among parasite populations. Eberhard et al\n11 generated evidence of nonsusceptibility to DEC \nin W. bancrofti which indicates the possible threat of wide-\nspread resistance to this drug. The genetic variation of micro -\n\ufb01larias is an important factor that may in\ufb02uence the ef\ufb01cacy of the medicine as well as the development and spread of drug resistance among parasite populations. DEC quickly reduces MECHANISMS OF PARASITE DRUG RESISTANCE\nThe development of drug resistance in veterinary pa -\nrasitology suggests that the resistance to the treatment of \nlymphatic \ufb01lariasis in human nematode parasites could be also produced. The occurrence of anthelmintic resistance in \ufb01larial parasites such as W. bancrofti is dif\ufb01cult to demonstrate be -\ncause these parasites do not have a free-living stage and can -\nnot be cultured in animal models. In this context, parasitologi -\ncal evidence of anthelmintic drug resistance can only be found by demonstrating the persistence of parasites after treatment over a long period of time. However, due to the dif\ufb01culty to monitor the anthelmintic resistance in lymphatic \ufb01lariasis, molecular markers for anthelmintic resistance are needed. \nDrug resistance for lymphatic \ufb01lariasis could become a \ngrowing risk which may be probably due to the selective pres -\nsure on parasite populations\n9. Large scale exposure to anti-\n\ufb01larial drugs through MDA programme can lead to the rapid emergence and spread of drug-resistant strains doing useless the efforts to eradicate the infection. \nALB is currently one of the drugs give for MDA in the \nGPELF programme, so as a component of this treatment it would be necessary to monitor the possibility of emerging of resistance to this medicine in lymphatic \ufb01lariasis. However, not only drug pressure is responsible for the emergence of resis -\ntance, but also untreated populations of W. bancrofti might \nhave drug-resistant alleles for ALB\n13-32. The resistance-associa-\nted mutation could be found at a high frequency even before the MDA program had been started, although these mutations may be found at a high frequency in worms from treated pa -\ntients\n13. \nALB resistance in lymphatic \ufb01lariasis and in many other \nnematodes is associated with single nucleotide polymor -\nphisms (SNPs). Molecular markers for anthelmintic resistance have shown that this resistance is known to be produced by substituting tyrosine for phenylalanine in parasite \u03b2-tubulin \nat either position 167 or 200\n33-34. The mutation at codon 200 \nappears to be more common in nematodes and has been de -\nmonstrated to be recessive35. The deletion of phenylalanine \nand the substitution for tyrosine at codons 167 and 200 is the key factor for the high-af\ufb01nity binding of ALB and other ben -\nzimidazoles to nematode tubulin leading to sensitivity to these anthelmintics\n36.\nA study showed that in worms collected from patients \ntreated with ALB plus IVM there were higher 200-genotype mutation than in untreated patients or those treated only with ALB. The overall allele frequency was 31.6% higher in the trea -\nted versus the non-treated worm population, which indicates that this mutation appears after drug treatment\n13. Moreover, \nthe same study shows that in patients who had been submit -\nted to two rounds of treatment with ALB + IVM the allele fre -\nquency was an additional 25.9% higher.\nResistance to IVM had been previously found in nemato -\ndes infecting animals37, although until now no con\ufb01rmed resis -\ntance to IVM in lymphatic \ufb01lariasis has been reported. Howe -Bacteriemia por S aureus de origen respiratorio y  mortalidad F. Cobo\nRev Esp Quimioter 2016;29(6): 288-295 292Using the same EPIFIL system, Schwab et al. attempt to \nanalyse the population genetics of potential multi-drug resis -\ntance in W. bancrofti due to combination chemotherapy55. This \nmodel predict a decrease of the possibility that IVM resistance \nwill produce a parasite increase, although this decrease may occult an increase in the number of adult worms resistant to \nboth ABZ and IVM. This work also suggests that some changes \nin the proportion of ABZ and IVM resistant micro\ufb01lariae could be observed during the treatment period. According to this model, the presence of IVM resistance would increase the rate \nof ABZ resistance and vice versa.\nOn the other hand, the model also indicates that children \nwill have a higher proportion of resistance than adults, be -\ncause acquisition of new infections will be higher in children, whereas could be reduced in adults because of protecting an-\ntibodies against \ufb01larial infections.\nGenetic diversity of the parasite populations may in -\nfluence the drug response and the clinical outcome, but \nalso it can be a consequence of the drug pressure due to \ndifferent chemotherapy strategies. With respect to this, Ra -\nmasamy et al. described the different genetic structure of W. bancrofti populations depending on the chemotherapy strategy\n56. One hundred and seventy-eight blood samples \nfrom microfilaria carriers were analysed using the RAPD technique and genetic profiles were generated. From 74 populations of W. bancrofti under MDA treatment with \nDEC alone, there was 100% of polymorphism percentages, showing high levels of genetic diversity and could be clus -\ntered into eight groups. Furthermore, from 60 W. bancrof-ti parasite populations under treatment with DEC + ALB, there were 70% polymorphisms and 18 polymorphic loci, showing 5 clusters. Finally, 34 W. bancrofti populations \nwith selective treatment with a standard dose of DEC du -\nring a long time were analysed, being the percentage of po -\nlymorphisms of 92%, showing 4 groups.    \nThese results demonstrate the in\ufb02uence of the different \ntreatment strategies on the genetic structure of W. bancrof-\nti. Genetic diversity of \ufb01larial parasites is usually maintained at high levels because of some circumstances, but anti-\ufb01larial treatment causes a break in that stable state. Several treatment combinations at different doses may reduce genetic diversity and can lead to the selection of drug resistance alleles\n57.\nThe study of cytochrome oxidase subunit 1 (COI) which \nis a useful marker for taxonomic and population genetic stu -\ndies, has also been used in order to detect genetically different \nW. bancrofti strains. A study sequenced 22 samples from two \nGhana districts58. Genetic analysis shows 11 haplotypes, and \n58 polymorphic sites were found between populations, being the southern population more polymorphic than the northern population. Furthermore, the COI gene from 16 patients in -\nfected with W. bancrofti was sequenced and the authors dis-\ncovered 109 unique haplotypes with one common haplotype present in 15 of them\n59. These data con\ufb01rmed the high levels \nof genetic diversity in populations of W. bancrofti.\nBecause of the genetic variability may have important the quantity of micro\ufb01lariae in the blood, but according with \nsome works this drug does not completely eliminate micro\ufb01la-riae from the blood\n48-49. Because of the mode of action of DEC \nis poorly understood, the mechanism of resistance against this drug is currently unknown, so research is needed in order to discover it. \nGENETIC DIVERSITY OF FILARIAL PARASITES \nRELATED TO DRUG RESISTANCE  \nGenetic diversity is mainly produced by mixing genetica -\nlly different populations, although anti\ufb01larial drug pressure on \nthe parasite populations could also play an important role in increasing this gene diversity. The introduction of new drugs for the treatment of \ufb01lariasis can lead to the selection of alle -\nles encoding resistance to these drugs, affecting the ef\ufb01cacy about the parasite.\nSome studies have shown the existence of genetic varia-\nbility of W. bancrofti parasite populations using techniques \nsuch as the random ampli\ufb01ed polymorphic DNA (RAPD)\n50-51. \nThe RAPD pro\ufb01le was performed in order to analyse the phylo -\ngenetic relationships between the populations. The analysis of the RAPD pro\ufb01les showed a high degree of genetic variability. In four endemic locations in India, population genetic analysis was carried out based on RAPD pro\ufb01les of 31 individual popu -\nlations. The highest number of polymorphic loci was found in the urban parasite populations. A phylogenetic tree was cons -\ntructed using RAPD pro\ufb01les and four different clusters were found in a rural area and three different clusters in an urban area. On the other hand, the pro\ufb01les from the urban area showed that only one locus was common and the percentage of polymorphic loci among individual parasite populations was very high, so a high heterogeneity was found.\nMoreover, genetic heterogeneity of micro\ufb01laria popula-\ntion within a carrier was analysed. Twenty-one individual mi -\ncro\ufb01larias were investigated and gene diversity was found to be very high. In this case, four different lineages were obtained through the phylogenetic tree constructed, so at least four genotypes of micro\ufb01laria exist. Finally, the results of analysis showed that the parasite heterogeneity and number of geno -\ntypes increased with age probably due to the acquisition of new infections.  \nOther studies have used the EPIFIL system which consists \nof a model that describes some parasites population dyna -\nmics\n52-53. Based on this model, the authors could describe the \ntrend in drug resistance by examining factors affecting the spread of ABZ resistance under several assumptions\n54. The \nspeed of ABZ resistance spread is higher with treatment with ABZ + DEC than with ABZ + IVM. Moreover, the spread of ABZ resistance is strongly dependent on treatment coverage because this model also indicates that treatment with ABZ + DEC for 10 years at 85% coverage could increase the resis-tant genotype frequency to approximately 13%. Thus, hig-her levels of therapeutic coverage can lead to rapid spread of ABZ resistance\n54.Bacteriemia por S aureus de origen respiratorio y  mortalidad F. Cobo\nRev Esp Quimioter 2016;29(6): 288-295 293include arachidonic acid, \u03b2-tubulin, antioxidant defence sys-\ntem, DNA topoisomerases, GABA receptor channel, glutamate-gated chloride channel and nicotinic acetylcholine receptor\n68.  \nCONCLUDING REMARKS\nThe goal of the GPELF is to eliminate the parasite infec -\ntion based on the annual administration of ALB, IVM or DEC in two different regimens according the areas of endemicity. MDA to the general population is currently the main strategy of WHO to make in practice this objective in endemic areas. However, the majority of the medicines have only demonstra -\nted a micro\ufb01laricidal effect, but they are ineffective on the eli-mination of adult worms. Moreover, it is well known that the \ufb01larial control programmes based on strong selective pressure on parasite populations could lead to the emergence of drug-resistant strains, and the duration of the programme may in-crease the probability of treatment failure related to parasite resistance.  \nDrug pressure may have in\ufb02uence about genetic variation \namong parasite populations and genetic structure of \ufb01larial parasites seems an important factor that may explain the de-crease of drugs ef\ufb01cacy in some circumstances. In view of this threat, efforts should be taken on the study of mechanisms of resistance related to parasite genetic structure in order to determinate the existence of drug-resistant strains, as well as the \ufb01nding of new \ufb01larial genetic markers for drug resistance. Development of methods to monitor the emergence of drug resistance as well as the discovery of new potential targets for the investigation of new anti-\ufb01larial drugs is essential for the future control of the disease.  \nCONFLICT OF INTEREST\nAuthor declares no con\ufb02ict of interest\nFUNDING\nAuthor declares no funding for this work\nREFERENCES\n1. WHO, \u201cLymphatic \ufb01lariasis\u201d, Geneva, Switzerland, March 2014, \nhttp://www.who.int/mediacentre/factsheets/en/.\n2. Michael E, Bundy DAP. Global mapping of lymphatic \ufb01lariasis. Pa -\nrasit Today 1997; 13: 472-6. \n3. Ramaiah KD, Guyatt H, Ramu K, Vanamail P, Pani SP, Das PK. Treatment costs and loss of work time to individuals with chronic lymphatic \ufb01lariasis in rural communities in South India. Trop Med Int Health 1999; 4: 19-25.\n4. World Health Organization. Elimination of lymphatic \ufb01lariasis. Wkly Epidemiol Rec 2002; 77: 177-9.\n5. Gyapong JO, Kumaraswami V, Biswas G, Ottesen EA. Treatment strategies underpinning the global programme to eliminate implications in chemotherapy resistance and clinical respon -\nse, further studies using more genetic markers and comparing \nthe in\ufb02uence of different treatment regimens on the genetic structure of \ufb01larias will be necessary in order to identify diffe -\nrent parasites strains which can explain in depth the difference in drug response of lymphatic \ufb01lariasis.  \nNEED FOR NEW ANTI-FILARIAL DRUGS \nOverall, treatment with anti-\ufb01larial drugs through the \nMDA programme had proved in a signi\ufb01cant reduction of mor-bidity caused by micro\ufb01larias, although in some areas such as the Polynesian Islands over 50 years of MDA using DEC did not eliminate the infection\n60. However, broad use of the three \ndrugs currently available increases the risk for the emergence and spread of drug resistance, which may be a threat to the development of the GPELF. Since there is no available vaccine and the vector control programs have failed, the short-term goal is to identify and develop new classes of drugs and alter -\nnative chemotherapeutic strategies. \nIn the 1970\u2019s a group of intracellular bacteria called Wol-\nbachia was discovered. This microorganism acts as endosym -\nbiont of \ufb01larial nematodes except in Loa Loa, and it is well \nknown that \ufb01larial parasites depend on these endosymbionts for metabolic and reproductive functions\n61. Many antibiotics \nbut, above all doxycycline are known to be effective in the treatment of human \ufb01lariasis through the action in Wolba-chia\n62. In LF doxycycline at a dose of 100-200 mg/day for six \nweeks is micro\ufb01laricidal63, and at a dose of 200 mg/day for 4 \nweeks cause sterility and death of adult worms64. However, \nthe macro\ufb01larial effect of doxycycline in onchocerciasis is not 100% and is contraindicated in pregnant or breastfeeding wo -\nmen and children under 9 years, so new drugs will be neces -\nsary for these populations.\nThere have been two recent scienti\ufb01c advances that provi-\nde new perspectives for target validation for anti-\ufb01larial drug discovery like the development of RNA interference (RNAi) and the large-scale production of gene sequence information. RNAi provides an adequate but also a dif\ufb01cult technique for sear -\nching biological functions of genes in parasitic nematodes\n65. \nIn this sense, a Scienti\ufb01c Working Group (SWG) recommended strategic guidelines for the research in this \ufb01eld\n66. RNAi scree-\nning of the \ufb01larial genome may found essential genes, some of which may be adequate targets for anti-\ufb01larial drug discovery.\nOn the other hand, the \ufb01larias genome sequencing may \nalso serve as identi\ufb01cation of drug targets for LF. Genome pro -\njects are based on the identi\ufb01cation, cloning and sequencing of all genes of the parasites. Currently, about 20 million base pairs of expressed \ufb01larial parasite DNA sequence are available in genomic libraries\n67. Moreover, the sequencing of the mito -\nchondrial genomes for \ufb01larial parasites may provide additional targets for potential useful drugs.\nAdditional biochemical compounds have been proposed \nas potential targets for the investigation of new anti-\ufb01larial drugs. The targets which have been validated to anti\ufb01larials Bacteriemia por S aureus de origen respiratorio y  mortalidad F. Cobo\nRev Esp Quimioter 2016;29(6): 288-295 294bamazine. Parasitol Research 2008; 103: 717-21.\n23. Hewitt RI, White E, Wallace WS. Experimental chemotherapy of \n\ufb01lariasis. Effect of piperazine derivates against naturally acquired \ufb01larial infections in cotton rats and dogs. J Lab Clin Med 1947; 32: 1304-13.\n24. Ottesen EA, Ismail MM, Horton J. The role of Albendazole in pro -\ngrammes to eliminate lymphatic \ufb01lariasis. Parasitol today 1999; 15: 382-6.\n25. Friedman PA, Platzer EG. Interaction of antihelminthic benzimida -\nzoles and benzimidazole derivates with bovine brain tubulin. Bio -\nchim Biophys Acta 1978; 544: 605-14.\n26. Bertram GK. Clinical pharmacology of the antihelminthic drugs. In: Basic and clinical pharmacology. 5\nth edition, 1992, Chapter 55, pp \n748. Appleton and Lange, London.\n27. Michael E, Malecela-Lazaro MN, Simonsen PE, Pedersen EM, Bar -\nker G, Kumar A, et al. Mathematical modelling and the control of lymphatic \ufb01lariasis. Lancet Infect Dis 2004; 4: 223-34.\n28. Jayakody RL, de Silva CSS, Weerasinghe WMT. Treatment of ban-croftian \ufb01lariasis with albendazole: evaluation of ef\ufb01cacy and ad -\nverse reactions. Trop Biomed 1993; 10: 19-24.\n29. Campbell WC. Ivermectin: an update. Parasitol Today 1985; 1: 10-16.  \n30. Schulz-Key H. Observations on the reproductive biology of Oncho-cerca volvulus. Acta Leiden 1990; 59: 27-44.\n31. Bennett JL, Williams JF, Dave V. Pharmacology of ivermectin. Para-sitol Today 1988; 4: 226-8.\n32. Schwab AE, Churcher TS, Schwab AJ, Bas\u00e1\u00f1ez MG, Prichard RK. An analysis of the population genetics of potential multi-drug resis -\ntance in Wuchereria bancrofti due to combination chemotherapy. Parasitology 2007; 134: 1025-40.\n33. Kwa MSG, Veenstra JG, Roos MH. Molecular characterization of \u03b2-tubulin genes present in benzimidazole-resistant populations of Haemonchus contortus. Mol Biochem Parasitol 1993; 60: 133-44.\n34. Kwa MSG, Veenstra JG, Roos MH. Benzimidazole resistance in Hae-\nmonchus contortus is correlated with a conserved mutation at amino acid 200 in beta-tubulin isotype 1. Mol Biochem Parasitol 1993; 63: 299-303.\n35. Elard L, Humbert JF. Importance of the mutation of amino acid 200 of the isotype 1 \u03b2-tubulin gene in the benzimidazole resistance of \nthe small-ruminant parasite Teladorsagia circumcincta. Parasitol \nRes 1999; 85: 452-6.  \n36. Prichard R. Genetic selection following selection of Haemonchus \ncontornus with anthelmintics. Trends Parasitol 2001; 17: 445-53.\n37. Prichard RK. Anthelmintic resistance in nematodes: extent, recent understanding and future directions for control and research. Int J Parasitol 1990; 20: 515-23.\n38. Osei-Atweneboana MY, Eng JK, Boakye DA, Gyapong JO, Prichard RK. Prevalence and intensity of Onchocerca volvulus  infection and \nef\ufb01cacy of ivermectin in endemic communities in Ghana: a two-phase epidemiological study. Lancet 2007; 369: 2021-9. \n39. Bourguinat C, Pion SD, Kamgno J, Gardon J, Duke BO, Boussinesq M, et al. Genetic selection of low fertile Onchocerca volvulus by lymphatic \ufb01lariasis. Expert Opin Pharmacother 2005; 179-200.\n6. McCarthy J. Is anthelmintic resistance a threat to the program to eliminate lymphatic \ufb01lariasis? Am J Trop Med Hyg 2005; 73: 232-3.\n7. Conway DP. Variance in effectiveness of thiabendazole against Haemonchus contortus in sheep. Am J Vet Res 1964; 25: 844-5.\n8. Prichard RK. Anthelmintic resistance in nematodes: exent, recent understanding and future directions for control and research. Int J Parasitol 1990; 20: 515-23.\n9. Grant WN. Genetic variation in parasitic nematodes and its impli -\ncations. Int J Parasitol 1994; 24: 821-30.\n10. Anderson TJ, Jaenike J. Host speci\ufb01city, evolutionary relationships and macrogeographic differentiation among Ascaris populations \nfrom humans and pigs. Parasitology 1997; 115: 325-42.\n11. Eberhard ML, Lammie PJ, Dickinson CM, Roberts JM. Evidence of nonsusceptibility to diethylcarbamazine in Wuchereria bancrofti. J Infect Dis 1991; 1157-60.\n12. Awadzi K, Boakye DA, Edwards G, Opoku NO, Attah SK, Osei-Atwe -\nneboana MY, et al. An investigation of persistent micro\ufb01larider -\nmias despite multiple treatments with ivermectin, in two oncho -\ncerciasis-endemic foci in Ghana. Ann Trop Med Parasitol 2004; 98: 231-49.\n13. Schwab AE, Boakye DA, Kyelem D, Prichard RK. Detection of benzi -\nmidazole resistance-associated mutations in the \ufb01larial nematode Wuchereria bancrofti and evidence for selection by albendazole and ivermectin combination treatment. Am J Trop Med Hyg 2005; 73: 234-8.\n14. Fiftieth World Health Assembly: resolutions and decisions; annexes. Geneva, World Health Organization, 1997: 5-14 (WHA50/1997/REC/1). \n15. Transmission assessment surveys in the Global Programme to Eliminate Lymphatic Filariasis. WHO position statement. Geneva, World Health Organization, 2012. (WHO/HTM/NTD/PCT/2012.9). \n16. Lymphatic \ufb01lariasis: monitoring and epidemiological assessment of mass drug administration programme. A manual for national eli -\nmination programmes. Geneva, World Health Organization, 2011. (WHO/HTM/NTD/PCT/2011.4). \n17. Global Programme to Eliminate Lymphatic Filariasis. Progress re -\nport 2000-2009 and strategic plan 2010-2020. Geneva. World Health Organization, 2010.\n18. Hawking F. Diethylcarbamazine and new compounds for treatment of \ufb01lariasis. Adv Pharmacol Chemother 1979; 16: 130-94.\n19. Mackenzie CD, Kron MA. Diethylcarbamazine: a review of its action in onchocerciasis, lymphatic \ufb01lariasis and in\ufb02ammation. Trop Dis Bull 1985; 82: R1-R36.\n20. Kanesa-thasan N, Douglas JG, Kazura JW. Diethylcarbamazine in -\nhibits endothelial and micro\ufb01larial prostanoid metabolism in vitro. Mol Biochem Parasitol 1991; 49: 11-20.\n21. Maizels RM, Denham DA. Diethylcarbamazine (DEC): immunophar -\nmacological interactions of an anti-\ufb01larial drug. Parasitology 1992; 105: S49-S60.\n22. Peixoto CA, Santos ACO, Ayres CFJ. Molecular evidence for apopto -\nsis in micro\ufb01lariae of Wuchereria bancrofti  induced by diethylcar -Bacteriemia por S aureus de origen respiratorio y  mortalidad F. Cobo\nRev Esp Quimioter 2016;29(6): 288-295 295ivermectin or diethylcarbamazine on the possible spread of alben-\ndazole resistance in Wuchereria bancrofti. Parasitology 2006; 133: 598-601.\n55. Schwab AE, Churcher TS, Schwab AJ, Bas\u00e1\u00f1ez MG, Prichard RK. An analysis of the population genetics of potential multi-drug resis -\ntance in Wuchereria bancrofti due to combination chemotherapy. Parasitology 2007; 134: 1025-40.\n56. Ramasamy D, Hoti SL, Sharma R, Das MK. In\ufb02uence of anti-\ufb01larial chemotherapy strategies on the genetic structure of Wuchereria \nbancrofti populations. Mem Inst Oswaldo Cruz 2011; 106: 240-7.\n57. Paul RE, Packer MJ, Walmsley M, Lagog M, Ranford-Cartwright LC, Paru R, et al. Mating patterns in malaria parasite populations of Papua New Guinea. Science 1995; 269: 1709-11.\n58. de Souza DK, Osei-Poku J, Blum J, Baidoo H, Brown CA, Lawson BW, et al. The epidemiology of lymphatic \ufb01lariasis in Ghana, ex -\nplained by the possible existence of two strains of Wuchereria bancrofti. Pan African Med J 2014; 17: 133. \n59. Small ST, Ramesh A, Bun K, Reimer L, Thomsen E, Baea M, et al. Population genetics of the \ufb01larial worm Wuchereria bancrofti in a \npost-treatment region of Papua New Guinea: insights into diversi -\nty and life history. PLOS Negl Trop Dis 2013; 7: e2308.\n60. Pichon G. Limitation and facilitation in the vectors and other as-pects of the dynamics of \ufb01larial transmission: the need for vector control against Anopheles transmitted \ufb01lariasis. Ann Trop Med Pa -\nrasitol 2002; 96: S143-S152.\n61. Taylor MJ. Wolbachia bacteria of \ufb01larial nematodes in the patho -\ngenesis of disease and as a target for control. Trans R Soc Trop Med Hyg 2000; 94: 596-98.\n62. Townson S, Hutton D, Siemienska J, Hollick L, Scanlon T, Tagboto SK, et al. Antibiotics and Wolbachia in \ufb01larial nematodes: anti\ufb01-larial activity of rifampicin, oxytetracycline and chloramphenicol against Onchocerca gutturosa, Onchocerca lienalis and Brugia pa-\nhangi. Ann Trop Med Parasitol 2000; 94: 801-16.\n63. Hoerauf A, Mand S, Fischer K, Kruppa T, Marfo-Debrekyei Y, De -\nbrah AY, et al. Doxycicline as a novel strategy against bancroftian \ufb01lariasis-depletion of Wolbachia endosymbionts from Wuchereria \nbancrofti and stop of micro\ufb01laria production. Med Microbiol Im -\nmunol 2003; 192: 211-6.\n64. Debrah AY, Mand S, Marfo-Debrekyei Y, Batsa L, Pfarr K, Butt -\nner M, et al. Macro\ufb01laricidal effect of 4 weeks of treatment with doxycicline on Wuchereria bancrofti. Trop Med Int Health 2007; 12: 1433-41.\n65. Aboobaker AA, Blaxter ML. Use of RNA interference to investigate gene function in the human \ufb01larial nematode parasite Brugia ma-\nlayi. Mol Biochem Parasitol 2003; 129: 41-51.\n66. Behm CA, Bendig MM, McCarter JP, Sluder AE. RNAi-based disco -\nvery and validation of new targets in \ufb01larial nematodes. Trends Pa -\nrasitol 2005; 21: 97-100.\n67. Parkinson J, Mitreva M, Hall N, Blaxter M, McCarter JP. 400000 ne -\nmatode ESTs on the net. Trends Parasitol 2003; 19: 283-6. \n68. Tripathi RP, Katiyar D, Dwivedi N, Singh BK, Pandey J. Recent de -\nvelopments in search of anti\ufb01larial agents. Curr Med Chem 2006; 13:3319-34.ivermectin treatment. PLOS Negl Trop Dis 2007; 1: e72.\n40. Ardelli BF, Guerriero SB, Prichard RK. Ivermectin imposes selection pressure on P-glycoprotein from Onchocerca volvulus: Linkage di -\nsequilibrium and genotype diversity. Parasitology 2006; 132: 375-86.\n41. Bourguinat C, Ardelli BF, Pion SD, Kamgno J, Gardon J, Duke BO, et al. P-glycoprotein-like protein, as possible genetic marker for iver -\nmectin resistance selection in Onchocerca volvulus. Mol Biochem \nParasitol 2008; 158: 101-11.\n42. Ardelli BF, Prichard RK. Reduced genetic variation of an Onchocer-\nca volvulus ABC transporter gene following treatment with iver -\nmectin. Trans R Soc Trop Med Hyg 2007; 101: 1223-32.\n43. Prichard RK, Poulet A. ABC transporters and beta-tubulin in ma-crocyclic lactone resistance: Prospects for marker development. Parasitology 2007; 134: 1123-32.\n44. Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 2003; 4: 397-410.\n45. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockm\u00f6ller J, Jo -\nhne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473-8.\n46. Ardelli BF, Guerriero SB, Prichard RK. Genomic organization and effects of ivermectin selection on Onchocerca volvulus P-glyco-\nprotein. Mol Biochem Parasitol 2005; 143: 58-66. \n47. Kudzi W, NO Dodoo A, Mills JJ. Genetic polymorphisms in MDR1, CYP3A4 and CY3A5 genes in a Ghanaian population: a plausible explanation for altered metabolism of ivermectin in humans? BMC Med Genet 2010; 11: 111.\n48. Eberhard ML, Lowrie RC, Lammie PJ. Persistence of micro\ufb01laremia in bancroftian \ufb01lariasis after diethylcarbamazine citrate therapy. Trop Med Parasitol 1988; 39: 128-130.\n49. Eberhard ML, Lammnie PJ, Roberts JM, Lowrie RC. Effectiveness of spaced doses of diethylcarbamazine citrate for the control of ban -\ncroftian \ufb01lariasis. Trop Med Parasitol 1989; 40: 111-3.\n50. Pradeep Kumar N, Patra KP, Hoti SL, Das PK. Genetic variability of the human \ufb01larial parasite, Wuchereria bancrofti in South India. \nActa Tropica 2002; 82: 67-76.\n51. Hoti SL, Thangadurai R, Dhamodharan R, Das PK. Genetic hetero -\ngeneity of Wuchereria bancrofti populations at spatially hierarchi -\ncal levels in Pondicherry and surrounding areas, south India. Infect Genet Evol 2008; 8: 644-52.\n52. Chan MS, Srividya A, Norman RA, Pani SP, Ramaiah KD, Vana -\nmail P, et al. EPIFIL: a dynamic model of infection and disease in lymphatic \ufb01lariasis. Am J Trop Med Hyg 1998; 59: 606-14.\n53. Norman RA, Chan MS, Srividya A, Pani SP, Ramaiah KD, Vanamail P, et al. EPIFIL: the development of an age-structured model for describing the transmission dynamics and control of lymphatic \ufb01 -\nlariasis. Epidemiol Infect 2000; 124: 529-41.\n54. Schwab AE, Churcher TS, Schwab AJ, Bas\u00e1\u00f1ez MG, Prichard RK. Population genetics of concurrent selection with albendazole and Rev Esp Quimioter 2016;29(6): 296-301 296Gripe estacional en octogenarios y nonagenarios \ningresados en un hospital general: epidemiolog\u00eda, cl\u00ednica y factores pron\u00f3sticos \nRESUMEN\nIntroducci\u00f3n. La gripe epid\u00e9mica estacional es res -\nponsable de una elevada morbi-mortalidad cada a\u00f1o en el \nmundo especialmente en pacientes de edad avanzada. El objetivo del estudio fue presentar las caracter\u00edsticas epi -\ndemiol\u00f3gicas, cl\u00ednicas y pron\u00f3sticas de la gripe estacional en octogenarios y nonagenarios ingresados en un hospital general y analizar los factores asociados con la mortalidad. \nMaterial y m\u00e9todos. Estudio descriptivo transversal \nretrospectivo de los pacientes ingresados con gripe diag -\nnosticados por biolog\u00eda molecular en el Hospital General Universitario de Alicante desde el 1 de enero del 2015 hasta 31 de abril del 2015.\nResultados. En el periodo de estudio fueron diagnos -\nticados 219 pacientes, de ellos 55 (25,1%) eran \u226464 a\u00f1os, \n77 (35,2%) adultos de entre 65 y 79 a\u00f1os, 67 (30,6%) en -\ntre 80-89 a\u00f1os y 20 (9,1%) \u226590 a\u00f1os. La mayor\u00eda de los \nepisodios fueron gripe causada por influenza A (n=181; 82,6%). Los pacientes \u2265  80 a\u00f1os ten\u00edan unos valores me-\ndios de un filtrado glomerular inferior (media: 49,7 mL/min vs. 62.2 mL/min; p=0,006), mayor requerimiento de ventilaci\u00f3n mec\u00e1nica no invasiva (22% vs 9,3%; p=0,02), una mayor comorbilidad por insuficiencia cardiaca (40,5% vs. 16,4%p<0,001) y enfermedad renal cr\u00f3nica (32,9 vs. 20%, p=0,03), as\u00ed como mayor mortalidad (19% vs. 2,9%; p<0,001).  En el an\u00e1lisis multivariado, la mortalidad fue superior en  los mayores de 80 a\u00f1os (odds ratio ajustada [ORa]: 9,2, intervalo de confianza [IC] del 95%: 1,65-51,1), con adquisici\u00f3n de la gripe en un centro socio sanitarios (ORa: 11,9, IC 95%: 1,06-134) y la hiperlactacidemia (ORa: 1,89, IC 95%: 1,20-3,00).ABSTRACT\nBackground. Seasonal in\ufb02uenza is responsible for high an -\nnual morbidity and mortality worldwide, especially in elderly pa -\ntients. The aim of the study was to analyse the epidemiological, \nclinical and prognostic features of in\ufb02uenza in octogenarians and nonagenarians admitted to a general hospital, as well as risk fac -\ntors associated with mortality.\nMethods.  Retrospective, cross-sectional, descriptive study \nin patients admitted and diagnosed with in\ufb02uenza by molecular biology in the General University Hospital of Alicante from 1 Jan -\nuary to 31 April 2015.\nResults.  A total of 219 patients were diagnosed with in\ufb02uen-\nza in the study period: 55 (25.1%) were \u226464 years-old; 77 (35.2%) \nwere aged 65\u201379; 67 (30.6%) were aged 80\u201389 years; and 20 (9.1%) were aged \u226590 years. Most \ufb02u episodes were caused by \nin\ufb02uenza A (n=181, 82.6%). Patients aged 80 years or older had lower glomerular \ufb01ltration rate (mean: 49.7 mL/min vs. 62.2 mL/min; p=0.006), a greater need for non-invasive mechanical venti -\nlation (22% vs 9.3%; p=0.02), greater co-morbidity due to cardiac insuf\ufb01ciency (40.5% vs. 16.4%; p<0.001) and chronic renal dis -\nease (32.9 vs. 20%, p=0.03), and greater mortality (19% vs. 2.9%; p<0.001). In a multivariate analysis, mortality was higher in those aged 80 or over (adjusted odds ratio [ORa] 9.2, 95% con\ufb01dence interval [CI] 1.65\u201351.1), those who had acquired the \ufb02u in a long-term care facility (ORa 11.9, 95% CI 1.06\u2013134), and those with hyperlactataemia (ORa 1.89, 95% CI 1.20\u20133.00).\nConclusions. Seasonal in\ufb02uenza is a serious problem leading \nto elevated mortality in octogenarian and nonagenarian patients admitted to a general hospital.\nKey words: Human in\ufb02uenza; In\ufb02uenza A virus; Aged care; Frail elderly; \nGeriatric careSeasonal in\ufb02uenza in octogenarians and nonagenarians \nadmitted to a general hospital: epidemiology, clinical presentation and prognostic factors\n1Department of Internal Medicine, Hospital General Universitario de Alicante. Alicante, Spain\n2 Department of Clinical Medicine, Universidad Miguel Hern\u00e1ndez de Elche, Campus of San Juan de Alicante, Alicante, Spain\n3Service of Microbiology, Hospital General Universitario de Alicante. Alicante, Spain.\n4Unit of Infection Diseases, Hospital General Universitario de Alicante. Alicante, SpainJos\u00e9 M. Ramos1,2\nM. Mar Garc\u00eda-Navarro1\nM. Pilar Gonz\u00e1lez de la \nAleja1\nRosario S\u00e1nchez-Mart\u00ednez1\nAdelina Gimeno-Gasc\u00f3n3\nSergio Reus4\nEsperanza Merino4\nJuan C. Rodr\u00edguez-D\u00edaz3\nJoaqu\u00edn Portilla1,2,4\nCorrespondence:\nJos\u00e9 Manuel RamosServicio de Medicina Interna. Hospital General Universitario de Alicante. C/ Pintor Baeza 12, 03010 Alicante. Espa\u00f1a.E-mail: jramosrincon@yahoo.esOriginalSeasonal in\ufb02uenza in octogenarians and nonagenarians admitted to a general hospital: epidemiology, \nclinical presentation and prognostic factorsJ. M. Ramos, et al.\nRev Esp Quimioter 2016;29(6): 296-301 297The health department also has a long-term care facility that \nadmits patients with medical problems requiring longer stays. \nWe selected all patients admitted to hospital due to in-\n\ufb02uenza virus using data collected from the Minimum Basic Data Set (MBDS) database. All patients had to be diagnosed from real-time polymerase chain reaction (qPCR) samples ob-tained by nasal lavage with the GeneXpert test, using the Xpert Flu\u00ae and Xpert Flu/RSV XC\u00ae (RS Cepheid) assays.\nNasal lavage was performed in all patients suspected of \nhaving in\ufb02uenza. Patients were placed in mandatory isolation until the microbiological results were available; con\ufb01rmed cases remained in isolation, while those testing negative we -\nre de-isolated. All patients with a positive result received oral treatment with oseltamivir, with dosage varying according to their weight and renal function. \nWe reviewed patients\u2019 clinical records, collecting data on \nthe following variables: age, sex, place of in\ufb02uenza acquisition, basic analytical and biochemical parameters, co-morbidities, number of co-morbidities, complications during hospital stay, treatment used, need for non-invasive mechanical ventilation (NIMV), virus type of the infecting in\ufb02uenza, clinical evolution, ward of hospitalisation and length of hospital stay. \nStatistical analysis. The variables were exported from the \nMBDS database in the form of a spreadsheet and completed from clinical records, and they were then analysed using SPSS Statistics software, version 22 (IBM Corporation). The qualita -\ntive variables are presented as a number and percentage, and the quantitative variable as a mean and standard deviation (SD). The differences between episodes of in\ufb02uenza in patients aged \u226580 and <80 and those related to clinical evolution we -\nre compared. Differences in qualitative variables were studied Conclusiones. La gripe es un grave problema con elevada \nmortalidad en pacientes octogenarios y nonagenarios ingresa -\ndos en un hospital general. \nPalabra clave: Gripe, virus de gripe A; cuidados del anciano; paciente fr\u00e1gil; \npaciente geri\u00e1trico.\nINTRODUCTION\nIn\ufb02uenza is a disease of the respiratory tract, caused by \nOrthomyxovirus types A or B, and it affects people of all ages. \nIn\ufb02uenza has a seasonal form, appearing each autumn and \nwinter in countries of temperate climate in both hemisphe -\nres. The different clinical expression of in\ufb02uenza is related to prior exposure, natural or vaccine-induced, to antigens of the in\ufb02uenza virus\n1,2. In addition, a pandemic \ufb02u appears more \nrarely, about every 40 years, and it is associated with higher morbidity and mortality. The last pandemic was in\ufb02uenza A subtype H1N1 in 2009\n1. \nMost people infected with the in\ufb02uenza virus exhibit self-\nlimited, uncomplicated, acute febrile respiratory symptoms or are asymptomatic. However, severe disease and complications due to infection, including hospitalisation and death, may occur in the elderly\n3, in children, in people with underlying \nmedical conditions (including pulmonary and cardiac disea -\nse, diabetes, and immunosuppression), and in some otherwise healthy people\n2. Seasonal in\ufb02uenza is a serious infection, and \nfrequently it is complicated with viral or bacterial pneumonia and other bacterial infections\n2\u20134.\nThe geriatric population, and especially those aged 80 or \nolder, are among the patients most affected by seasonal in -\n\ufb02uenza and those who suffer the greatest mortality and se -\nrious complications related to it2,5\u20137. In \nrecent years, there have been numerous scienti\ufb01c contributions related to the pan -\ndemic in\ufb02uenza A H1N1\n1,3,4; however, no \nSpanish studies have been published on the relevance of seasonal in\ufb02uenza to hospital admissions in the advanced geriatric popu -\nlation. \nThe aim of our study was to analyse the \nepidemiological, clinical and prognostic fea -\ntures of in\ufb02uenza in octogenarians and no -\nnagenarians admitted to a general hospital and risk factors associated with mortality. \nMATERIAL AND METHODS\nA retrospective, cross-sectional, des -\ncriptive study was carried out in patients with in\ufb02uenza admitted to the General Uni -\nversity Hospital of Alicante, from 1 January to 31 April 2015. This centre is a tertiary hospital covering an area with 245,000 in -\nhabitants. It has 765 beds and offers servi -\nces of all medical and surgical specialties. Table 1  Distribution of influenza cases by month, sex, and age \ngroup.\nOR: odds ratio; CI: confidence interval.Total cases of influenza Total admitted % OR (95% CI)\nTotal 219 9,650 2.3\nMonth\nJanuary 45 2,411 1.9 1\nFebruary 128 2,476 5.2 2.9 (2.0\u20134.0)\nMarch 41 2,452 1.7 0.9 (5.6\u20131.4)\nApril 4 2,221 0.2 0.09 (0.03\u20130.3)\nSex\nMale 101 4,641 2.2 1\nFemale 118 4,919 2.4 1.1 (0.4\u20131.4)\nAge group\n\u2264 64 years 55 6,286 0.9 1\n65\u201379 years 77 2,555 3.0 3.5 (2.5\u20135.0)\n> 80 years 87 1,768 4.9 5.9 (4.1\u20138.2)Seasonal in\ufb02uenza in octogenarians and nonagenarians admitted to a general hospital: epidemiology, \nclinical presentation and prognostic factorsJ. M. Ramos, et al.\nRev Esp Quimioter 2016;29(6): 296-301 298using the Chi-squared test, or alter -\nnatively Fisher\u2019s exact test when the \nnumber of expected cases was under \ufb01ve in one of the cells. Quantitative variables were analysed according to the Student\u2019s t-test if they followed a normal distribution; otherwise the U Mann Whitney test was used. Va -\nriables presenting a p value < 0.05 in the univariate study were included in the binary logistic regression multi-variate analysis. The association was measured according to the adjusted odds ratio (ORa) and its 95% con\ufb01-dence interval (CI).  The Institutional Ethics Committee of Hospital Gene-ral Universitario de Alicante appro-ved the study protocol.\nRESULTS\nDuring the study period, 9,560 \npatients over 15 years old were ad-mitted, and 219 (2.3%) had a diagno-sis of in\ufb02uenza by molecular biology. The risk of admission due to in\ufb02uen -\nza was higher in February than in Ja -\nnuary (OR 2.9, 95% CI 2.0\u20134.0) (table 1). Of the 219 patients with in\ufb02uen -\nza, 55 (25.1%) were \u2264 64 years old, \n77 (35.2%) were aged between 65\u201379 years old, 67 (30.6%) were aged 80\u201389, and 20 (9.1%) were aged \u2265 90. Compared to patients aged \u2264 64 \nyears, the risk of admission due to in\ufb02uenza was greater in adults aged 65\u201379 years (OR 3.5, 95% CI 2.5\u20135.0) and especially in those aged \u2265 80 years (OR 5.9, 95% CI 4.1\u20138.2) (ta-ble 1). Most patients with in\ufb02uenza (n=156, 71.2%) were admitted to the General Internal Medicine, Infectious Diseases, or Respiratory Medicine Departments, and only 11 (5.0%) patients were admitted into the In-tensive Care Unit. Regarding the pla -\nce of infection by in\ufb02uenza, 76.7% (n=168) of cases were community-acquired, 4.1% (n=9) were associa -\nted with long-term care facilities, and 19.2% (n=42) were nosocomial infections.  In\ufb02uenza virus type A produced most of the in\ufb02uenza ca -\nses (n=175, 79.9%), while in\ufb02uenza virus type B virus was identi\ufb01ed in 38 (17.4%) patients, and pandemic Table 2  Epidemiologic characteristics of influenza in octogenarians \nand nonagenarians.\nCRP: C reactive protein; NIMV: non-invasive mechanical ventilation; SD: standard deviation.\n* includes Influenza A H1N1 > 80 years\n(total=79)\nN (%)< 80 years\n(total =140)\nN (%)P value\nSex 0.07\n   Male 30 (38) 71 (50.7)\n   Female 49 (62) 69 (49.3)\nPlace of acquisition\n  Community 59 (74.7) 109 (77.9) 0.8\n   Long-term care facility 6 (7.6) 3 (2.1) 0.6\n   Nosocomial 14 (17.7) 28 (20) 0.8\nWard of admittance   Intensive care 3 (3.8) 8 (5.7) 0.5\nAnalytical and biochemical parameters    Haemoglobin (g/L), mean \u00b1 SD 11.9 \u00b1 1.9 12.5 \u00b1 2.3 0.05\n   Leucocytes (x10\n9/L), mean \u00b1 SD 10.3 \u00b112.4 8.2 \u00b1 4.5 0.06\n   Neutrophils (x109/L), mean \u00b1 SD 7.0 \u00b1 4.0 6.3 \u00b1 4.1 0.2\n   CRP (mg/dL), mean \u00b1 SD 8.6 \u00b1 8.3 7.9 \u00b1 9.2 0.6\n   Creatinine (mg/dL), mean \u00b1 SD 1.5 \u00b1 1.4 1.5 \u00b1 1.8 0.2\n   Urea (mg/dL), mean \u00b1 SD 65 \u00b1 35.9 53.6 \u00b1 37.5 0.9\n   Glomerular filtration (mL/min), mean \u00b1 SD 49.7 \u00b1 22.7 62.2 \u00b1 30.9 0.006\n   pH, mean \u00b1 SD (N=164) 7.4 \u00b1 0.8 7.4 \u00b1 0.7 0.7\n   Lactate (mmol/L), mean \u00b1 SD (N=164) 2.1 \u00b1 0.8 2.2 \u00b11.5 0.3\nType of influenza 0.9\n   Influenza A* 64 (81.0) 117 (80)\n   Influenza B 15 (19.0) 23  (20)\nTreatment   NIMV 18 (22.8) 13 (9.3) 0.02\n   Antibiotic treatment 51 (64.6) 81 (67.9) 0.2\n   Steroid treatment 39 (40.6) 57 (59.3) 0.3\nForms of presentation   Pneumonia 16 (20.3) 16 (11.4) 0.07\nCo-morbidities   Diabetes mellitus 19/79 (24.1) 27/140 (19.3) 0.4\n   Hypertension 34/79 (43.0) 58/140 (41) 0.8\n   Cardiac insufficiency 32/79 (40.5) 23/140 (16.4) <0.001\n   Chronic renal diseases 26/79  (32.9) 28/140 (20) 0.03\nOutcome   Mortality 15 (19) 4(2.9) <0.001\n   Length of hospital stay, mean \u00b1 SD 10.4 \u00b1 11.2 9.9 \u00b1 9.3 0.7Seasonal in\ufb02uenza in octogenarians and nonagenarians admitted to a general hospital: epidemiology, \nclinical presentation and prognostic factorsJ. M. Ramos, et al.\nRev Esp Quimioter 2016;29(6): 296-301 299subtype H1N1 was found in 6 (2.7%) \ncases.  \nThe clinico-epidemiological cha -\nracteristics of in\ufb02uenza episodes in octogenarians and nonagenarians are presented in table 2. There were some statistically signi\ufb01cant diffe -\nrences between patients under 80 and those aged 80 years or older. The older patients had a lower glo -\nmerular \ufb01ltration rate (p=0.006), a greater need for NIMV (p=0.02), and higher mortality (p<0.001). Pneumo -\nnia was also more common in this group, but the difference was not statistically signi\ufb01cant (20.3% vs. 11.4%; p=0.07). The mean length of hospital stay was 10.4 (\u00b1 11.2) days in patients aged 80 or older, very si -\nmilar to that registered in younger patients. \n Nineteen (8.7%) patients died: \n2 (3.6%) of the 55 patients aged 64 or under, 2 (2.6%) of the 77 pa -\ntients aged 65 to 79, and 15 (17.2%) of the 87 patients aged 80 or older (p=0.001). Table 3 shows the factors related to mortality. In the multiva -\nriate analysis, mortality was higher among those aged 80 or older (ORa 9.2, 95% CI 1.65\u201351.35), those who had acquired in\ufb02uenza in a long-term care facility (ORa 11.9, 95% CI 1.06\u2013134), and those with hyperlac -\ntataemia (ORa 1.89, 95% CI 1.20\u20133.00) (table 4).\nDISCUSSION\nIn our study, the risk of hospi-\ntalisation for in\ufb02uenza was higher in geriatric patients aged 65 years or older and particularly in those aged 80 or older. During the study period, mortality in patients with in\ufb02uenza was positively associated with ad-vanced age ( \u226580 years), presence of \nco-morbidities, infection by in\ufb02uen -\nza virus in a long-term care facility and diagnosis of lactic acidosis du -\nring the course of the disease. \nThe most frequently observed \nco-morbidities in our patients we-re: diabetes mellitus, hypertension, chronic renal disease and cardiac in-Dead\n(n=19)\nN (%)Not dead\n(n=200)\nN (%)OR (95% CI) P value\nSex 0.7\n   Male 8 (42.1) 93 (46.5) 1\n   Female 11 (57.9) 107 (53.5) 1.19 (0.46\u20133.09)\nAge <0.001\n   < 80 years 4 (21.1) 136 (68.0) 1\n   \u2265 80 years 15 (78.9) 64 (32.0) 7.96 (2.54\u201324.9)\nPlace of acquisition\n   Community 11 (57.9) 157 (78.5) 0.37 (1.43\u20130.99) 0.04\n   Long-term care facility 3 (15.8) 6 (3.0) 6.06 (1.38\u201326.5) 0.007\n   Nosocomial 5 (26.3) 37 (18.5) 1.57 (0.53\u20134.64) 0.4\nCo-morbidities   Diabetes  mellitus 4 (21.1) 42 (21) 0.99 (0.31\u20133.16) 0.9\n   Hypertension 9 (47.4) 83 (41.5) 1.26 (0.49\u20133.26) 0.6\n   Chronic cardiac insufficiency 8 (42.1) 47 (23.5) 2.36 (0.90\u20136.23) 0.07\n   Anaemia 4 (21.1) 38 (19) 1.13 (0.35\u20133.62) 0.8\n   Chronic renal disease 4 (21.1) 50 (25.0) 0.80 (0.25\u20132.52) 0.7\n   Chronic pulmonary disease 2 (10.5) 17 (8.5) 1.26 (0.27\u20135.95) 0.7\nHaemogram and biochemistry   Leucocytes (x10\n9/L), mean \u00b1 SD 10.92 \u00b1 5.3 8.8 \u00b1 8.5 1.09 (0.92\u20131.32) 0.36\n   Neutrophils (x109/L), mean \u00b1 SD 8.7 \u00b1 4.7 6.4 \u00b14.0 1.11 (1.01\u20131.21) 0.03\n   CRP (mg/dL), mean \u00b1 SD 14.6  \u00b1 12.7 7.6 \u00b1 8.2 1.06 (1.02\u20131.11) 0.002\n   PH, mean \u00b1 SD (N=164) 7.3 \u00b1 0.10 7.41 \u00b10.8 0.007 (0.0\u20132.33) 0.09\n   Lactate (mmol/L), mean \u00b1 SD (N=164) 3.1 \u00b1 3.0 2.1 \u00b10.9 1.49 (1.05\u20132.14) 0.02   Creatinine (mg/dL), mean \u00b1 SD 1.44 \u00b1 0.81 1.56 \u00b1 1.7 0.93 (0.65\u20131.32) 0.7\n   Urea (mg/dL), mean \u00b1 SD 75.1 \u00b1 34.8 56.1 \u00b1 37.2 1.01 (1.00\u20131.02) 0.03\n   Glomerular filtration (mL/min), mean \u00b1 SD 45.1 \u00b1 19.9 58.9 \u00b1 29.2 0.98 (0.96\u20131.00) 0.08Type of influenza 0.8\n   Influenza A 16 (84.2) 165 (82.5) 1\n   Influenza B 3 (15.8) 35 (17.5) 1.13 (0.31\u20134.09)\nRequirements and complications   NIMV 7 (36.8) 24 (12) 4.27 (1.5\u201311.9) 0.003\n   Pneumonia 8 (42.1) 24 (120) 5.33 (1.9\u201314.5) 0.001Table 3  Bivariate analysis of the risk factors for mortality associated with \ninfection from the influenza virus.\nCRP: C reactive protein; NIMV: non-invasive mechanical ventilation; SD: standard deviation.Seasonal in\ufb02uenza in octogenarians and nonagenarians admitted to a general hospital: epidemiology, \nclinical presentation and prognostic factorsJ. M. Ramos, et al.\nRev Esp Quimioter 2016;29(6): 296-301 300Seasonal in\ufb02uenza is a serious, potentially fatal entity13. \nIndeed, in a document published by the prestigious Statens \nSerum Institut in Copenhagen, the excess all-cause mortality registered between December 2014 and February 2015 was attributed to a rise in the number of in\ufb02uenza H3N2 cases in that time period\n14.  It is well known that mortality due to the \nseasonal in\ufb02uenza virus is more frequent in those aged 65 or older\n5,6,15, but in our study, we have demonstrated that mor -\ntality is particularly high in patients aged 80 years or older. Population ageing is a social reality, and we have shown that the advanced geriatric population (aged \u226580) is at increased \nrisk of dying due to in\ufb02uenza. \nThe severity of influenza in chronically ill and elderly \npopulations (especially octogenarians and nonagenarians) strongly advises adherence to recommendations on in-fluenza vaccination\n2,15. Different epidemiological studies \nhave demonstrated that the influenza vaccine reduces hospitalisations and mortality related to that cause\n16,17. In \nour health department, influenza vaccination is free and easily accessible in primary healthcare centres and in hos -\npital.  However, during the 2014\u201315 influenza season, an -\ntigenic drift caused most of the influenza A (H3N2) viruses in circulation to be different from the influenza A (H3N2) component of the 2014\u201315 northern hemisphere seaso -\nnal vaccines, resulting in a reduction in vaccine effective -\nness\n18,19. The lack of protection from the flu vaccine during \nthe study period probably had a negative influence on our patients\u2019 outcomes.\nThe limitations of this study include the fact that we only \nhave information on patients admitted to hospital with in -\n\ufb02uenza, not on the results for outpatients. Among the infected patients who do not require hospitalisation, mortality is lower. \nIn\ufb02uenza in the advanced geriatric population is a serious \ninfection. Patients over 80 have more cardiovascular disease and poorer renal function than younger patients with in\ufb02uen -\nza. Advanced age, acquisition of the infection in a long-term care facility, and hyperlactaemia are associated with poor outcomes for seasonal in\ufb02uenza infection in admitted pa -\ntients. Vaccine programmes, chemoprophylaxis during out-breaks in hospital or long-term care settings, antiviral agents, and treatment of co-morbidities can improve prognosis of el-derly people with in\ufb02uenza.\nACKNOWLEDGEMENTS\nWe want to thank the entire staff at the Hospital General \nUniversitario de Alicante for the care they provide daily to oc -\ntogenarians and nonagenarian patients.\nFUNDING \nThis study was funded by grant of II Grant of  Fundaci\u00f3n \npara el Fomento de la Investigaci\u00f3n Sanitaria y Biom\u00e9dica de la Comunidad Valenciana (FISABIO)-Alicante (2015) (Grant num -\nber: UGP 15-301)Variables Adjusted OR (95% CI) P value\nLactate (mmol/L) 1.89 (1.20\u20133.00) 0.006\nAge \u226580 years 9.2 (1.65\u201351.35) 0.01\nAcquisition in long-term care facility 11.9 (1.06\u2013134) 0.04\nPneumonia 3.7 (0.85\u201316.1) 0.08\nCRP  (mg/dL), 1.04 (0.97\u20131.11) 0.2\nCommunity acquisition 0.45 (0.09\u20132.25) 0.3\nNeutrophils (x109/L) 1.05 (0.98\u20131.22) 0.5\nNIMV 1.89 (0.45\u20135.61) 0.4\nUrea (mg/dL) 1.0 (0.97\u20131.02) 0.9Table 4  Multivariate analysis of risk factors \nfor mortality.\nCI: confidence interval; CRP: C reactive protein; NIMV: non-invasive mechanical \nventilation.\nsuf\ufb01ciency. People at high risk of complications from in\ufb02uenza \ninclude patients with chronic obstructive pulmonary disease, cardiovascular disease, immunosuppressive disorders, chronic renal dysfunction, cancer, cognitive dysfunction, and diabetes mellitus, among other disorders, as well as residents of any age in long-term care institutions. These conditions are quite fre -\nquent in elderly people, who often require hospital admission and antiviral treatment\n2.\nIn\ufb02uenza is associated with heart failure and other car -\ndiovascular disease, as found by a recent systematic review and meta-analysis\n8. In our study, the prevalence of heart fai-\nlure in patients admitted with in\ufb02uenza was higher, but it was more common in people aged 80 or older. Moreover, in our study, renal insuf\ufb01ciency as evaluated by estimated glomeru -\nlar \ufb01ltration rate was lower in patients aged \u2265 80 years than \nin younger patients. In addition to advanced age, obesity and pro-in\ufb02ammatory mediators have also been associated with kidney failure in patients with in\ufb02uenza\n9; however, we did not \nanalyse these features in our study.  Pneumonia is a severe complication in patients aged over 65 years who are hospita -\nlised with in\ufb02uenza\n10. In our study, this pathology was a more \nfrequent complication in octogenarians and nonagenarians with in\ufb02uenza compared to younger patients, but the diffe -\nrence did not reach statistical signi\ufb01cance.\nThe World Health Organization (WHO) and the US Centers \nfor Disease Control and Prevention (CDC) recommend neura -\nminidase inhibitors such as oseltamivir and zanamivir as the \ufb01rst-line antiviral drugs for patients infected with in\ufb02uenza A and B\n11,12. Current guidelines recommend antiviral treatment \nwith oseltamivir within 48 h of symptom onset in all patients admitted with laboratory con\ufb01rmed or highly suspected in -\n\ufb02uenza\n2.  In our hospital, we followed these recommendations \nduring the study period. All of patients received the treatment with oseltamivir 12 hours previously laboratory con\ufb01rmed diagnosis or during the \ufb01rst 8 hours after that. Seasonal in\ufb02uenza in octogenarians and nonagenarians admitted to a general hospital: epidemiology, \nclinical presentation and prognostic factorsJ. M. Ramos, et al.\nRev Esp Quimioter 2016;29(6): 296-301 301CONFLICT OF INTEREST \nOn behalf of all authors, the corresponding author states \nthat there is no con\ufb02ict of interest\nREFERENCES\n1. Vaqu\u00e9 J. Epidemiology of in\ufb02uenza A (H1N1) worldwide and in Spain. Arch Bronconeumol. 2010; 46 Suppl 2:3-12.\n2. Harper SA, Bradley JS, Englund JA, File TM, Gravenstein S, Ha -\nyden FG, et al.; Expert Panel of the Infectious Diseases Society of America.  Seasonal in\ufb02uenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak manage -\nment: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2009; 48:1003-32. \n3. Reina J, L\u00f3pez C, Morales C, Busquets M. Age change in the in\ufb02uen -\nza A (H1N1)pdm09 after the evolution from pandemic to seasonal epidemic. Med Clin (Barc) 2014; 143:468-70. \n4. Thiberville SD, Gaudart J, Raoult D, Charrel RN. In\ufb02uenza-attri -\nbutable deaths in south-eastern France (1999 to 2010): mortality predictions were undependable. BMC Public Health. 2015; 15:539. \n5. Matias G, Taylor R, Haguinet F, Schuck-Paim C, Lustig R, Shinde V. Estimates of mortality attributable to in\ufb02uenza and RSV in the United States during 1997-2009 by in\ufb02uenza type or subtype, age, cause of death, and risk status. In\ufb02uenza Other Respir Viruses 2014; 8:507-15. \n6. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Ander -\nson LJ, et al. Mortality associated with in\ufb02uenza and respiratory syncytial virus in the United States. JAMA 2003; 289:179\u201386.\n7. Reina J, L\u00f3pez C, Morales C, Busquets M. Analysis of co-infections between in\ufb02uenza A and in\ufb02uenza B viruses and other respiratory viruses, 2012-2013. Enferm Infecc Microbiol Clin. 2014; 32:693-5. \n8. Kwok CS, Aslam S, Kontopantelis E, Myint PK, Zaman MJ, Buchan I, et al. In\ufb02uenza, in\ufb02uenza-like symptoms and their association with cardiovascular risks: a systematic review and meta-analysis of observational studied. Int J Clin Pract. 2015; 69:928-37. \n9. Cruz-Lagunas A, Jim\u00e9nez-Alvarez L, Ram\u00edrez G, Mendoza-Milla C, Garc\u00eda-Sancho MC, Avila-Moreno F, et al. Obesity and pro-in -\n\ufb02ammatory mediators are associated with acute kidney injury in patients with A/H1N1 in\ufb02uenza and acute respiratory distress syn -\ndrome. Exp Mol Pathol. 2014; 97 :453-7. \n10. Chaves SS, P\u00e9rez A, Miller L, Bennett NM, Bandyopadhyay A, Farley MM, Fowler B et al. Impact of Prompt In\ufb02uenza Antiviral Treatment on Extended Care Needs After In\ufb02uenza Hospitalization Among Community-Dwelling Older Adults.  Clin Infect Dis. 2015; 61:1807-14.\n11. Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E.  Effectiveness of in\ufb02uenza vaccine in the community-dwelling elderly. N Engl J Med. 2007; 357:1373\u201381.\n12. Molbak K, Espenhain L, Nielsen J, Tersago K, Bossuyt N, Denissov G, et al. Excess mortality among the elderly in European coun -\ntries, December 2014 to February 2015. Euro Surveill.2015; 20. pii: 21065.13. Muthuri SG, Venkatesan S, Myles PR, Leonardi-Bee J, Al Khuwaitir TS, Al Mamun A, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with in\ufb02uenza A H1N1pdm09 virus infection: a meta-analysis of individual parti -\ncipant data. Lancet Respir Med 2014; 2:395-404. \n14. Wang CB1, Chiu ML, Lin PC, Liang WM, Chen CY, Chang YJ, et al. Prompt Oseltamivir Therapy Reduces Medical Care and Mortality for Patients With In\ufb02uenza Infection. An Asian Population Cohort Study. Medicine 2015; 94:e1070. \n15. Cohen C, Moyes J, Tempia S, Groome M, Walaza S, Pretorius M, et al. Mortality amongst patients with in\ufb02uenza-associated severe acute respiratory illness, South Africa, 2009-2013. PLoS One. 2015; 10:e0118884.\n16. Reed C, Kim IK, Singleton JA, Chaves SS, Flannery B, Finelli L, et al. Estimated in\ufb02uenza illnesses and hospitalizations averted by vac -\ncination--United States, 2013-14 in\ufb02uenza season. MMWR Morb Mortal Wkly Rep.2014; 63:1151-4. \n17. Castilla J, Guevara M, Mart\u00ednez-Baz I, Ezpeleta C, Delfrade J, Irisarri F, et al.Enhanced Estimates of the In\ufb02uenza Vaccination Effect in Preventing Mortality: A Prospective Cohort Study. Medicine (Balti -\nmore). 2015; 94:e1240.  \n18. Appiah GD, Blanton L, D\u2019Mello T, Kniss K, Smith S, Mustaquim D, et al.; Centers for Disease Control and Prevention. In\ufb02uenza activity - United States, 2014-15 season and composition of the 2015-16 in\ufb02uenza vaccine. MMWR Morb Mortal Wkly Rep. 2015; 64:583-90\n19. Pebody RG, Warburton F, Ellis J, Andrews N, Thompson C, von Wissmann B, et al. Low effectiveness of seasonal in\ufb02uenza vac -\ncine in preventing laboratory-con\ufb01rmed in\ufb02uenza in primary care in the United Kingdom: 2014/15 mid-season results. Euro Surveill. 2015; 20:21025.Rev Esp Quimioter 2016;29(6): 302-307 302Demographic and clinical features of diagnosed \nindividuals of enterobiasis in the southern Gran Canaria: sampling assessment \nABSTRACT\nIntroduction. Enterobius vermicularis, also known as pin -\nworn, is the responsible agent for Human Enterobiasis. It is one \nof the most prevalent, but underrated, parasitic disease in chil -\ndren population. Diagnosis involves demonstration of either eggs or adult worms by Graham test. The aim of this study is to describe the clinical, demographic and microbiological features of patients with suspected diagnosis of Enterobiasis in south -\nern Gran Canaria.\nMaterial and methods. Descriptive and prospective study \nof perianal samples evaluated by Graham test in the Microbiol -\nogy Department of `Insular de Gran Canaria\u00b4 University Hospi -\ntal between November 2014 and November 2015. Descriptive analysis to evaluate the correlation between clinical and demo -\ngraphic variables and the results of Graham test microbiologi -\ncal observation.\nResults. 1,128 samples were analyzed. E. vermicularis was \nfound in 11.4% of the samples. Among the positives samples, 88.4% belonged to children under 14 years, and 53.5% were male. Abdominal pain (18.6%), anal itching (11.6%), eosino -\nphilia (8.5%) and intestinal parasitosis suspicion (7.8%) were the reasons of parasitological investigation request in positive samples. Nevertheless, a high proportion of the requests was not founded in a suspicious diagnosis or was unrelated to En -\nterobiasis.\nConclusions. Enterobiasis is a common disease in primary \nhealth care and is of great importance in Gran Canaria. Quality in sample collection as well as diagnosis suspicious information are necessary for a good microbiological analysis.\nKey words: Enterobius vermicularis , Graham test, samples collection, intes -\ntinal parasitosis, Gran Canaria.RESUMEN\nIntroducci\u00f3n. La enterobiasis, causada por Enterobius \nvermicularis es una de las parasitosis m\u00e1s prevalentes en po-blaci\u00f3n infantil, cuyo diagn\u00f3stico implica la demostraci\u00f3n de los huevos o gusanos mediante el m\u00e9todo de Graham. El ob -\njetivo del estudio es describir las caracter\u00edsticas cl\u00ednico-demo -\ngr\u00e1\ufb01cas y microbiol\u00f3gicas de pacientes con sospecha de Ente -\nrobiasis en el \u00e1rea Sur de Gran Canaria.\nMaterial y m\u00e9todos. Estudio descriptivo y prospectivo de \nlos resultados de muestras perianales evaluadas mediante el m\u00e9todo de Graham por el Servicio de Microbiolog\u00eda del Hos -\npital Universitario Insular de Gran Canaria entre Noviembre de 2014 y Noviembre de 2015. Se ha realizado un an\u00e1lisis descrip -\ntivo y de asociaci\u00f3n de riesgo de las variables cl\u00ednicas y demo -\ngr\u00e1\ufb01cas y los resultados del Test de Graham.\nResultados. Se obtuvieron 1.128 muestras v\u00e1lidas. En \nel 11,4% se observaron huevos de E. vermicularis; el 88,4% \nde las muestras positivas en menores de 14 a\u00f1os y el 53,5% en  g\u00e9nero masculino. Dolor abdominal (18,6%), prurito anal (11,6%), eosino\ufb01lia (8,5%) y parasitosis intestinal (7,8%) fue -\nron los motivos de solicitud en las muestras positivas. Predo -\nmino elevado sin diagn\u00f3stico de sospecha o diagn\u00f3sticos no relacionados con enterobiasis. \nConclusiones. La enterobiasis es un motivo de consulta en \natenci\u00f3n primaria y una patolog\u00eda de inter\u00e9s en Gran Canaria. La calidad de recogida de muestras y el diagn\u00f3stico de sospecha es necesaria para realizar un buen an\u00e1lisis microbiol\u00f3gico.\nPalabras clave: Enterobius vermicularis , t\u00e9cnica de Graham, toma de mues -\ntras, parasitosis intestinal, Gran Canaria.Caracter\u00edsticas cl\u00ednico-demogr\u00e1\ufb01cas de la poblaci\u00f3n \ndel Sur de Gran Canaria con diagn\u00f3stico de enterobiasis: valoraci\u00f3n de la toma de muestras\n1Servicio Canario de Salud.\n2Servicio de Medicina Preventiva. Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria. Servicio \nCanario de la Salud.\n3Servicio de Microbiolog\u00eda y Parasitolog\u00eda. Complejo Asistencial Universitario de Salamanca.\n4Servicio de Microbiolog\u00eda. Hospital Universitario Insular de Gran Canaria. Servicio Canario de la Salud.Deyanira Carrillo-Quintero1\nLaura del Otero Sanz2\nSara Hern\u00e1ndez-Egido3\nAntonio Manuel Mart\u00edn \nS\u00e1nchez4\nCorrespondencia:\nSara Hern\u00e1ndez-EgidoServicio de Microbiolog\u00eda y Parasitolog\u00eda. Complejo Asistencial Universitario de Salaman-ca. Paseo de San Vicente 58  CP 37007. SalamancaE-mail: shegido@gmail.esOriginalCaracter\u00edsticas cl\u00ednico-demogr\u00e1\ufb01cas de la poblaci\u00f3n del Sur de Gran Canaria con diagn\u00f3stico de \nenterobiasis: valoraci\u00f3n de la toma de muestrasD. Carrillo-Quintero, et al.\nRev Esp Quimioter 2016;29(6): 302-307 303paciente que no lave la zona perianal antes de la toma, pues \nlos huevos se pueden detectar a primera hora de la ma\u00f1ana antes del aseo. Es recomendable realizar esta prueba de forma seriada debido a la irregularidad de las migraciones del par\u00e1si -\nto, aumentando de esta manera su sensibilidad. \nLa informaci\u00f3n disponible en Espa\u00f1a acerca de las in-\nfecciones parasitarias y especialmente de las producidas por nematodos es escasa y fragmentaria. Adem\u00e1s muchas investi -\ngaciones presentan casos aislados, de peque\u00f1os grupos o s\u00f3lo consideran determinados  grupos etarios (series pedi\u00e1tricas). Por ello, el objetivo de este estudio es describir las caracte-r\u00edsticas cl\u00ednicas y demogr\u00e1\ufb01cas de los pacientes con sospecha diagn\u00f3stica de enterobiasis, valorando la adecuada toma de muestras y la correlaci\u00f3n  con el diagn\u00f3stico de sospecha ini -\ncial del m\u00e9dico en Atenci\u00f3n Primaria. \nMATERIALES Y M\u00c9TODOS \nEstudio descriptivo y prospectivo de los resultados de las \nmuestras perianales evaluadas mediante el m\u00e9todo de Gra -\nham, procedentes de los centros de salud del \u00e1rea Sur de Gran Canaria y procesadas por el Servicio de Microbiolog\u00eda del Hos -\npital Universitario Insular de Gran Canaria en el periodo com -\nprendido entre noviembre de 2014 y noviembre de 2015.\nCriterios de inclusi\u00f3n. Todas las muestras recibidas en el \nServicio de Microbiolog\u00eda en el periodo de estudio y procesa-das como v\u00e1lidas por dicho servicio.\nCriterios de exclusi\u00f3n.  Muestras que fueron rechazadas \ny clasi\ufb01cadas como mal recogidas y no v\u00e1lidas para su pro -\ncesamiento por traer cinta adhesiva opaca, cinta con heces, portaobjetos sin cinta o con cinta pegada por ambos lados del INTRODUCCI\u00d3N\nEnterobius vermicularis es el agente causal \nde la oxiuriosis, enterobiasis u oxiuriasis huma -\nna. Helminto distribuido desde las zonas \u00e1rticas \nhasta las regiones tropicales.  Son redondos, \ufb01 -\nliformes; el macho mide de 2-5mm y la hembra 8-13 mm; de color blanco nacarado\n (\ufb01gura 1)1.\nSe estima que entre el 20 y 30% de la po -\nblaci\u00f3n infantil en el mundo presenta entero-biasis\n2, representando la helmintiasis m\u00e1s fre -\ncuente en EEUU, Europa Occidental y Espa\u00f1a3-7.\nLa transmisi\u00f3n est\u00e1 favorecida por hacina -\nmiento o convivencias en grupos (familia, es-cuelas y asilos), siendo frecuente en ni\u00f1os de 5 a 10 a\u00f1os. Tambi\u00e9n puede detectarse en adultos, en la mayor\u00eda de los casos asintom\u00e1tica, por lo que no debe subestimarse su presencia en esta etapa del desarrollo humano\n8,9. \nEste par\u00e1sito no requiere hu\u00e9sped inter-\nmedio, ni prolongada incubaci\u00f3n ex\u00f3gena para completar su ciclo, permitiendo la transmisi\u00f3n a trav\u00e9s de varios mecanismos, lo que explica su elevada prevalencia mundial y diseminaci\u00f3n\n2. El primer me-\ncanismo es la trasmisi\u00f3n directa persona-persona, la hembra al oviponer en la regi\u00f3n perianal secreta una sustancia pruri -\nginosa, conllevando al rascado, trans\ufb01ri\u00e9ndose as\u00ed los huevos a las manos y u\u00f1as. El segundo mecanismo, la diseminaci\u00f3n de microaerosoles, en la que los huevos que son livianos, ayu -\ndados por corrientes de aire, penetran la mucosa nasal y son inhalados, contaminando tambi\u00e9n, super\ufb01cies, alimentos y f\u00f3-mites. El tercero, la retroinfecci\u00f3n, consiste en la capacidad de los huevos de eclosionar inmediatamente en la regi\u00f3n perianal proporcionando la ventaja a las larvas reci\u00e9n eclosionadas de penetrar directamente dentro del hospedador humano\n1. \nLa infecci\u00f3n por E. vermicularis es generalmente asinto -\nm\u00e1tica. El s\u00edntoma m\u00e1s frecuente es el prurito anal, produ -\ncido no solo por la acci\u00f3n mec\u00e1nica del verme, sino tambi\u00e9n por la reacci\u00f3n de hipersensibilidad local ocasionada por las secreciones uterinas de la hembra en el margen perianal es -\ntimulada por el calor, m\u00e1s intenso en horas nocturnas y tras la defecaci\u00f3n\n8. Otros s\u00edntomas asociados son p\u00e9rdida de peso, \nirritabilidad, insomnio, falta de descanso y bruxismo. Cuando la carga de gusanos es muy alta puede provocar dolor abdominal, n\u00e1useas y v\u00f3mitos\n8,10.\nEl diagn\u00f3stico implica la demostraci\u00f3n de los huevos o \ngusanos. Los m\u00e9todos parasitol\u00f3gicos coprosc\u00f3picos conven -\ncionales utilizados para otras helmintiasis intestinales, como el Kato-Katz, resultan poco sensibles para la detecci\u00f3n de huevos, con una tasa de positividad del 1 al 5%\n1,8,11. En 1941, Graham \nintrodujo la cinta adhesiva como m\u00e9todo diagn\u00f3stico y aun -\nque ha sufrido algunas modi\ufb01caciones, sigue siendo el m\u00e9to -\ndo espec\u00ed\ufb01co usado para diagnosticar E. vermicularis con una \nsensibilidad elevada12.  \nPara la realizaci\u00f3n de la prueba de Graham se aconseja al Figura 1  Fotograf\u00eda a 400X de huevos de Enterobius vermicularis  \nen la t\u00e9cnica de Graham.\nCaracter\u00edsticas cl\u00ednico-demogr\u00e1\ufb01cas de la poblaci\u00f3n del Sur de Gran Canaria con diagn\u00f3stico de \nenterobiasis: valoraci\u00f3n de la toma de muestrasD. Carrillo-Quintero, et al.\nRev Esp Quimioter 2016;29(6): 302-307 304dolor abdominal (19,9%), seguido por el prurito anal (10,4%), \neosino\ufb01lia (5,6%) y parasitosis intestinal (5,1%). Predomin\u00f3 el elevado n\u00famero de muestras donde no \ufb01guraba el diagn\u00f3sti -\nco de sospecha (8,9%) o donde exist\u00edan diversos diagn\u00f3sticos (31%) (amigdalitis, bronquitis aguda, bajo peso, l\u00edquido sino -\nvial, dermatitis) agrupados como \u201cotros diagn\u00f3sticos\u201d por no corresponder con el diagn\u00f3stico de enterobiasis o parasitosis. Las caracter\u00edsticas demogr\u00e1\ufb01cas y cl\u00ednicas de los resultados de las muestras analizadas se presentan en la tabla 1. Se observa-ron diferencias signi\ufb01cativas para las variables edad, motivo de petici\u00f3n y eosino\ufb01lia.\nEl 26% (293) tuvieron un recuento perif\u00e9rico elevado de \neosin\u00f3\ufb01los en el hemograma, en los cuales se observaron hue -\nvos de E. vermicularis en el 42,6% (55). As\u00ed mismo, el 88,4% de las muestras positivas correspondieron a menores de 14 a\u00f1os y portaobjetos y etiqueta identi\ufb01cativa del pa -\nciente colocada sobre la cinta.\nVariables recogidas. Edad, g\u00e9nero, motivo \nde solicitud, recuento de eosino\ufb01lia perif\u00e9rica, \ncentro de petici\u00f3n de la prueba, resultado de la prueba y n\u00famero de portas que cumplieron con los requisitos adecuados para ser procesados en el laboratorio. \nVariable resultado. Las 14 categor\u00edas de \nclasi\ufb01caci\u00f3n de los resultados de la observaci\u00f3n microbiol\u00f3gica del Test de Graham fueron clasi -\n\ufb01cadas en 2 (resultado positivo y negativo) para llevar a cabo los an\u00e1lisis estad\u00edsticos. \nM\u00e9todo diagn\u00f3stico. Consiste en colocar \nsobre un depresor de madera una cinta adhesiva transparente con el lado adherente hacia afue -\nra, haciendo presi\u00f3n sobre el margen perianal, permitiendo que los huevos se adhieran a la misma. La cinta se coloca sobre un portaobjetos y se visualiza al microscopio con el objetivo 10X. Es necesario recoger 3 muestras durante 3 d\u00edas consecutivos, y transportarlas al laboratorio en sobre cerrado o frasco, nunca sueltos, ya que los huevos de E. vermicularis son infectivos durante las siguientes 4-6 horas\n13,14.\nAn\u00e1lisis estad\u00edstico. Revisi\u00f3n y valoraci\u00f3n \nde las observaciones de la prueba de Graham por el Servicio de Microbiolog\u00eda. La informaci\u00f3n microbiol\u00f3gica y demogr\u00e1\ufb01ca de las muestras seleccionadas se obtuvo mediante el sistema inform\u00e1tico Modulab-Izasa. Los datos fueron migrados al programa estad\u00edstico inform\u00e1tico SPSS 19.0 para su depuraci\u00f3n y an\u00e1lisis estad\u00eds -\ntico. \nSe realiz\u00f3 an\u00e1lisis descriptivo y univariado \nde cada una de las variables de inter\u00e9s; para las cuantitativas se expres\u00f3 la media y la desviaci\u00f3n est\u00e1ndar, y para las cualitativas se construyeron tablas de frecuencia. Se calcul\u00f3 la asociaci\u00f3n con sus Intervalos de Con\ufb01anza del 95% para resultado positivo en el Test de Graham. Se consider\u00f3 signi\ufb01cativo un valor de p menor de 0,05. \nRESULTADOS\nEn el periodo de estudio se recibieron un total de 1.189 \nmuestras de pacientes de las cuales el 5,1% fueron mal re -\ncogidas (61/1.189). Se observaron huevos de E. vermicu-\nlaris en el 11,4% (129/1.128) de las muestras v\u00e1lidas. El 58,5% (660/1.128) correspondieron al g\u00e9nero femenino y el 41,5% (468/1.128) al masculino. La edad media fue 12 a\u00f1os (DE=14,52), siendo el grupo etario m\u00e1s numeroso el compren -\ndido entre 0 y 14 a\u00f1os (82%).   \nEl motivo m\u00e1s frecuente de solicitud de la prueba fue el Tabla 1  Descripci\u00f3n demogr\u00e1fica y cl\u00ednica de resultados \nmicrobiol\u00f3gicos  de enterobiasis en \u00e1rea Sur de Gran Canaria.\nResultados negativos Resultados positivos Valor de p\nN % N %\n999 129\nG\u00e9nero 0,43\nMasculino 408 40,3 60 53,5\nFemenino 591 59,2 69 46,5\nGrupos de edad (a\u00f1os) <0,05\nMenor de 14 816 81,7 114 88,4\n14 \u2013 25 41 4,1 9 7,0\nMayor de 25 142 14,2 6 4,7\nCentro <0,05\nAtenci\u00f3n Primaria 930 93,1 116 90,0\nCAE Telde 31 3,2 7 5,4\nCAE Vecindario 28 2,8 6 4.6\nMotivo de solicitud <0,05\nDolor abdominal 201 20,1 24 18,6\nEosinofilia 52 5,2 11 8,5\nPrurito anal 102 10,2 15 11,6\nParasitosis intestinal 47 4,7 10 7,8\nDiarrea 42 4,2 3 2,3\nVulvovaginitis y prurito genital 61 6,1 10 5,3\nOtros 315 31,5 35 27,1\nSin diagn\u00f3stico 90 9,0 10 7,8\nRecuento de eosin\u00f3filos <0,05\nPositivo 238 23,8 55 42,8\nNormal 397 39,7 30 23,3\nNo disponible 364 36,4 44 34,1Caracter\u00edsticas cl\u00ednico-demogr\u00e1\ufb01cas de la poblaci\u00f3n del Sur de Gran Canaria con diagn\u00f3stico de \nenterobiasis: valoraci\u00f3n de la toma de muestrasD. Carrillo-Quintero, et al.\nRev Esp Quimioter 2016;29(6): 302-307 305su elevada distribuci\u00f3n mundial, por ser la segunda parasitosis \nm\u00e1s frecuente encontrada en Gran Canaria6 y por la elevada \npoblaci\u00f3n inmigrante residente en Gran Canaria (8,8%)26.\nPor otra parte, se observ\u00f3 un predominio no signi\ufb01cativo \nde resultados positivos en el g\u00e9nero masculino2,9,18.22. Existen \ndiferentes hip\u00f3tesis para explicar estos resultados comentados en diferentes publicaciones\n1,2,22. \nA pesar de que nuestro estudio se realiz\u00f3 principalmente \nen el \u00e1mbito de Atenci\u00f3n Primaria donde se encuentran re -\npresentada poblaci\u00f3n de todas las edades, los resultados ob -\ntenidos concuerdan con la evidencia disponible, pues la mayor parte de los estudios publicados sobre esta parasitosis fueron realizados en poblaci\u00f3n infantil o escolar\n1,2,9,16-18,21,23,24. Esta ma-\nyor afectaci\u00f3n puede deberse a que en edades tempranas los h\u00e1bitos higi\u00e9nicos son inadecuados, propios de esta etapa de desarrollo como onicofagia, geofagia, rascado de regi\u00f3n pe -\nrianal, etc\u2026 llevando posteriormente las manos a la boca sin lavado adecuado, y a que existen m\u00e1s oportunidades de con-tacto con el par\u00e1sito y un menor nivel inmunol\u00f3gico\n1,9,22. \nEn relaci\u00f3n a las caracter\u00edsticas cl\u00ednicas, los resultados de \nlas muestras positivas concuerdan con algunos de los s\u00ednto -\nmas de sospecha descritos en la literatura (dolor abdominal, prurito, etc.)\n8. El 18,6% de las muestras positivas se relacio-\nnaron con dolor abdominal, el principal s\u00edntoma de sospecha en nuestra serie, lo que probablemente se deba a una elevada carga parasitaria. Sin embargo, si valoramos todas las muestras analizadas por el laboratorio nos encontramos con porcentaje importante (31%) con sospechas diagn\u00f3sticas no relacionadas con enterobiasis como amigdalitis, bronquitis aguda, l\u00edqui -\ndo sinovial, dermatitis, etc.  Adem\u00e1s, el 8,9% de las muestras son recibidas en el servicio sin diagn\u00f3stico de sospecha lo que complica la valoraci\u00f3n diagn\u00f3stica del microbi\u00f3logo y limita la realizaci\u00f3n de otras pruebas microbiol\u00f3gicas complementarias que ayuden a optimizar el resultado. \nFrente a una sintomatolog\u00eda de prurito anal siempre hay \nque sospechar E. vermicularis, sobre todo en ni\u00f1os;  mientras que en los adultos, este prurito puede estar relacionado con causas como \ufb01suras, hemorroides o alergias en varones y pru -\nrito genital, candidiasis o tricomoniasis en las mujeres\n8,10,27. No \ndebemos olvidar que puede haber casos de E. vermicularis aso-ciados a infecciones en el tracto urinario y genital en ni\u00f1as, debido a la migraci\u00f3n  err\u00e1tica de las hembras gr\u00e1vidas hacia la \nvagina y uretra\n27. \nOtras localizaciones ect\u00f3picas son: pr\u00f3stata, ovarios, trom -\npas de Falopio, h\u00edgado y el ap\u00e9ndice en menor frecuencia2,4,8, \ndando lugar a una cl\u00ednica variada que puede despistarnos a la hora de realizar el diagn\u00f3stico\n1. De manera que en situaciones \nen las cu\u00e1les no se sospecha una etolog\u00eda y hay afectaci\u00f3n en estas localizaciones anat\u00f3micas, se debe tener en cuenta la po -\nsibilidad de incluir E. vermicularis en el diagn\u00f3stico diferencial. \nEn algunos casos se ha recurrido a la biolog\u00eda molecu -\nlar para con\ufb01rmar la presencia del par\u00e1sito\n1,7,28 con nuevas \nt\u00e9cnicas como PCR directamente de la cinta adhesiva con resultados similares a la t\u00e9cnica de Graham y con una bue -\nna sensibilidad\n29; el problema de estas t\u00e9cnicas es el elevado el 53,5% al g\u00e9nero masculino, mostrando un riesgo mayor de \npresentar enterobiasis tanto los menores de 14 a\u00f1os (RR: 3,3; IC95%: 1,4-7,6; p<0,05) como los j\u00f3venes entre 14 y 25 a\u00f1os (RR: 5,1; IC95%: 1,7-15,4; p<0,05) con respecto a las personas de edad adulta.\nLos motivos de solicitud m\u00e1s frecuentes encontrados en \nlas muestras positivas fueron el dolor abdominal (18,6%), el prurito anal (11,6%), la eosino\ufb01lia (8,5%) y la parasitosis in -\ntestinal (7,8%). \nPor otra parte, de las muestras que resultaron negati -\nvas para el Test de Graham  se les realiz\u00f3 diagn\u00f3stico copro-paratol\u00f3gico al 88, 6%, se observaron quistes de Blastocystis hominis (30) y de Giardia intestinalis (16) en el 4,6% de las \nmuestras. El 68% del total de la muestras ten\u00edan solicitado am-bos test diagn\u00f3sticos.\nDISCUSI\u00d3N\nEl presente estudio ha puesto de mani\ufb01esto que la entero-\nbiasis es motivo frecuente de consulta y de diagn\u00f3stico m\u00e9dico en la poblaci\u00f3n del \u00e1rea Sur de Gran Canaria. Existen multitud de publicaciones sobre la prevalencia y caracter\u00edsticas epide -\nmiol\u00f3gicas de esta helmintiasis en pa\u00edses latinoamericanos y en otros pa\u00edses con importantes grupos de poblaci\u00f3n rural\n1-9, \nencontr\u00e1ndose en Espa\u00f1a escasos estudios recientemente pu -\nblicados en relaci\u00f3n con el objetivo del estudio. Adem\u00e1s, ni el Sistema de Informaci\u00f3n Microbiol\u00f3gica ni el Sistema Nacional de Vigilancia de las Enfermedades de Declaraci\u00f3n Obligatoria espa\u00f1ol informan espec\u00ed\ufb01camente de esta parasitosis\n15.\nEn nuestro estudio el porcentaje de muestras positivas \npara enterobiasis fue del 11,4%, inferior a las prevalencias en -\ncontradas en otras publicaciones nacionales, 20,44% y 21,5% en el Valle de Guadalquivir y Castell\u00f3n\n16,17, 36,7% en Gran Ca -\nnaria6, pero similar a la encontrada en Valencia en poblaci\u00f3n \nescolar (9,6%), grupo etario m\u00e1s frecuente en nuestro estu -\ndio18. Recientemente se ha publicado un art\u00edculo breve reali -\nzado en Zaragoza, con metodolog\u00eda y resultados similares al nuestro\n19.\nEstos datos de infestaci\u00f3n en Espa\u00f1a se encuentran entre \nlas tasas descritas por autores internacionales como en Ma -\nrruecos 25,8%20, Venezuela 17,7-25,6%2,9,21, Argentina 29,1%22, \nCorea 10,8%23 o Tailandia 21,9%24.\nSeg\u00fan un estudio realizado en Dinamarca con motivo de \nun estudio de cohorte poblacional para la enfermedad in\ufb02a -\nmatoria intestinal25, la tasa de enterobiasis calculada a trav\u00e9s \nde los registros nacionales de prescripci\u00f3n de mebendazol fue del 14% en ni\u00f1os y la tasa de infestaci\u00f3n de los convivientes de los ni\u00f1os del 25%. Esta metodolog\u00eda de c\u00e1lculo de carga de enfermedad en la poblaci\u00f3n nos puede servir para realizar futuras comparaciones conjuntamente con el an\u00e1lisis de pres -\ncripci\u00f3n de mebendazol en el sistema sanitario. \nPor tanto, consideramos que nuestros resultados apoyan \nla evidencia de que la enterobiasis es una patolog\u00eda de inte -\nr\u00e9s en el \u00e1mbito de la Atenci\u00f3n Primaria en Gran Canaria, por Caracter\u00edsticas cl\u00ednico-demogr\u00e1\ufb01cas de la poblaci\u00f3n del Sur de Gran Canaria con diagn\u00f3stico de \nenterobiasis: valoraci\u00f3n de la toma de muestrasD. Carrillo-Quintero, et al.\nRev Esp Quimioter 2016;29(6): 302-307 306coste, superior a la prueba Gold Standard, y que al tratarse \nde una patolog\u00eda relacionada con las condiciones socioeco -\nn\u00f3micas de la poblaci\u00f3n es dif\u00edcil su implantaci\u00f3n como m\u00e9 -\ntodo de elecci\u00f3n en determinadas regiones, y que el test de Graham tiene una sensibilidad aceptable\n1,12. Todo esto hace \nque la biolog\u00eda molecular en la actualidad se utilice m\u00e1s con \ufb01nes epidemiol\u00f3gicos que en la pr\u00e1ctica diaria, pero podr\u00eda tener gran utilidad dirigida a la poblaci\u00f3n adulta por la mayor comodidad en la toma de muestra.\nTambi\u00e9n es importante destacar el elevado porcentaje de \nmuestras mal recogidas (5,1%); pocos estudios\n30 se\u00f1alan que \nuno de los factores que in\ufb02uye en la prevalencia de entero -\nbiasis es el conocimiento de los padres sobre esta parasitosis, de manera que es complicado que la toma de muestras y las medidas de higiene se lleven a cabo de una forma adecuada. Consideramos que es necesario e importante enfatizar y reali -\nzar actividades de intervenci\u00f3n educativa continuada dirigidas a familiares y a la comunidad, con el \ufb01n de prevenir y disminuir \nsu transmisi\u00f3n\n1. En relaci\u00f3n a esto, a lgunos estudios recientes \nsugieren realizar tratamiento del grupo familiar una vez efec -\ntuada la detecci\u00f3n del verme en alg\u00fan miembro de la familia, bas\u00e1ndose en la diseminaci\u00f3n horizontal que posee este hel -\nminto\n9,25,31,32. \nPor otra parte, el 68% de la muestras del estudio, ten\u00edan \nsolicitado tambi\u00e9n un test coproparasitol\u00f3gico lo que resulta de utilidad para el diagn\u00f3stico diferencial de la oxiuriasis con otras parasitosis, como la giardiasis. \nFinalmente, entre las limitaciones del estudio, conside-\nramos que puede existir  sesgo de selecci\u00f3n, ya que nuestro estudio se fundamenta en muestras solicitadas desde Atenci\u00f3n Primaria; adem\u00e1s puede haber sesgo de clasi\ufb01caci\u00f3n debido a la propia capacidad diagn\u00f3stica de la prueba de Graham y al estado de las muestras para su an\u00e1lisis microbiol\u00f3gico. Tampo -\nco se realiz\u00f3 un seguimiento de pacientes para conocer la evo -\nluci\u00f3n sintom\u00e1tica posterior a la instauraci\u00f3n del tratamiento. A pesar de ello, nuestro estudio aporta un importante tama\u00f1o muestral y alta representatividad de la poblaci\u00f3n canaria, al in -\ncluirse todos los usuarios del sistema sanitario del \u00e1rea sur de Gran Canaria. Por tanto, en este art\u00edculo se ha evidenciado que la enterobiasis es una patolog\u00eda de inter\u00e9s en Gran Canaria, la importancia de la calidad de la recogida de muestras  para el diagn\u00f3stico tanto cl\u00ednico como microbiol\u00f3gico y la relaci\u00f3n del grado de conocimiento de los padres con una tasa menor de muestras positivas.\nFINANCIACI\u00d3N\nLos autores declaran no haber recibido \ufb01nanciaci\u00f3n para \nla realizaci\u00f3n de este estudio. \nCONFLICTO DE INTERESES\nLos autores declaran que no existe ning\u00fan tipo de con\ufb02ic -\nto de inter\u00e9s. BIBLIOGRAF\u00cdA\n1. Cazorla Perfetti D. Aspectos relevantes de la enterobiasis humana. \nRevisi\u00f3n cr\u00edtica. Saber 2014; 26(3): 221-42.\n2. Requena Certad I, Lizardi V, Mej\u00eda LM, Castillo H, Devera R. Infecci\u00f3n por Enterobius vermicularis en ni\u00f1os preescolares de Ciudad Bol\u00ed -\nvar, Venezuela. Rev Biomed 2002; 13: 231-40. \n3. V\u00e1zquez L\u00f3pez S, Cenzual \u00c1lvarez G, Merino Fern\u00e1ndez FJ. Epide -\nmiolog\u00eda  de las helmintiasis en una zona del sur de Madrid. Rev Clin Esp 2013; 213(2): 122-4.\n4. Mar\u00edn A, Heredero E, Sainz de Baranda C, Crespo MD, S\u00e1nchez V, Serrano M et al. Parasitosis intestinales en el \u00c1rea Sanitaria de Al -\nbacete. Enferm Infecc Microbiol Clin 2004; 22 (Supl 1): 206.\n5. Mu\u00f1oz C, P\u00e9rez Arellano JL. Caracter\u00edsticas generales de las Enfer -\nmedades parasitarias. Tratado SEIMC de Enfermedades Infecciosas y Microbiolog\u00eda cl\u00ednica. Madrid: Editorial Panamericana,  2006.\n6. Novo Veleiro I, Mart\u00edn S\u00e1nchez AM, Elcuaz Romano R, Muro A, Afonso Rodr\u00edguez O, Garc\u00eda Bardeci D et al. Parasitosis en Gran Ca -\nnaria (Espa\u00f1a). Estudio prospectivo multic\u00e9ntrico durante un a\u00f1o. Rev Ibero-Latinoam Parasitol 2012; 71 (1): 34-41.\n7. Liu D. Molecular detection of human parasitic pathogens. 1\u00aa ed: Florida: Taylor & Francis CRC Press, Boca Raton, 2012.\n8. Cano Tim\u00f3n I, Pi\u00f1ero S\u00e1enz C, S\u00e1nchez Tejero EA, Navarro Mart\u00ednez A. Geohelmintiasis y Nematodosis tisulares. Medicine 2014; 11(53): 3142-51. \n9. Maniscalchi MT, Lemus Espinoza D, Kiriakos D, Pacheco F, Aponte C, Villarroel O et al. Enterobius vermicularis en ni\u00f1os del \u00e1rea rural del estado Anzo\u00e1tegui, Venezuela. Revista de la Sociedad Venezolana de Microbiolog\u00eda 2010; 30: 128-33.\n10. Zuccati G, Lotti T, Mastrolorenzo A, Tiradritti L. Pruritus ani  Derma -\ntol Ther 2005; 18(4): 355\u201362.\n11. Knopp S, Steinmann P, Keiser J, Utzinger J. Nematode Infections Soil-Transmitted Helminths and Trichinella. Infect Dis Clin N Am 2012; 26: 341-58.\n12. Beltr\u00e1n FM, T H, Tello CR. Evaluaci\u00f3n de los m\u00e9todos de Graham y pin tape en el diagn\u00f3stico de Enterobius vermicularis. Rev. Peru \nMed  Exp Salud P\u00fablica 2005; 22(1): 76-8.\n13. Ca\u00f1avate C, Cuadros J, Mart\u00ednez Ruiz R, Martin-Rabad\u00e1n P. El labo -\nratorio de microbiolog\u00eda ante las enfermedades parasitarias impor -\ntadas. En: Cercenado E, Cant\u00f3n R, editores. Procedimientos en Mi -\ncrobiolog\u00eda Cl\u00ednica. Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica (SEIMC). Madrid, 2009; 1\u201335.\n14. Graham C. A device for the diagnosis of Enterobius infection. Am  J \nTrop Med 21(2): 159-61.\n15. Instituto de Salud Carlos III [sede Web]. Madrid: Instituto de Salud Carlos III, 2016 [acceso 17 de mayo de 2016]. Epidemiolog\u00eda. Dis -\nponible en: http://www.isciii.es/ISCIII/es/contenidos/fd-servicios-cienti\ufb01co-tecnicos/vigilancias-alertas.shtml\n16. P\u00e9rez Armengol C, Ariza Astol\ufb01 C, \u00dabeda Ontiveros JM, Guevara A, Ben\u00edtez DC, Rojas Alvarez M, et al. Epidemiolog\u00eda del parasitismo in -\ntestinal infantil en el Valle del Guadalquivir, Espa\u00f1a. Rev Esp Salud P\u00fablica 1997; 71: 547-52.\n17. Catal\u00e1n J, Ariza C, de Rojas M, L!beda JM, Guevara DC. Epidemiolo-\ng\u00eda del parasitismo intestinal infantil en la provincia de Castell\u00f3n. Rev Esp Microbiol Clin 1992; 7:265-270.\n18. Belda Rustarazo S, Morales Su\u00e1rez-Varela M, Gracia Antequera M, Caracter\u00edsticas cl\u00ednico-demogr\u00e1\ufb01cas de la poblaci\u00f3n del Sur de Gran Canaria con diagn\u00f3stico de \nenterobiasis: valoraci\u00f3n de la toma de muestrasD. Carrillo-Quintero, et al.\nRev Esp Quimioter 2016;29(6): 302-307 307Esteban Sanchis JG. Enteroparasitosis en poblaci\u00f3n escolar de Va -\nlencia. Aten Primaria 2008; 40:641-5.\n19. B\u00e1ez L\u00f3pez N, Pereira Boan J, Ruiz Aliende S, Marne Trapero C. Prue -\nba de Graham y enterobiasis: resultados de 11 a\u00f1os. Rev Pediatr Aten Primaria 2013; 15 (57): 53e1-53e3.\n20. Tligui H, Agoumi A. Pr\u00e9valence du portage parasitaire intestinal chez l\u2019enfant scolaris\u00e9 \u00e0 Ti\ufb02et (Maroc). Revue Francophone des La -\nboratoires 2006; 386: 65\u20138.\n21. Cervantes J, Otazo G, Rojas M, Vivas F, Yousseph Y, Zechini V et al. Enteroparasitosis, enterobiasis y factores de riesgo en ni\u00f1os prees -\ncolares. Arte y Cuidado 2012; 5(1): 91-6.\n22. Pezzani BC, Minvielle MC, De Luca MM, C\u00f3rdoba MA, Apeztegu\u00eda MC, Basualdo JA. Enterobius vermicularis infection among popu -\nlation of General Mansilla, Argentina. World J Gastroenterol  2004; 10(17): 2535-39.\n23. Sung-Hee H, Young-Il J, Jin-Hee L, Shin-Hyeong Ch, Won-Ja Le, Sang-Eun. Prevalence of Enterobius vermicularis among Preschool Children in Muan-gun, Jeollanam-do, Korea. Korean J Parasitol 2012; 50(3): 259\u2013262.\n24. Nithikathkul C, Changsap B, Wannapinyosheep S, Poister C, Boon -\ntan P. The prevalence of enterobiasis in children attending mobile health clinic of Huachiew Chalermprakiet University. Southeast Asian J Trop Med Public Health 2001;32 (Suppl 2): 138-42.\n25. Bager P, Vinkel-Hansen A, Wohlfahrt J, Melbye M. Helminth in -\nfection does not reduce risk for chronic in\ufb02ammatory disease in a population-based cohort study. Gastroenterology 2012; 142 (1): 55-62.\n26. INEbase [base de datos en Internet]. Madrid: Instituto Nacional de Estad\u00edstica  [actualizada en abril 2016; acceso 17 de mayo de 2016]. Disponible en: http://www.ine.es/inebaseDYN/cp30321/cp_resulta-dos.htm\n27. L\u00f3pez-Olmos J, Gasull J. Enterobius vermicularis (oxiuros) en la pr\u00e1ctica ginecol\u00f3gica: cl\u00ednica y citolog\u00eda. Experiencia de 3 casos. Clin Invest Ginecol Obstet  2011; 38 (5): 197-201.\n28. Elston, M. What\u2019s eating you? Enterobius vermicularis (pinworms, threadworms). Cutis  2003; 71 (4): 268-70.\n29. Zelck UE, Bialek R, Weiss M. Molecular phylogenetic analysis of En-terobius vermicularis and development of an 18S ribosomal DNA-targeted diagnostic PCR. J Clin Microbiol 2011; 49 (4): 1602-4.\n30. Don-Hee Kim et al.; Parents\u2019 Knowledge about Enterobiasis Might Be One of the Most Important Risk Factors for Enterobiasis in Chil -\ndren Korean J Parasitol 2010; 48 (2): 121\u20136. \n31  Mensa J, Gatell J, Garc\u00eda S\u00e1nchez J. Gu\u00eda de terap\u00e9utica antimicro-biana. 25 ed. Madrid: Antares  Ediciones, 2015.\n32. P\u00e9rez-Molina J, D\u00edaz-Men\u00e9ndez M, P\u00e9rez-Ayala A, Fe rrere F, Monge \nB, Norman F et al. Tratamiento de las enfermedades causadas por par\u00e1sitos. Enferm Infecc Microbiol Clin 2010; 28:44-59.Rev Esp Quimioter 2016;29(6): 308-317 308efectivo y seguro (per\ufb01l lip\u00eddico, hep\u00e1tico y renal). Sin embar -\ngo, deber\u00edan dise\u00f1arse estudios espec\u00ed\ufb01cos que comparasen \nDRV/r vs. DRV/COBI en monoterapia para comprobar estos re-sultados.\nPalabras clave: Monoterapia con inhibidores de la proteasa potenciados, \ndarunavir/ritonavir, darunavir/cobicistat. \nDarunavir/cobicistat monotherapy. Experience \nin a tertiary hospital\nABSTRACT\nIntroduction. Ritonavir-boosted protease inhibitor (IP/r) \nmonotherapy: darunavir/ritonavir (DRV/r) or lopinavir/ritonavir \n(LPV/r) monotherapy is only provided in the major treatment guidelines in pretreated patients to prevent toxicity associat -\ned with nucleoside/nucleotide reverse transcriptase inhibitor (NRTI), reduce costs and simplify antiretroviral treatment. To start IP/r monotherapy, according to GESIDA guidelines 2016, patients need to meet the following criteria: absence of chron-ic hepatitis B, plasma viral load <50 copies/ mL for at least 6 months and absence of protease inhibitors mutations or previ -\nous virologic failures to IP/r. \nCurrently, there are no studies that evaluate the ef\ufb01cacy \nand safety of darunavir/cobicistat (DRV/COBI) monotherapy. \nMethods. This prospective study analyzed pretreated HIV \npatients with DRV/r monotherapy that were switched to DRV/COBI monotherapy. The aim of the study is to describe the ef -\nfectiveness and safety of the DRV/COBI monotherapy. \nResults. Seventy-eight patients were evaluated. Patients \nhad a median of 31.29 months of DRV/r monotherapy before DRV/COBI monotherapy. Nine of the 78 patients developed \u201cblips\u201d (plasma viral load: 50-200 copies/ml) and four patients had plasma viral load \u2265200 copies/mL. An 83.3% (65/78) of the \npatients remained with undetectable plasma viral load. RESUMEN\nIntroducci\u00f3n. La monoterapia con inhibidores de la pro -\nteasa potenciados con ritonavir (IP/r): darunavir (DRV/r) o lo -\npinavir (LPV/r), s\u00f3lo est\u00e1 contemplada en las principales gu\u00edas de tratamiento en pacientes pretratados para evitar toxicidad asociada a inhibidores de transcriptasa inversa an\u00e1logos de nucle\u00f3sidos/nucle\u00f3tidos (ITIAN), reducir costes y simpli\ufb01car el tratamiento antirretroviral (TAR). Para iniciar una monoterapia basada en IP/r seg\u00fan las gu\u00edas GESIDA del a\u00f1o 2016, es nece -\nsario que el paciente cumpla los siguientes criterios: ausencia de hepatitis cr\u00f3nica B, carga viral plasm\u00e1tica (CVP) (<50 copias/mL) durante al menos 6 meses y ausencia de mutaciones en el gen de la proteasa o fracasos virol\u00f3gicos (FV) previos a IP/r. Ac -\ntualmente no hay estudios que eval\u00faen la e\ufb01cacia y seguridad de una monoterapia con darunavir/cobicistat (DRV/COBI). \nMaterial y M\u00e9todos . Se trata de un estudio prospectivo \nen el que se incluyeron pacientes VIH pretratados con DRV/r en monoterapia que cambiaron a una monoterapia con DRV/COBI. El objetivo de nuestro estudio es describir la efectividad y seguridad de la monoterapia con DRV/COBI. \nResultados. Se estudiaron 78 pacientes. Los pacientes \ntuvieron una mediana de 31,29 (6-74,82) meses de monote -\nrapia con DRV/r previo al cambio a DRV/COBI en monoterapia. Nueve de los 78 pacientes desarrollaron \u201cblips\u201d  (CVP: 50-200 \ncopias/ml) y cuatro pacientes tuvieron CVP \u2265 200 copias/mL. \nUn 83,3% (65/78) se mantuvieron con CVP indetectable. En cuanto a la seguridad, no hubo diferencias importantes en el per\ufb01l lip\u00eddico, funci\u00f3n hep\u00e1tica (transaminasas) y funci\u00f3n renal entre DRV/r y DRV/COBI en monoterapia. \nConclusiones. DRV/COBI en monoterapia, parece ser Monoterapia con darunavir/cobicistat. Experiencia \nen un hospital de tercer nivel\n1Servicio de Farmacia. Hospital Regional Universitario de M\u00e1laga. \n2Servicio de Enfermedades Infecciosas. Hospital Regional Universitario de M\u00e1laga.Lucia Yunquera-Romero1\nRoc\u00edo Asensi-D\u00edez1\nJuan Carlos del Rio-\nValencia1\nIsabel Mu\u00f1oz-Castillo1\nManuel \u00c1ngel Casta\u00f1o-Carracedo\n2\nCorrespondencia:\nRoc\u00edo Asensi-D\u00edezServicio de Farmacia. Hospital Regional Universitario de M\u00e1laga. Avenida de Carlos Haya s/n. CP.29010. M\u00e1laga. Tfno.: 951291435. Fax: 951291493. E-mail: rocio.asensi.sspa@juntadeandalucia.esOriginalMonoterapia con darunavir/cobicistat. Experiencia en un hospital de tercer nivel L. Yunquera-Romero, et al.\nRev Esp Quimioter 2016;29(6): 308-317 309excluyen vacunaciones o infecciones intercurrentes (pueden \nproducir elevaciones transitorias de CVP). El FV generalmente se resuelve con la reintroducci\u00f3n de 2 ITIAN. Los factores que predicen el \u00e9xito de la monoterapia son: adherencia elevada, supresi\u00f3n virol\u00f3gica prolongada y profunda y cifra nadir de linfocitos CD4+ mayor de 100 c\u00e9lulas/\u00b5L\n1-3. Actualmente no \nexisten ensayos cl\u00ednicos disponibles que comparen la e\ufb01cacia de una monoterapia entre los diferentes IP/r\n2.\nLos potenciadores disponibles en la actualidad, RTV y co -\nbicistat (COBI), act\u00faan inhibiendo el metabolismo mediado por CYP3A que aumenta la exposici\u00f3n sist\u00e9mica de la mayor\u00eda de \nIP y en el caso de COBI tambi\u00e9n de elvitegravir (EVG), un INI \nutilizado para el tratamiento del VIH\n2. A pesar de tener una \nalta barrera gen\u00e9tica y un buen per\ufb01l de tolerabilidad y seguri -\ndad, RTV est\u00e1 relacionado con la aparici\u00f3n de efectos adversos gastrointestinales, numerosas interacciones con otros f\u00e1rma-cos, resistencia a la insulina, lipodistro\ufb01a e hiperlipidemia.\n4,5 \nDiferentes estudios han evaluado la e\ufb01cacia de DRV/r una vez al d\u00eda en combinaci\u00f3n con otros TAR (Estudio ARTEMIS\n6, en pa-\ncientes \u201cnaive\u201d y estudio ODIN7, en pacientes pretratados) o en \nmonoterapia en pacientes pretratados (Estudios MONET, MO-NOI, Monarch y PROTEA)\n8-11.\nCOBI ha demostrado en ensayos Fase III la no inferiori-\ndad y bioequivalencia con respecto a RTV, as\u00ed como una bue -\nna tolerancia. COBI est\u00e1 relacionado con menores alteraciones lip\u00eddicas y menos interacciones con otros f\u00e1rmacos, aunque son imprescindibles m\u00e1s estudios que as\u00ed lo demuestren. A di -\nferencia de RTV, COBI no tiene actividad antirretroviral por lo que la aparici\u00f3n de resistencias al tratamiento no se presenta como un posible problema\n5. Por otra parte, se ha de conside -\nrar que COBI puede disminuir el \ufb01ltrado glomerular estimado y aumentar los niveles de creatinina, atribuibles a una inhibici\u00f3n de la secreci\u00f3n tubular de la misma, pero sin alterar la funci\u00f3n renal\n4,5.\nLa autorizaci\u00f3n de la combinaci\u00f3n a dosis \ufb01jas de daru-\nnavir/cobicistat (DRV/COBI) 800/150 mg se basa fundamental -\nmente en los resultados del ensayo GS-US-216-13012, donde \nse eval\u00faa la e\ufb01cacia y seguridad de los componentes por se-parado, principalmente en pacientes \u201cnaive\u201d a los que se les administr\u00f3 como TAR de inicio DRV/COBI + 2 ITIAN que result\u00f3 equivalente en e\ufb01cacia virol\u00f3gica respecto a los estudios AR -\nTEMIS\n6 y ODIN7. En un estudio Fase III en el que se estudi\u00f3 el \ngrado de satisfacci\u00f3n de los pacientes en tratamiento con co -\nformulaciones que conten\u00edan COBI en vez de RTV, as\u00ed como la incidencia de efectos secundarios gastrointestinales, se obser-v\u00f3 un aumento de la satisfacci\u00f3n y una disminuci\u00f3n de la in -\ntolerancia gastrointestinal desde la semana 4 de tratamiento\n13.\nHasta el momento, en los estudios publicados en los que \nse compara la seguridad y efectividad de DRV/COBI o EVG/CO -\nBI, los pacientes fueron tratados con una terapia triple con dos ITIAN\n12,14 siguiendo las recomendaciones de las gu\u00edas de TAR \nactuales. \nActualmente, no se dispone de estudios que comparen la \nefectividad de una monoterapia con DRV/COBI (ni por separa -\ndo, ni en coformulaci\u00f3n) con otros TAR, pero su utilizaci\u00f3n en As for safety, there were no signi\ufb01cant differences in lipid \npro\ufb01le, liver function (transaminases) and renal function be -\ntween DRV/r and DRV/COBI monotherapy.\nConclusions. DRV/COBI monotherapy seems to be effec-\ntive and safe (lipid pro\ufb01le, liver and kidney function). However, it \nwould be necessary to design speci\ufb01c studies comparing DRV/r vs DRV/COBI monotherapy to con\ufb01rm these results.\nKey words: Ritonavir-boosted protease inhibitor monotherapy, darunavir/\nritonavir, darunavir/cobicistat. \nINTRODUCCI\u00d3N\nLa disponibilidad de tratamientos antirretrovirales (TAR) \nha permitido considerar en la actualidad la infecci\u00f3n por el \nVIH-1 como una patolog\u00eda cr\u00f3nica. Esto ha supuesto un cam -\nbio en los objetivos del TAR, adquiriendo una mayor importan -\ncia la mejora de la calidad de vida del paciente y una gesti\u00f3n m\u00e1s e\ufb01ciente de los recursos, sin comprometer la efectividad de los tratamientos. Tanto en primera l\u00ednea, en pacientes \u201cnaive\u201d, como en l\u00edneas sucesivas tras fracaso del TAR, los reg\u00edmenes de tratamiento preferentes siguen siendo la combinaci\u00f3n de tres principios activos frente al VIH: dos inhibidores de la transcrip -\ntasa inversa an\u00e1logos de nucle\u00f3sido/nucle\u00f3tido (ITIAN) con un inhibidor de la proteasa (IP) potenciado con ritonavir (RTV), un inhibidor de la integrasa (INI) o un inhibidor de la transcriptasa inversa no nucle\u00f3sido (ITINN)\n1-3.\nActualmente, la monoterapia con inhibidores de la pro -\nteasa potenciados con ritonavir (IP/r): darunavir/ritonavir (DRV/r) o lopinavir/ritonavir (LPV/r) s\u00f3lo est\u00e1 contemplada en las principales gu\u00edas de tratamiento en pacientes pretratados para evitar la toxicidad asociada a ITIAN, reducir costes y sim-pli\ufb01car el TAR. La monoterapia con atazanavir/ritonavir (ATV/r) no se recomienda debido a los peores resultados obtenidos en ensayos cl\u00ednicos. Para iniciar una monoterapia basada en IP/r es necesario que el paciente cumpla los siguientes criterios: ausencia de hepatitis cr\u00f3nica B, carga viral plasm\u00e1tica (CVP) <50 copias/mL durante al menos 6 meses y ausencia de mu -\ntaciones en el gen de la proteasa o fracasos virol\u00f3gicos (FV) previos a IP/r\n1. Los IP/r son f\u00e1rmacos que poseen una elevada \nbarrera gen\u00e9tica y utilizados en monoterapia permiten man -\ntener la supresi\u00f3n virol\u00f3gica en la mayor\u00eda de pacientes, pero con tasas inferiores a la triple terapia. El uso de monoterapia con lopinavir/ritonavir (LPV/r) y darunavir/ritonavir (DRV/r) es -\nt\u00e1 relacionado con mayor frecuencia de \u201cblips\u201d, de\ufb01nidos como valores de CVP aislados y transitorios entre 50 y 200 copias/mL. Los \u201cblips\u201d, aunque en la mayor\u00eda de los estudios no est\u00e1n relacionados con el aumento de riesgo de FV, s\u00ed hacen reco -\nmendable la reevaluaci\u00f3n del TAR (grado de adherencia y la barrera gen\u00e9tica) y en algunos pacientes pueden seleccionar mutantes resistentes\n1. El FV ocurre cuando, en un paciente con \nadherencia estricta y \u00f3ptima tolerabilidad al TAR, se dan cua-lesquiera de las dos situaciones siguientes: a) CVP detectable tras 24 semanas del inicio del TAR; b) si tras alcanzar la in -\ndetectabilidad, la CVP vuelve a ser >50 copias/mL en dos de -\nterminaciones consecutivas (separadas por 2-4 semanas), si se Monoterapia con darunavir/cobicistat. Experiencia en un hospital de tercer nivel L. Yunquera-Romero, et al.\nRev Esp Quimioter 2016;29(6): 308-317 310terol, triglic\u00e9ridos), hep\u00e1tico (GOT, GPT) y renal (creatinina y \n\ufb01ltrado glomerular).\n Variable de adherencia. El c\u00e1lculo se realiz\u00f3 con la si -\nguiente f\u00f3rmula:\n% adherencia: N\u00famero de unidades de medicaci\u00f3n ARV \ntotal dispensada/N\u00famero de unidades de medicaci\u00f3n ARV pre -\nvista.\nSe consideraron unidades previstas las necesarias para \ncumplir el tratamiento en los d\u00edas incluidos desde la primera dispensaci\u00f3n hasta la \u00faltima en el periodo de tiempo conside -\nrado para el c\u00e1lculo. Se calcul\u00f3 la adherencia en 2 periodos: 6 meses antes del cambio y posterior al cambio hasta la fecha de corte del estudio.\nEn el caso de que alguno de los pacientes tuviera un ingre -\nso en nuestro hospital, el Servicio de Farmacia le facilita el TAR durante todo el periodo de hospitalizaci\u00f3n, por lo que para el c\u00e1lculo de la adherencia tambi\u00e9n se tuvo en cuenta el registro de medicaci\u00f3n dispensada en dosis unitaria a pacientes hospi-talizados.\nAn\u00e1lisis estad\u00edstico. El an\u00e1lisis de los datos fue descripti -\nvo. Los valores de las variables fueron expresados como medias \u00b1 desviaci\u00f3n est\u00e1ndar (DE), medianas, rangos y porcentajes. Se consider\u00f3 que no exist\u00edan problemas \u00e9ticos en la realizaci\u00f3n del estudio, ya que se trat\u00f3 de un trabajo observacional, en el que la informaci\u00f3n recopilada se consider\u00f3 con\ufb01dencial y se utiliz\u00f3 \u00fanica y exclusivamente en el \u00e1mbito profesional.\nRESULTADOS\nSe incluyeron 82 pacientes que iniciaron tratamiento con \nDRV/COBI en monoterapia durante el per\u00edodo de inclusi\u00f3n. Los pacientes con DRV/COBI representaron un 5,25% del total de pacientes VIH activos tratados con TAR en el mismo periodo de tiempo en nuestro hospital (N=1.562). Se excluy\u00f3 un paciente por no disponer de datos su\ufb01cientes para su posterior an\u00e1lisis y tres pacientes m\u00e1s por no cumplir los criterios de inclusi\u00f3n.\nEl 100% de los pacientes tuvo una CVP<50 copias/mL du -\nrante al menos 6 meses antes del cambio a DRV/r y cumpl\u00edan adem\u00e1s criterios seg\u00fan Gu\u00edas GESIDA\n1 para el cambio a una \nmonoterapia. Antes del cambio a DRV/COBI en monoterapia todos los pacientes ten\u00edan CVP indetectable.\nDe los 78 pacientes evaluados, el 73,08 % eran varones y \nla media de edad fue de 49,09 \u00b1 9,58 a\u00f1os. Los pacientes tu -\nvieron una mediana de 31,29 (6-74,82) meses de monoterapia con DRV/r previo a la monoterapia con DRV/COBI (teniendo en cuenta que nuestros registros inform\u00e1ticos comenzaron en el a\u00f1o 2008).\nEl 100% de los pacientes (N=78) tuvo al menos un r\u00e9gimen \nde TAR diferente previo al cambio a la monoterapia con DRV/r, el 55,13% (N=43) dos reg\u00edmenes de TAR previos y el 14,10% (N=11) tres reg\u00edmenes de TAR previos diferentes (tabla 1).\nEl esquema de TAR m\u00e1s utilizado fue 2 ITIAN+IP/r en to -\ndas las l\u00edneas de tratamiento, en concreto, la triple terapia con tenofovir+emtricitabina (TDF+FTC) y un tercer f\u00e1rmaco pacientes seleccionados se ha planteado como una alternati -\nva para evitar comorbilidades a largo plazo relacionada con el \nTAR, mejorar la satisfacci\u00f3n de los pacientes y la aumentar la adherencia, repercutiendo de forma directa en la efectividad de los tratamientos y disminuci\u00f3n de la aparici\u00f3n de resisten -\ncias\n6. \nEl objetivo de nuestro estudio es describir la efectividad \ny seguridad que supone el cambio de DRV/r en monoterapia a DRV/COBI en monoterapia en pacientes VIH pretratados en un hospital de tercer nivel.\nMATERIAL Y M\u00c9TODOS\nSelecci\u00f3n de pacientes y b\u00fasqueda de datos. Estu-\ndio observacional, prospectivo llevado a cabo en un hospital de tercer nivel. Criterios de inclusi\u00f3n: todos los pacientes VIH adultos (\u226518 a\u00f1os) pretratados con DRV/r y que cambiaron a un r\u00e9gimen de monoterapia con DRV/COBI. Periodo de inclu-si\u00f3n: Septiembre de 2015 a Noviembre de 2015 ambos inclu -\nsive. Periodo de seguimiento: septiembre de 2015 a mayo de 2016. Los pacientes deb\u00edan haber estado al menos 24 semanas en tratamiento con DRV/r en monoterapia. Se excluyeron del estudio aquellos pacientes de los que no se dispon\u00eda informa -\nci\u00f3n cl\u00ednica y/o anal\u00edtica su\ufb01ciente para su posterior an\u00e1lisis y aquellos que no hubieran tenido una l\u00ednea de tratamiento inmediatamente anterior con DRV/r en monoterapia. \nLa informaci\u00f3n se obtuvo de la base de datos AdvanCed \nHIV 2009 de la UGC de Enfermedades Infecciosas de nuestro hospital, de las historias cl\u00ednicas electr\u00f3nicas y de los registros de dispensaciones de los programas inform\u00e1ticos de pacientes externos (Cafydim\u00ae y ATHOS-Prisma\u00ae) del Servicio de Farmacia.\nVariables empleadas. Para la recogida de datos se elabo -\nr\u00f3 una base de datos en Excel que inclu\u00eda:\n1-. Variables demogr\u00e1\ufb01cas: edad y sexo.\n2-. Variables cl\u00ednicas. A distinguir: Tratamiento con DRV/r:\u00b7 Semanas de tratamiento con DRV/r previo al cambio.\u00b7 N\u00ba de l\u00edneas y esquemas de TAR diferentes utilizados \nprevio al cambio con DRV/r\n\u00b7 Respuesta virol\u00f3gica. Valores de CVP (copias/mL) jus-\nto antes del cambio.\n\u00b7 Respuesta inmunol\u00f3gica: Valores de linfocitos CD4 \n(c\u00e9lulas/\u00b5L) calculados por citometr\u00eda de \ufb02ujo antes del cambio. \n\u00b7 Per\ufb01l lip\u00eddico (colesterol, LDL-colesterol, HDL-coles -\nterol, triglic\u00e9ridos), hep\u00e1tico (GOT, GPT) y renal (creatinina y \n\ufb01ltrado glomerular).\nTratamiento con DRV/COBI:\n\u00b7 Respuesta virol\u00f3gica. Valores de CVP (copias/mL) tras \nel cambio. \n\u00b7 Respuesta inmunol\u00f3gica: Valores de linfocitos CD4 \n(c\u00e9lulas/\u00b5L) calculados por citometr\u00eda de \ufb02ujo tras el cambio.\n\u00b7 Per\ufb01l lip\u00eddico (colesterol, LDL-colesterol, HDL-coles -Monoterapia con darunavir/cobicistat. Experiencia en un hospital de tercer nivel L. Yunquera-Romero, et al.\nRev Esp Quimioter 2016;29(6): 308-317 311Tras el cambio a DRV/COBI, 9 de los 78 pacientes \n(11,53%) desarrollaron \u201cblips\u201d (\ufb01gura 2). La mediana de CVP \nde estos 9 pacientes fue de 101,5 copias/mL (53-151 copias/mL). El 44,44% de los pacientes (N=4) hab\u00eda presentado 1 \u201cblip\u201d anterior durante el tratamiento con otro esquema de TAR previo a la monoterapia con DRV/COBI. No existe un consenso respecto al tratamiento \u00f3ptimo de los pacientes con CVP detectable, pero con <200 copias/mL. Si el estu -\ndio genot\u00edpico no muestra MR, se recomienda mantener el mismo TAR, aunque el r\u00e9gimen ha de ser de alta barrera ge -\nn\u00e9tica, seg\u00fan las Gu\u00edas actuales de tratamiento de GESIDA\n1. \nEn nuestro estudio, el 33,34% (3/9) de los pacientes tuvo un cambio de tratamiento para asegurar la efectividad del TAR (tabla 3).\nPor otro lado, el 5,12% (4/78) de los pacientes tuvo de -\nterminaciones de CVP \u2265 200 copias/mL. Una CVP de entre \n200-1.000 copias/mL, se asocia a un mayor riesgo de FV y de selecci\u00f3n de MR. Se aconseja realizar una prueba de re -\nsistencia y elaborar una pauta de rescate teniendo en cuenta las MR, los FV previos, los problemas de adherencia, la to -\nxicidad, el riesgo de interacciones y la comodidad de los f\u00e1rmacos, seg\u00fan las Gu\u00edas GESIDA del a\u00f1o 2016\n1 (\ufb01gura 2). \nLas CVP de estos pacientes estuvieron comprendidas en -\ntre 200-43.210 copias/mL. En nuestro caso el 100% de los pacientes con CVP>200 copias/mL tuvo un cambio de tra -\ntamiento, por lo que no podemos asegurar si dichos pacien -\ntes hubieran tenido una segunda determinaci\u00f3n consecutiva de CVP>50 copias/mL. Los pacientes cambiaron a otro r\u00e9gimen de TAR: 2 pacientes cambiaron a un r\u00e9gimen de triple terapia con TDF+FTC+EVG/COBI, un paciente a lamivudina+abacavir+dolutegravir (3TC+ABC+DTG) y otro a 3TC+ABC+ DRV/COBI (tabla 4).\nA pesar de los \u201cblips\u201d y FV, un 83,3% (65/78) de los pacien -\ntes, se mantuvo con una CVP<37 copias/mL. \nCon respecto al nivel de linfocitos CD4, expresados en c\u00e9l/\n\u00b5L, la mediana durante el tratamiento con DRV/r fue de 691 (119-1.722) y de 671 (4-1.492) con DRV/COBI. \nAsimismo, analizamos el per\ufb01l lip\u00eddico, hep\u00e1tico y funci\u00f3n \nrenal de los pacientes previo y posterior al cambio. En cuanto al per\ufb01l lip\u00eddico, no hubo diferencias signi\ufb01cativas en los nive -\nles de colesterol, LDL colesterol, HDL colesterol y triglic\u00e9ridos durante el tratamiento con DRV/r y tras el cambio a DRV/COBI (\ufb01gura 3 y tabla 5). \nEn relaci\u00f3n a los valores de creatinina de los pacientes los \nvalores fueron de 0,92 \u00b1 0,64 mg/dL durante el tratamiento con DRV/r y de 1,05 \u00b1 0,70 mg/dL durante el tratamiento con DRV/COBI. Con respecto a la funci\u00f3n renal, la media del \ufb01ltrado glomerular estimado seg\u00fan la ecuaci\u00f3n CKD-EPI de pacientes tratados con DRV/r y DRV/COBI fue de 84,75 \u00b113,57 ml/min y de 79,65 \u00b1 16,05 ml/min respectivamente (\ufb01gura 4).\nPara el estudio de la funci\u00f3n hep\u00e1tica analizamos los ni -\nveles de transaminasas: GOT y GPT de los pacientes durante el tratamiento con DRV/r y con DRV/COBI. Se obtuvieron los siguientes valores: para GOT: 30,29 \u00b1 5,22 UI/L y 26,31 \u00b1 11,47 \nUI/L y para GPT de 34,76 \u00b1 37,44 UI/L y 35,97 \u00b1 20,26 respec-tivamente (\ufb01gura 5). ITIAN: Inhibidores de la transcriptasa an\u00e1logos de nucle\u00f3sidos/nucle\u00f3tidos, IP/r: Inhibi-\ndores de la proteasa potenciados con ritonavir; ITINN: Inhibidor transcriptasa inversa no nucle\u00f3sido; INI: Inhibidores de la integrasa; ICCR5: Antagonista del correceptor CCR5;Esquemas de TAR previos a DRV/r 1 TAR previo 2 TAR previos 3 TAR previos \n2 ITIAN+ IP/r 44 22 5\n2 ITIAN+ ITINN 19 6 1\nITIAN+ IP/r + INI 6 2 1\n2 ITIAN + INI 1 1 0\nIP/r monoterapia 2 7 1\nICCR5 +INI+ IP/r 2 0 0\nINI + IP/r 2 2 1\n2 ITIAN+ IP/r + INI 1 0 0\nITIAN+ IP/r 1 2 0\nICCR5+ IP/r 0 0 1\nITINN + INI 0 0 1\nITINN+INI+IP/r  1  \nTOTAL PACIENTES 78 43 11Tabla 1  N\u00famero de esquemas de TAR previos a la \nmonoterapia con DRV/r.\nTDF: tenofovir; FTC: emtricitabina; RPV: rilpivirina; NVP: nevirapina; LPV/r: lopi-\nnavir/ritonavir; FPV/r: fosamprenavir/ritonavir; EFV: efavirenz; ATV/r: atazanavir/ritonavir; ETR: etravirina; Tabla 2  N\u00famero de esquemas con TDF+FTC+ 3\u00ba \nf\u00e1rmaco previos a la monoterapia con DRV/r.\nTDF+FTC+ 3\u00ba f\u00e1rmaco 1\u00aa l\u00ednea TAR 2\u00aa l\u00ednea TAR 3\u00aa l\u00ednea TAR\nTDF+FTC+RPV 1  1\nTDF+FTC+NVP 4   \nTDF+FTC+LPV/r 11 4  \nTDF+FTC+FPV/r 6   \nTDF+FTC+EFV 9 1  \nTDF+FTC+DRV/r 7 10 1\nTDF+FTC+ATV/r 5  1\nTDF+FTC+ETR  2  \nTDF+FTC+FPV/r  2  \nTOTAL PACIENTES 43 19 3\n(tabla 2).\nPodemos ver los esquemas de TAR inmediatamente ante-\nrior al cambio a la monoterapia con DRV/r en la \ufb01gura 1.\nLa mediana de tiempo de tratamiento con DRV/COBI fue \nde 7,93 (6-9,61) meses. La primera anal\u00edtica de control tras el cambio a DRV/COBI se obtuvo a las 24 semanas del cambio.Monoterapia con darunavir/cobicistat. Experiencia en un hospital de tercer nivel L. Yunquera-Romero, et al.\nRev Esp Quimioter 2016;29(6): 308-317 312opci\u00f3n de tratamiento en pacientes con CV suprimida durante \nal menos los 6 \u00faltimos meses, sin mutaciones de resistencia a IP/r y ausencia de infecci\u00f3n cr\u00f3nica por VHB. La monoterapia con DRV/r o LPV/r puede representar una opci\u00f3n de tratamien -\nto en personas con intolerancia a los ITIAN, como simpli\ufb01ca -\nci\u00f3n de tratamiento o en pacientes consumidores de drogas il\u00edcitas y con frecuentes interrupciones del TAR. \u00c9sta, se aso -\ncia con mayores rebrotes virol\u00f3gicos que la terapia triple, sin embargo, las resistencias rara vez ocurren y la re-supresi\u00f3n se puede volver a conseguir con la reintroducci\u00f3n de ITIAN. En las recomendaciones de las gu\u00edas GESIDA\n1 del a\u00f1o 2016 con -\nsideran que no existe evidencia su\ufb01ciente para recomendar el cambio proactivo a monoterapia con DRV/r o LPV/r en los pa-En cuanto al coste, el cambio de DRV/r a DRV/COBI, no \nsupuso un incremento del gasto por paciente, puesto que am -\nbos eran equiparables en cuanto a coste en nuestro hospital. El \nestudio no revel\u00f3 diferencias en la adherencia al tratamiento: 94 \u00b1 7,96% para el tratamiento DRV/r antes del cambio y 94 \u00b1 7,40% para DRV/COBI. \nDISCUSI\u00d3N\nLa monoterapia con IP/r no representa el gold est\u00e1ndar \ndel TAR actual, pero est\u00e1 incluido en algunas gu\u00edas de trata -\nmiento como la European AIDS Clinical Society (EACS)3, como Figura 1  Esquemas de TAR inmediatamente anterior al cambio a la monoterapia \ncon DRV/r.\nTDF: tenofovir; FTC: emtricitabina; DRV: darunavir; COBI: cobicistat; DTG: dolutegravir; ABC: abacavir; 3TC: lamivudina. Tabla 3  Pacientes con \u201cblips\u201d tras el cambio a DRV/COBI. Niveles de CVP y CD4 antes y tras el cambio a DRV/COBI.\nPACIENTEN\u00ba de \u201dblips\u201d \nprevios a DRV/COBICVP con DRV/r\n(copias/mL)CD4 con DRV/r\n(c\u00e9lulas/\u00b5L)CV con DRV/COBI\n(copias/mL)CD4 con DRV/COBI\n(c\u00e9lulas/\u00b5L)CAMBIO DE TAR\n1 1 <37 1.204 151,3 1.469\n2 1 <37 1.001 101 1.381\n3 no <37 469 65 454\n4 no <37 644 101,5 817\n5 1 <37 386 119,7 4 TDF+FTC+DRV/COBI\n6 no <37 1.100 104 1.120 DTG+DRV/r\n7 no <37 1.145 110,6 963\n8 1 <37 894 80 534\n9 no <37 691 53,34 562 ABC+3TC+DRV/COBIMonoterapia con darunavir/cobicistat. Experiencia en un hospital de tercer nivel L. Yunquera-Romero, et al.\nRev Esp Quimioter 2016;29(6): 308-317 313narch10 y PROTEA11; de LPV/r: OK Pilot, OK-04, KalMo, KALE -\nSOLO, KRETA, MOST y DREAM; de ATV/r: MODAT o de los tres: \nPIVOT. Los autores concluyen que en pacientes con CV supri -\nmida basal, la monoterapia con IP/r estuvo asociada con ma -\nyores elevaciones de RNA del VIH vs terapia triple. A pesar de esto, la mayor\u00eda de pacientes con elevaciones del RNA del VIH en las ramas de monoterapia con IP/r mostraron re-supresi\u00f3n tras la intensi\ufb01caci\u00f3n con ITIAN y en el an\u00e1lisis \u201c switch inclu-\nded\u201d (intercambio incluido), siendo la e\ufb01cacia de la monotera -\npia comparable a la de la terapia triple. Destacan, sin embargo, importantes limitaciones al tratarse de estudios abiertos y sin rama de placebo. Los an\u00e1lisis puros por intenci\u00f3n de tratar (ITT) o \u201cswicth included\u201d fueron interpretados de manera diferente \nen los distintos estudios. El seguimiento a largo plazo tras el cambio de medicaci\u00f3n es importante en este punto. Los resul -cientes que cumplan los criterios para el uso de esta estrategia. \nSin embargo, el panel considera que tampoco existen eviden -\ncias para oponerse al uso de monoterapia con DRV/r o LPV/r si el cl\u00ednico quiere evitar o prevenir los efectos adversos causados por los ITIAN. Los factores que predicen el \u00e9xito de la monote-rapia son: adherencia elevada, supresi\u00f3n virol\u00f3gica prolonga -\nda y profunda y cifra nadir de linfocitos CD4>100 c\u00e9lulas/\u00b5L. Sit\u00faan a la monoterapia en categor\u00eda B-I (DRV/r o LPV/r). La monoterapia con IP/r, sin embargo, no est\u00e1 recomendada en otras gu\u00edas de tratamiento\n2,15,16.\nRecientemente se ha publicado un meta-an\u00e1lisis17 acerca \nde la e\ufb01cacia de los IP/r en monoterapia vs. terapia triple en donde se incluyeron 2.303 pacientes de 13 ensayos cl\u00ednicos aleatorizados diferentes; de DRV/r: MONET\n8, MONOI9,18, Mo-Figura 2  Valores de carga viral (copias/mL) previo y posteriores al cambio con DRV/\nCOBI.\nEn el eje de ordenadas se representa la carga viral plasm\u00e1tica (CVP) y en el eje de abscisas el n\u00famero de pacientes analizados. La \nl\u00ednea azul representa la carga viral plasm\u00e1tica de los pacientes durante el tratamiento con DRV/r y la l\u00ednea naranja la carga viral plasm\u00e1tica de los mismos pacientes una vez que modificaron tratamiento a DRV/COBI\n3TC: lamivudina; ABC: abacavir; DTG: dolutegravir; DRV: darunavir; COBI: cobicistat; TDF: tenofovir; FTC: emtricitabina; EVG: elvitegravir, COBI: cobicistat. Tabla 4  Pacientes con CV\u2265200 copias/mL tras el cambio a DRV/COBI. Niveles de CVP y CD4 antes y \ntras el cambio.\nPACIENTEN\u00ba de \u201cblips\u201d  \nprevios a DRV/\nCOBICVP con DRV/r\n(copias/mL)CD4 con DRV/R\n(c\u00e9lulas/\u00b5L)CV con DRV/COBI\n(copias/mL)CD4 con DRV/COBI\n(c\u00e9lulas/\u00b5L)CAMBIO DE TRATAMIENTO\n1 1 <37 784 43.210 479 3TC+ABC+DTG\n2 no <37 364 200 224 3TC+ABC+DRV/COBI\n3 no <37 897 1.039 710 TDF+FTC+EVG/COBI\n4 1 <37 846 410,2 889 TDF+FTC+EVG/COBIMonoterapia con darunavir/cobicistat. Experiencia en un hospital de tercer nivel L. Yunquera-Romero, et al.\nRev Esp Quimioter 2016;29(6): 308-317 314estudios, publicado en 2016, \nel PROTEA11, se trata de un \nestudio fase 3b, aleatoriza -\ndo abierto y controlado pa -\nra evaluar la e\ufb01cacia y segu -\nridad de la monoterapia con DRV/r como alternativa a la terapia triple. El porcentaje de pacientes con RNA-VIH <50 copias/mL fue inferior en la rama de DRV/r en mo-noterapia vs. terapia triple 75,2% vs 85,3% (RAR 10,1% IC95% -19,5%-0,7%). Sin embargo, en el an\u00e1lisis de los datos \u201cswitch included\u201d en el que la reintroducci\u00f3n de los ITIAN estaba permi-tida se demostr\u00f3 que DRV/r era no inferior a la terapia triple. Estos hallazgos, est\u00e1n en consonancia con el me-ta-an\u00e1lisis de Arribas et al\n17, \nen el que se constataba que \nhab\u00eda repuntes virol\u00f3gicos en las ramas de monoterapia con IP/r, sin embargo este rebrote desaparec\u00eda cuando se introdu -\nc\u00eda la intensi\ufb01caci\u00f3n con ITIAN. \nLa monoterapia con DRV/r o con LPV/r no ha demostrado \na largo plazo la no-inferioridad frente a la terapia triple en los an\u00e1lisis por ITT si se considera el cambio de terapia aleatori -\nzada igual a fracaso\n1. La no-inferioridad s\u00ed se ha demostrado \nen los an\u00e1lisis por ITT puros o \u201c switch included\u201d (ignorando los \ncambios de tratamiento, fundamentalmente las reinducciones con ITIAN). No existe acuerdo sobre cu\u00e1l de estos an\u00e1lisis es m\u00e1s relevante cl\u00ednicamente\n1. \nEn pacientes tratados con monoterapia con DRV/r o LPV/r \ncon seguimiento virol\u00f3gico adecuado no se ha demostrado un incremento en el riesgo de selecci\u00f3n de MR a la proteasa. Comparada con la TAR triple, la monoterapia con DRV/r o LPV/r no ha demostrado bene\ufb01cios a largo plazo aparte del ahorro econ\u00f3mico. Sin embargo, tampoco hay datos emp\u00edricos que justi\ufb01quen que si un paciente es capaz de mantener la supre -\nsi\u00f3n virol\u00f3gica con DRV/r o LPV/r en monoterapia sea necesa -\nrio utilizar adem\u00e1s dos ITIAN\n1. \nEn junio de 2015 se comercializa en Espa\u00f1a DRV/COBI co-\nformulado. Es una combinaci\u00f3n de dosis \ufb01jas de DRV y COBI que act\u00faa como potenciador farmacocin\u00e9tico. Hasta la fecha de aparici\u00f3n de COBI, DRV se utilizaba en combinaci\u00f3n con RTV, utilizado como potenciador, a dosis bajas. Cuando RTV se utiliza a estas dosis, existe el riesgo potencial de que el virus VIH-1 desarrolle mecanismos de resistencia al ser un f\u00e1rmaco con actividad antirretroviral\n5. Por lo general, las mutaciones acu -\nmuladas asociadas con la resistencia a RTV, pueden disminuir la susceptibilidad a otros inhibidores de proteasa debido a la resistencia cruzada. COBI, por el contrario, no tiene actividad antiviral\n12.tados del estudio PIVOT19,20 no se incluyeron en el an\u00e1lisis de \ne\ufb01cacia debido a que los datos se presentaron en curvas de \nKaplan-Meier, lo cual no era compatible con los an\u00e1lisis del resto de estudios. Seg\u00fan este estudio, la monoterapia con IP/r con monitorizaci\u00f3n regular de la CV y r\u00e1pida reintroducci\u00f3n de triple terapia si hay rebrote viral, preserva futuras opciones de tratamiento sin cambiar variables cl\u00ednicas \ufb01nales o frecuencia de aparici\u00f3n de efectos adversos, considerando la monoterapia con IP/r una alternativa aceptable para el manejo cl\u00ednico de VIH a largo plazo. \nCentr\u00e1ndonos en los ensayos cl\u00ednicos llevados a cabo con \nDRV/r, se evaluaron 4 estudios que englobaban 784 pacientes: MONET, MONOI, Monarch y PROTEA. En todos ellos se estudi\u00f3 la monoterapia con DRV/r vs. 2 ITIAN+DRV/r. Para la variable principal de e\ufb01cacia que fue la CV indetectable a la semana 48 se llev\u00f3 a cabo un seguimiento de 144, 96, 48 y 96 semanas respectivamente en cada uno de los estudios. El \u00faltimo de los Figura 3  Perfil lip\u00eddico previo y posteriores al cambio con DRV/COBI.\nEn el eje de ordenadas se representa concentraci\u00f3n plasm\u00e1tica en mg/dl. Las columnas azules corresponden a los pacientes tra-\ntados con DRV/r antes del cambio de tratamiento y las columnas marrones representan los perfiles l\u00edpidos posterior al cambio de tratamiento.\nPERFIL LIP\u00cdDICO DRV/r DRV/COBI\nColesterol (mg/dL) 194 \u00b1 13 194 \u00b1 14\nLDL (mg/dL) 123 \u00b1 6 120 \u00b1 1,5\nHDL (mg/dL) 49 \u00b1 14 49 \u00b1 19 \nTriglic\u00e9ridos (mg/dL) 150 \u00b1 77 136 \u00b1 68Tabla 5  Valores de colesterol, LDL, \nHDL y triglic\u00e9ridos antes y despu\u00e9s del cambio a DRV/COBI (expresados como media \u00b1 desviaci\u00f3n est\u00e1ndar).Monoterapia con darunavir/cobicistat. Experiencia en un hospital de tercer nivel L. Yunquera-Romero, et al.\nRev Esp Quimioter 2016;29(6): 308-317 315fueron los acontecimientos \nadversos y las pruebas de laboratorio cl\u00ednico a las 24 semanas de tratamiento. Se explor\u00f3 la farmacocin\u00e9tica poblacional de DVR y COBI y el an\u00e1lisis del desarrollo de resistencia genot\u00edpica y fenot\u00edpica en sujetos que experimentan fracaso viro-l\u00f3gico. La respuesta virol\u00f3 -\ngica a la semana 24 y 48 se logr\u00f3 en el 83% y 82,7% de los sujetos sin tratamiento previo respectivamente y en el 50% de los sujetos con TAR previo. \nEl estudio ARTEMIS es \nun estudio aleatorizado, controlado y abierto, para comparar la e\ufb01cacia, seguri -\ndad y tolerabilidad de DVR/r en comparaci\u00f3n con LPV/r, en pacientes \u201cnaive\u201d con CV\u2265 5.000 copias/mL. En los dos grupos se administr\u00f3 un r\u00e9gimen de dosis \ufb01ja de TDF/FTC una vez al d\u00eda.\nLos resultados de e\ufb01ca -\ncia obtenidos en los ensayos GS-US-216-130 y ARTEMIS a la semana 48 son simila -\nres: 82,7 % vs 83,7% respec-tivamente. Entre los pacien -\ntes pretratados, con fracaso previo, no resulta adecuado hacer esta comparaci\u00f3n de-bido al escaso n\u00famero de pacientes del ensayo GS-US-216-130 (N=18). \nEl estudio GS-\nUS-216-130 es el \u00fanico ensayo pivotal empleado para la aprobaci\u00f3n de un f\u00e1rmaco con una metodolo-g\u00eda de ensayo cl\u00ednico abierto \nde una sola rama de tratamiento. Esta metodolog\u00eda presenta muchas limitaciones para realizar una valoraci\u00f3n y posiciona -\nmiento con los f\u00e1rmacos empleados para la misma patolog\u00eda. No se dispone de estudios cl\u00ednicos que comparen DRV/COBI con DRV/r o cualquier otro esquema de tratamiento. \nPor todo esto, a pesar de que el tratamiento con DRV/\nCOBI en monoterapia no aparece re\ufb02ejado en las principales gu\u00edas de tratamiento, en nuestro estudio todos los pacientes que se encontraban en tratamiento con DRV/r en monoterapia Figura 4  Valores de filtrado glomerular (ml/min) previo y posteriores al cambio con DRV/COBI.\nEn el eje de abscisas se representa el filtrado glomerular estimado de pacientes tratados con DRV/r y en el de ordenadas se repre-\nsenta el filtrado glomerular una vez que se tratan con DRV/COBI\nFigura 5  Niveles de transaminasas antes y despu\u00e9s del cambio a DRV/COBI.\nEn el eje de ordenadas se representan los niveles de las transaminasas en UI/L y en el eje de abscisas las transaminasas (GOT y GPT) analizadas de los pacientes durante los tratamientos con DRV/r y DRV/COBI.\nLa e\ufb01cacia de DRV/COBI se basa en el an\u00e1lisis de los datos a \nlas 48 semanas obtenidas a partir del estudio GS-US-216-13012 \ny los ensayos ARTEMIS6 y ODIN7dos ensayos fase III de sopor-\nte. El primero, es un estudio de fase III, multic\u00e9ntrico realizado \ncon un \u00fanico brazo y en r\u00e9gimen abierto para evaluar la far-macocin\u00e9tica, seguridad, tolerabilidad, y e\ufb01cacia de DRV/COBI m\u00e1s 2 ITIAN en 313 pacientes adultos infectados por el VIH-1. La variable principal de e\ufb01cacia fue la proporci\u00f3n de pacien-tes que alcanzaron una carga de ARN del VIH-1 <50 copias/mL en la semana 24 y 48, y el objetivo primario de seguridad Monoterapia con darunavir/cobicistat. Experiencia en un hospital de tercer nivel L. Yunquera-Romero, et al.\nRev Esp Quimioter 2016;29(6): 308-317 316cambiaron a DRV/COBI en monoterapia, simpli\ufb01c\u00e1ndose as\u00ed la \npauta posol\u00f3gica de dos comprimidos a uno lo que podr\u00eda es -\ntar relacionado con una mejora de la calidad de vida en estos pacientes y un aumento de la adherencia con la consiguiente mejora del control del VIH.\nEn nuestro estudio, todos los pacientes hab\u00edan sido pre -\nviamente tratados con DRV/r en monoterapia, ten\u00edan CV<37 copias/mL y no presentaban mutaciones de resistencia a IP. \nNo obstante, no todos los pacientes mantuvieron CV in -\ndetectables tras el cambio a DRV/COBI: 9 pacientes presen -\ntaron \u201cblips\u201d y 4 pacientes FV. Los \u201cblips\u201d aislados no tienen repercusi\u00f3n cl\u00ednica. Sin embargo, los \u201cblips\u201d frecuentes se han asociado a mayor riesgo de FV y aparici\u00f3n de MR. En presencia de \u201cblips\u201d, se recomienda evaluar la adherencia y la barrera ge -\nn\u00e9tica del TAR. De los pacientes con \u201cblips\u201d, en un 55,5% (5/9) observamos que ten\u00edan una adherencia al tratamiento <90%, pero igual a la que ten\u00edan cuando se trataban con DRV/r y te -\nn\u00edan CV <37 copias/mL, por lo que este hecho no explicar\u00eda este repunte virol\u00f3gico. No disponemos de los estudios de re-sistencias de los pacientes con FV, pero si sabemos que cuando estaban con DRV/r no presentaban MR a IP/r. \nA pesar de ello, un 83,3% (65/78) de los pacientes, se \nmantienen con CV<37 copias/mL, lo que ha permitido sim -\npli\ufb01car su tratamiento antirretroviral a un \u00fanico comprimido diario con la comodidad que esto representa para el paciente sin perder efectividad. Estos resultados est\u00e1n en consonancia con los obtenidos en otros estudios donde se ha estudiado la monoterapia con IP/r.\nCOBI tiene como especial peculiaridad inhibir a nivel renal \ntransportadores de cationes org\u00e1nicos tubulares MATE 1 y en este caso, lo mismo que RTV, aniones org\u00e1nicos, lo que se tra -\nduce en una reducci\u00f3n de la secreci\u00f3n tubular de creatinina y por lo tanto en un incremento en torno al 15% de los valores de creatinina plasm\u00e1tica. Esto, sin embargo, no tiene por qu\u00e9 traducirse en una alteraci\u00f3n del FG\n20. En nuestro estudio, sin \nembargo, se observ\u00f3 un ligero descenso en mil/min del \ufb01ltrado glomerular estimado durante el tratamiento con DRV/COBI. En el resto de par\u00e1metros de seguridad (per\ufb01l lip\u00eddico y hep\u00e1tico) DRV/COBI resulta ser similar a DRV/r.\nLos FV podr\u00edan estar relacionados con las caracter\u00edsticas \nfarmacocin\u00e9ticas de los f\u00e1rmacos potenciadores cobicistat y ritonavir. Los estudios farmacocin\u00e9ticos de DRV/COBI han de -\nmostrado que hay una clara y repetida bioequivalencia demos -\ntrada en C\nmax y el AUC entre DRV/COBI y DRV/r, pero el par\u00e1 -\nmetro de Cmin/C0h no ha llegado a demostrar la bioequivalencia \nseg\u00fan los criterios prede\ufb01nidos por los investigadores en los estudios entre DRV/COBI y DRV/r \n21.\nLambert-Niclot et al22 intentan explicar los factores asocia-\ndos con el fallo a la monoterapia con DRV/r. Concluyen diciendo que el riesgo de FV es mayor con la monoterapia con DRV/r que con la triple terapia, por lo que los pacientes han de ser seleccio -\nnados cuidadosamente. Los mejores candidatos a recibir mono-terapia con DRV/r ser\u00edan: pacientes con excelente adherencia y niveles de RNA-VIH <50 copias/mL. El riesgo de fracaso virol\u00f3 -\ngico resultar\u00eda menor entre los pacientes con reg\u00edmenes de TAR largos que hayan logrado la supresi\u00f3n virol\u00f3gica antes de pasar \na un r\u00e9gimen de monoterapia. Los TAR de larga duraci\u00f3n en los pacientes podr\u00edan resultar en niveles de viremia residual meno -\nres y menores niveles de DNA-VIH pro viral. \nRecientemente se ha publicado un estudio retrospectivo \npor L\u00f3pez-Cort\u00e9s et al\n23. Analizaron el cambio de tratamien-\nto de triple terapia a monoterapia con DRV/r o LPV/r en 1.060 pacientes VIH adultos con CV indetectable, incluyendo 205 pa -\ncientes con FV previo en reg\u00edmenes con monoterapia con IP. La variable principal de e\ufb01cacia fue el porcentaje de pacientes con CV suprimida despu\u00e9s de 96 semanas en un an\u00e1lisis por intenci\u00f3n de tratar (datos no completos/perdidas=fallos). A la semana 96 la variable principal de e\ufb01cacia fue 79,3% (IC95% 76,8-81,8). No hubo relaci\u00f3n entre los FV previos y FV tem -\npranos en reg\u00edmenes basados en IP, la presencia de mutacio -\nnes a IP mayores o menores, tiempo previo con supresi\u00f3n vi -\nral, recuento de CD4 nadir y coinfecci\u00f3n con VHC. El cambio a monoterapia con IP/r logr\u00f3 un control virol\u00f3gico de manera sostenida en la mayor\u00eda de pacientes, incluso en aquellos con FV previo en reg\u00edmenes con IP siempre y cuando no hubiera presentes mutaciones mayores de resistencia para el f\u00e1rmaco administrado.\nPor todo ello, a la vista de nuestros resultados, DRV/COBI \nen monoterapia, parece ser efectivo y seguro (per\ufb01l lip\u00eddico, hep\u00e1tico y renal). La principales limitaciones de nuestro estu -\ndio son, por un lado, el peque\u00f1o tama\u00f1o muestral, como para poder extraer conclusiones \ufb01ables en cuanto a qu\u00e9 r\u00e9gimen de monoterapia es el m\u00e1s e\ufb01caz y por otra, que se trata de un estudio observacional, por lo que deber\u00edan dise\u00f1arse estudios m\u00e1s espec\u00ed\ufb01cos que comparasen DRV/r vs. DRV/COBI en mono -\nterapia para comprobar estos resultados. \nAGRADECIMIENTOS\nAl servicio de Enfermedades Infecciosas del Hospital Re -\ngional Universitario de M\u00e1laga por la cesi\u00f3n de parte de los datos cl\u00ednicos para la realizaci\u00f3n de este estudio. \nFINANCIACI\u00d3N\nLos autores declaran no haber recibido \ufb01nanciaci\u00f3n para la \nrealizaci\u00f3n de este estudio. \nCONFLICTO DE INTER\u00c9S\nLos autores declaran no tener ning\u00fan con\ufb02icto de inte-\nreses. \nBIBLIOGRAF\u00cdA\n1. AIDS Study Group (GESIDA) of the Spanish Society of Infectious \nDiseases, Clinical Microbiology, the National AIDS Plan. Executive summary of the GESIDA/National AIDS Plan Consensus Document on Antiretroviral Therapy in Adults Infected by the Human Immu -\nnode\ufb01ciency Virus (Updated January 2016). Enferm Infecc Micro -\nbiol Clin. 2016;34(7):439-51-Monoterapia con darunavir/cobicistat. Experiencia en un hospital de tercer nivel L. Yunquera-Romero, et al.\nRev Esp Quimioter 2016;29(6): 308-317 3172. US Department of Health and Human Services Panel on Antiretroviral \nGuidelines or Adults and Adolescents. Guidelines for the use of an -\ntiretroviral agents in HIV-1- infected adults and adolescents (2016). [Acceso Junio 2016]. Disponible en: http:// aidsinfo.nih.gov/guidelines \n3. European AIDS Clinical Society (EACS) Guidelines. Clinical manage-ment and treatment of HIV infected adults in Europe, version 8.0 (2015). [Acceso Junio 2016]. Disponible en: http://www.eacsociety.\norg/guidelines/eacs-guidelines/eacs-guidelines.html.\n4. Kakuda TN, Brochot A, Tomaka FL, Vangeneugden T, Van De Caste-\nele T, Hoetelmans RM. Pharmacokinetics and pharmacodynamics \nof boosted once-daily darunavir. J Antimicrob Chemother 2014; 69: 2591\u2013605.\n5. Putcharoen O, Do T, Avhingsanon A, Ruxrungtham K. Rationale \nand clinical utility of the darunavir\u2013cobicistat combination in the treatment of HIV/AIDS. Drug Des, Devel Ther 2015; 23(9): 5763\u20139.\n6. Orkin C, DeJesus E, Khanlou H, Stoehr A, Supparatpinyo K, Lathou-wers E, et al. Final 192-week ef\ufb01cacy and safety of once-daily da-runavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infec -\nted treatment-na\u00efve patients in the ARTEMIS trial. HIV Med. 2013; 14(1):49-59. \n7. Cahn P, Fourie J, Grinsztejn B, Hodder S, Molina JM, Ruxrungtham K, et al. Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients. AIDS. 2011; 25(7):929-39. \n8. Arribas JR, Clumeck N, Nelson M, Hill A, van Delft Y, MoecklinghoffC.The MONET trial: week 144 analysis of the ef\ufb01cacy of darunavir/rito -\nnavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline. HIV Med. 2012; 13(7):398-405. \n9. Valantin MA, Lambert-Niclot S, Flandre P, Morand-Joubert L, Cabi\u00e8 A, Meynard JL, et al .MONOI ANRS 136 Study Group. Long-term ef\ufb01cacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 stu -\ndy. J Antimicrob Chemother. 2012; 67(3):691-5.\n10. Guaraldi G, Zona S, Cossarizza A, Vernacotola L, Carli F, LattanziA et al. Switching to darunavir/ritonavir monotherapy vs. triple-therapy on body fat redistribution and bone mass in HIV-infected adults: the Monarch randomized controlled trial.Int J STD AIDS. 2014; \n25(3):207-12.\n11. Girard PM, Antinori A, Arribas JR, Ripamonti D, Bicer C, Netzle-Sveine B et al. Week 96 ef\ufb01cacy and safety of darunavir/ritonavir monotherapy vs. darunavir/ritonavir with two nucleoside reverse transcriptase inhibitors in the PROTEA trial.HIV Med. 2016. In press.\n12. Tashima K, Crofoot G, Tomaka FL, Kakuda TN, Brochot A, Van de \nCasteele T, et al. Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial. AIDS Res Ther. 2014; 11:39.\n13. Gathe J, Arribas JR, Van Lunzen J , Garner W, Speck RM, Bender R, et al. \nPatient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to CoformulatedElvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Em -\ntricitabine and Tenofovir DF. Patient. 2015; 8(5):445-54.14. Arribas JR, Pialoux G, Gathe J, Di Perri G, Reynes J, Tebas P, et al. \nSimpli\ufb01cation to coformulated elvitegravir, cobicistat, emtrici -\ntabine, and tenofovir versus continuation of ritonavir-boosted \nprotease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial. Lancet In-fect Dis. 2014; 14(7):581-9.\n15. British HIV Association guidelines for the treatment of HIV-1-po -\nsitive adults with antiretroviral therapy 2015. (acceso 19/06/2016). Disponible en: http://www.bhiva.org/HIV-1-treatment-guidelines.\naspx.  \n16. G\u00fcnthard HF, Aberg JA, Eron JJ, Hoy JF, Telenti A, Benson CA et al. \nAntiretroviral Treatment of Adult HIV Infection. 2014 Recommen -\ndations of the International AIDS Society\u2013USA Panel. JAMA 2014; 312 (4): 410\u201325.\n17. Arribas JR, Girard PM, Paton N, Winston A, Marcelin AG, Elbirt D et al. Ef\ufb01cacy of protease inhibitor monotherapyvs triple therapy: meta-analysis of data from 2303 in 13 randomized trials. HIV Me -\ndicine 2016; 17(5): 358-67. \n18. Katlama C, Valantin MA, Algarte-Genin M, Duvivier C, Lambert-Ni -\nclot S, Girard PM et al. Ef\ufb01cacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral supression: a randomi -\nzed open-label, non inferiority trial. MONOI ARS 136. AIDS 2010; 24(15): 2365-74. \n19. Paton NI, St\u00f6hr W, Arenas-Pinto A, Fisher M, Williams I, Johnson M \net al. Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-infe -\nriority trial. Lancet HIV. 2015; 2(10):e417-26.\n20. Paton NI, St\u00f6hr W, Oddershede L, Arenas-Pinto A, Walker S, Scul -\npher M, et al. The Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) trial: a randomised controlled trial of a pro -\ntease inhibitor monotherapy strategy for long-term management of human immunode\ufb01ciency virus infection. Health Technol Assess 2016; 20 (21).\n21. Blanco JL. Darunavir como tratamiento de inicio de la infecci\u00f3n por el virus de la inmunode\ufb01ciencia humana y como estrategia de cambio no motivado por fracaso. Enferm Infecc Microbiol Clin 2016; 34 (Extraordinario 1): 3-11. \n22. Lambert-Niclot S, Fladre P, Valantin MA, Peytavin G, Duvivier C, Haim-Boukobza S et al. Factors associated with virological failure in HIV-1-Infected patients receiving Darunavir/ritonavir monothe -\nrapy. J Infect Dis 2011; 204: 1211-6.\n23. L\u00f3pez-Cort\u00e9s LF, Casta\u00f1o MA, L\u00f3pez-Ruz M, Rios-Villegas MJ, Hern\u00e1ndez-Quero M, Merino D et al. Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Re -\ngimens. PLoS ONE 2016; 11(2):e0148924. doi:10.1371/journal.po -\nne.0148924. Rev Esp Quimioter 2016;29(6): 318-327 318Cuestiones claves en la atenci\u00f3n del paciente \ninfectado en Urgencias\nRESUMEN\nObjetivo. Elaborar un conjunto de recomendaciones ba-\nsadas en la opini\u00f3n de expertos en medicina de urgencias so -\nbre aspectos claves relacionados con la atenci\u00f3n del paciente \ncon sospecha de infecci\u00f3n en los servicios de urgencias.\nMetodolog\u00eda. El estudio se desarroll\u00f3 en tres fases:  1) \nDise\u00f1o de un cuestionario por un grupo coordinador; 2) Rea -\nlizaci\u00f3n de una encuesta para conocer la opini\u00f3n de los profe -\nsionales en urgencias y emergencias sobre las cuestiones for -\nmuladas por el grupo coordinador; 3) Elaboraci\u00f3n de una serie de recomendaciones basadas en las respuestas al cuestionario y su posterior discusi\u00f3n. \nResultados. Un grupo de 28 expertos procedentes de dis -\ntintos servicio de urgencias hospitalarios espa\u00f1oles, as\u00ed como 5 miembros del grupo coordinador,  formado por m\u00e9dicos con experiencia en urgencias y patolog\u00eda infecciosa, realizaron una ronda de votaci\u00f3n a un cuestionario de 18 preguntas clasi\ufb01ca-das en tres bloques: identi\ufb01caci\u00f3n y estrati\ufb01caci\u00f3n del pacien -\nte infectado, diagn\u00f3stico y tratamiento, y gesti\u00f3n hospitalaria. \nConclusiones. Para garantizar una atenci\u00f3n adecuada y \ne\ufb01caz de estos pacientes se requiere una atenci\u00f3n estructu -\nrada y un entrenamiento adecuado de todo el equipo sanita -\nrio, as\u00ed como un amplio conocimiento en estos temas. Resulta fundamental educar y concienciar a todo el personal sanitario especialmente en los servicios de urgencias, punto de contacto inicial de la mayor\u00eda de los pacientes que padecen una infec -\nci\u00f3n. En base a las preguntas y su discusi\u00f3n, se consensuaron una serie de propuestas. \nPalabras clave: Infecci\u00f3n. Sepsis. Urgencias. Identi\ufb01caci\u00f3n precoz. ABSTRACT\nObjective. To develop a set of recommendations, by con -\nsensus of Emergency Medicine experts, on key aspects related to the care of adult patients with acute infection attended in Spanish emergency departments (ED).\nMethodology. The study was divided into three phases: 1) \nTo design a questionnaire by a coordinating group; 2) To con -\nduct a survey in ED physicians in order to know their opinion on the issues raised by the coordinating group; 3) To develop a number of recommendations based on the responses to the questionnaire and their subsequent discussion.\nResults. A group of 28 experts from different Spanish ED, \nas well as 5 members of the coordinating group, with knowl -\nedge and experience in the management of infectious diseases in ED, conducted a round of voting to a questionnaire of 18 issues grouped into three sections: 1) identi\ufb01cation and strat -\ni\ufb01cation of the severity; 2) diagnosis and treatment; 3) man -\nagement.\nConclusions. A monitoring system and proper training of \nthe entire healthcare team are required, as well as extensive knowledge on these issues, to ensure adequate and effective care for these patients. It is essential to educate and train all health staff, especially in the ED, because it is the initial point of contact for most patients with an infection. The experts es -\ntablished proposals based on survey questions and the discus -\nsion.\nKey words: Infection, Sepsis, EmergencyKey issues in the infected patient care in the \nEmergency Department\n1Clinical Microbiology Department, Hospital Universitario Cl\u00ednico San Carlos, Madrid, Spain.\n2Emergency Depar tment, Hospital Universitario Cl\u00ednico San Carlos, Madrid, Spain.\n3Health Research Institute, Hospital Universitario Cl\u00ednico San Carlos, Madrid, Spain.\n4Internal Medicine Department, Hospital Universitario Cl\u00ednico San Carlos, Madrid, Spain.Flavia Chiarella1\nJuan Gonz\u00e1lez-Del Castillo2,3\nFrancisco Javier Candel1,3\nEric Jorge Garc\u00eda- \nLamberechts2,3\nMar\u00eda Jos\u00e9 N\u00fa\u00f1ez-Orantos4\nFrancisco Javier Mart\u00edn-S\u00e1nchez\n2,3\nrepresenting the Infectious Disease Group of Spanish Emergency Medicine Society (Addendum*).\nCorrespondence:\nJuan Gonz\u00e1lez del CastilloServicio de Urgencias. Hospital Universitario Cl\u00ednico San Carlos. Calle Profesor Mart\u00edn-Lagos s/n, 28040 Madrid.Phone: (34) 91.330.37.50Fax: (34) 91.330.35.69E-mail: jgonzalezcast@gmail.comOriginalKey issues in the infected patient care in the Emergency Department F. Chiarella, et al.\nRev Esp Quimioter 2016;29(6): 318-327 31918 questions in 3 speci\ufb01c blocks in relation to acute infection \nprocess in the EDs: 1) identi\ufb01cation and strati\ufb01cation of the severity; 2) diagnosis and treatment; 3) management. \nRegarding the second phase, a group of 28 experts of EM \nphysicians was formed, representing the vast majority of the Spanish Autonomous Communities, with knowledge and ex -\nperience in the management of infectious diseases in ED. An expert meeting took place in April 2016, in which the survey was conducted through a closed anonymized electronic sys-tem. Subsequently, an open discussion was held regarding the responses. \nConcerning the third phase, the coordinating group sum -\nmarized the survey results and the discussion in a manuscript. Once the document was drafted, it was sent to all the experts for discussion and all participants approved the \ufb01nal version.\nRESULTS \nTable 1 shows questions and results of the survey con -\nducted. \nBlock I. Identi\ufb01cation and Strati\ufb01cation of Severely \nInfected Patients\nWith regard to the \ufb01rst question, the majority of experts \nsaid that the most vulnerable patients, who face the highest probability of error in identifying the symptoms associated with suspected infection, are the older patients. In relation to the second question, 90.9% of the experts believed that the new criteria should not replace the current ones until further evidence for the strategies are established in each centre. For the third question about classical criteria for sepsis, most of the consulted specialists argued that the use of such criteria is still useful in medical care, while 24.2% thought that they lack utility. Concerning the fourth question, 97.0% of the ex -\nperts argued that it is necessary to adopt the sepsis code in EDs. Respect to triage systems, 60.6% af\ufb01rmed that they are insuf\ufb01cient for proper strati\ufb01cation of infected patients. Lastly, 75.8% of the respondents use lactate as the primary prognos -\ntic biomarker of 30-day mortality.INTRODUCTION\nInfectious diseases represent a major health problem in \nthe world. They are associated with increased morbidity and \nmortality in all health settings. In Spain, they are one of the main causes of admission and mortality and represent 15% of hospital emergencies attended\n1. It is important to highlight \nthat there has been an increase in the prevalence of infections in the last years. Also, there has been a change in the infected patient pro\ufb01le showing an increase of age, number of comor-bidities, and risk factors for multidrug-resistant microorganism (MDRO) and sepsis syndrome. \nThe new de\ufb01nitions of sepsis and septic shock re\ufb02ect the \nimportance of early recognition of patients with severe infec -\ntion. The criteria for systemic in\ufb02ammatory response syndrome (SIRS), although repeatedly challenged on its non-speci\ufb01city, may guide physicians to identify an infectious process in pro -\ngress. The concept of \u201csevere sepsis\u201d is no longer part of the new classi\ufb01cation. Hypotension and serum lactate levels above 2 mmol/dl support the new criteria for septic shock, re\ufb02ect -\ning metabolic and cellular abnormalities of sepsis\n2. The early \nprescription of antibiotic treatment and hemodynamic resus -\ncitation, and proper monitoring are key to decrease mortality related to this process\n3,4.\nMoreover, inadequacy of antibiotic treatment in the in -\nfected patient may lead to an increase in the length of hospital stay, and therefore costs associated, and also in the mortality in critically ill patients\n5,6. \nTaking into account the above mentioned, objective was \nto establish a set of recommendations, by consensus of Emer-gency Medicine (EM) experts, on the identi\ufb01cation, diagnosis, immediate treatment and management of adult patients with acute infection attended in Spanish emergency departments (EDs).\nMETHODOLOGY\nThe study was divided into three phases: 1) To design a \nquestionnaire by a coordinating group; 2) To conduct a survey in ED physicians in order to know their opinion on the issues raised by the coordinating group; 3) To develop a number of recommendations based on the responses to the questionnaire and their subsequent discussion (\ufb01gure 1). \nIn the \ufb01rst phase, a coordinating group of 5 members was \nformed. They met the following requirements: having more than 3 years of experience as ED physician, being member of an infectious diseases hospital commission, and having prov -\nen practice in non-invasive hemodynamic monitoring proce-dures. The tasks of the coordinating group were to prepare the questionnaire, select the expert group, set up the timetable, collect and analyse the results, and formulate the \ufb01nal recom -\nmendations. For the design of the survey questions, a literature search of the most relevant articles in the last 5 years on infec -\ntious diseases and ED topics was performed. After examining the selected publications, the coordinating group formulated Figure 1 Systematization of the Method Used\nKey issues in the infected patient care in the Emergency Department F. Chiarella, et al.\nRev Esp Quimioter 2016;29(6): 318-327 320of patients with higher risk for errors during identi\ufb01cation in \nEDs, followed by those with clinical or therapeutic immuno-suppression. \nThe consensus document that establishes the new de\ufb01 -\nnitions of sepsis\n7 recognizes the need to modify the concept \nof sepsis, which is de\ufb01ned as an organic life-threatening dysfunction caused by a state of deregulation of the host re -\nsponse to infection. The new de\ufb01nitions of sepsis and septic \nshock re\ufb02ect the importance of early recognition of patients \nwith potentially fatal infection. The criteria for SIRS is consid -\nered to still be able to guide clinicians to identify a potential \noverall impact on an infection\n8. Despite the emergence of new \nde\ufb01nitions, experts believe that the SIRS should continue to be \nimplemented in the nursing triage and the Quick SOFA (qSO -\nFA) should be added to the \ufb01rst medical assessment. Also, they suggest that qSOFA should be validated in prospective studies and in special populations before eliminating the concept of SIRS. In addition, a specialized team, with skilled staff trained, is necessary in the triage when implementing the detection of sepsis.\nThe Sepsis Code project\n9 aims to improve patient care, op -\ntimizing the identi\ufb01cation and action times to achieve a re -\nduction in mortality associated with this process. Another ob -\njective is to improve the use of human and material resources, reducing hospital length of stay and associated costs. The majority of the participants said that it is necessary to adopt this Sepsis Code in emergency care, and that it should also be implemented in pre-hospital emergencies.\nThe majority of the experts said that early administration \nof intravenous broad-spectrum antibiotics would be crucial during the pre-hospital care.  For this, it is necessary to pro-vide the medical emergency system with the necessary tools to prescribe the antibiotic treatment, after taking microbiological cultures, in the \ufb01rst hour. This issue may become particularly important in septic shock patients with prolonged transport to the hospital. Therefore, it is still necessary to universalize cri -\nteria to ensure that the Sepsis Code is suitable in all settings. Furthermore, special emphasis was placed on the importance of the collaboration of all professionals involved in the man -\nagement of sepsis in order to achieve its implementation in all levels of healthcare.\nThe majority of the participants stated that current tri -\nage systems are not good enough for the risk strati\ufb01cation of infected patients. This may be especially complex and less re -\nliable in older patients with severe infection because this age group may present more atypical clinical signs and symptoms due to age-related physiological changes, comorbidity and polypharmacy\n10,11. Thus, the importance of the measurement \nof respiratory rate to minimize the underestimation of patients with severe infection.\nLastly, it was pointed out that biomarkers of in\ufb02ammatory \nresponse and infection have positioned themselves as helpful \ntools for ED physicians when making vital decisions. The most \nrepresentative ones are PCT, C-reactive protein (CRP) and lac -\ntate\n12. More than half of the respondents use lactate as the Block II. Diagnosis and Treatment\nRegarding empirical prescription of treatment against \nMDRO, 60.6% of the ED physicians argued that its coverage in \ncommunity infections should only be considered in exceptional cases. For 54.5% of the experts, procalcitonin (PCT) is the most useful biomarker in the management of infected patients, and 97% of the total believed that it is necessary to have rapid eti-ological diagnostic techniques. In relation to the fourth ques -\ntion, 60.6% of the ED physicians would choose carbapenems, while 33.3% would prefer ceftolozane/tazobactam to treat a severe infection with suspected beta-lactamase producing En -\nterobacteriaceae in a setting with high resistance to carbapen -\nems. In the \ufb01fth question, 78.8% of the experts suggested the need to administer, depending on the site of infection, the \ufb01rst dose of antibiotics intravenously prior to ED discharge.\nWith regard to delayed prescription, 21.2% stated that \nthis may sometimes be useful in EDs. Respect to the infec -\ntion site most bene\ufb01ciated from new emerged antimicrobials, 45.5% of experts said it would be skin and soft tissue infections (SSTI), while a 42.4% of them considered the intra-abdominal infections. A 90.9% of the respondents suggested that it is necessary to assess the extension of antimicrobial spectrum in patients with severe comorbidity. About the peripheral use of norepinephrine, 78.8% of experts initially used it by peripheral access. Lastly, 66.7% monitored of hemodynamic response to therapy by measuring arterial pressure. \nBlock III. Infection Management\nIn the \ufb01rst question, there was controversy among re -\nspondents as to whether one should establish different circuits \nfor the care of infected patients, even though 54.5% opted for the af\ufb01rmative response. In reference to isolation circuits, 93.9% of the participants believed that it is necessary an isola -\ntion circuit in the EDs with a separate entrance to the centre. A 51.5% of the respondents af\ufb01rmed that it is important the 24-hour presence of a microbiologist in the hospital. A 54.5% of experts said that hospitalization is the main cost associat -\ned element in the infection process, while a 45.5% of them considered it to be attributed to treatment failure. A 90.9% of the ED physicians found the short-stay units and outpatient \nparenteral antimicrobial therapy (OPAT) programs very useful and effective for the care of these patients. \nDISCUSSION\nBlock I. Identi\ufb01cation and Strati\ufb01cation of Severely \nInfected Patients \nAdvanced age is associated with an increased of the vul -\nnerability to infection. Also, it is common in this age group to \ufb01nd an atypical clinical presentation that leads to an in -\ncreased risk of delayed diagnosis and inadequate treatment, and therefore, worse short-term outcomes\n7. This aspect is in-\nteresting given that the vast majority of the experts thought that the older are a high-risk group of patients because they are frequently associated with signi\ufb01cant comorbidity and age-related immune changes. Thus, they constitute the group Key issues in the infected patient care in the Emergency Department F. Chiarella, et al.\nRev Esp Quimioter 2016;29(6): 318-327 321Block 1. Identification and Risk Stratification of Severely Infected Patients N (%)\n1. What is the most vulnerable population group that faces the highest probability of error during identification in the ED?\nPatients with significant comorbidity 3 (9.1)\nImmunosuppressed patients 1 (3)\nElderly patients 29 (87.9)\n2. How will the new definitions of sepsis affect the management of patients?\nWe should forget the SIRS and use the SOFA 2 (6.1)\nNo way, we must use only the SIRS criteria 1 (3)\nContinue using SIRS and add SOFA in the assessment 30 (90.9)\n3. Are the classical criteria for sepsis useful?\nYes, except in elderly patients 5 (15.2)\nYes, except in immunosuppressed patients 1 (3)\nYes 19 (57.6)\nNo 8 (24.2)\n4. Is adopting a sepsis code necessary in emergencies?\nYes 32 (97)\nNo 1 (3)\n5. Are standardized triage systems useful in the risk stratification of infected patients?\nOnly Manchester 1 (3)\nNone 20 (60.6)\nSET 0 (0)\nBoth 12 (36.4)\n6. What is the prognostic biomarker most widely used in routine clinical practice?\nCRP 2 (6.1)\nPCT 6 (18.2)\nLactate 25 (75.8)\nBlock 2. Diagnosis and Treatment\n1. Should we consider the etiologic diagnosis of multidrug-resistant microorganisms in community-acquired infections?\nYes, but only in some sites of infection 4 (12.1)\nYes, but only regarding those that have received recent antibiotic therapy 7 (21.2)\nNo, never 2 (6.1)\nAs an exception, since it is very rare 20 (60.6)\n2. What is the most useful biomarker in the management of infected patients?\nCRP 6 (18.2)\nPCT 18 (54.5)\nLactate 9 (27.3)\n3. Do you consider it necessary to implement rapid etiologic diagnostic techniques?\nYes 32 (97)\nNo 1 (3)Table 1  Survey Questions and Results Key issues in the infected patient care in the Emergency Department F. Chiarella, et al.\nRev Esp Quimioter 2016;29(6): 318-327 322Table 1  Survey Questions and Results (cont.)\n4. In an environment with high rate of resistance to carbapenems, would you modify your choice of antibiotherapy if you suspect an \ninfection by extended spectrum beta-lactamases producing Enterobacteriaceae?\n \n  Yes, I would change it to piperacillin-tazobactam 2 (6.1)\n Yes, I would change it to ceftalozane-tazobactam 11 (33.3)\nNo, I would keep the carbapenem 20 (60.6)\n5. Is it necessary to administer the first dose of intravenous antibiotics before discharging infected patients from the emergency department?\nIt is only necessary in some sites of infection 26 (78.8)\nYes, always 1 (3)\nIt is not necessary as the patient (getting discharged) is not in a serious condition 6 (18.2)\n6. Is a deferred prescription suitable?\nYes, though only on rare occasions 7 (21.2)\nNo, never 26 (78.8)\nYes 0 (0)\n7. Which site of infection do you think will benefit the most from new antimicrobial agents against gram-positive and -negative bacteria?\nI don\u2019t see its place in emergencies 1 (3)\nSkin and soft tissue infections 15 (45.5)\nPneumonia 1 (3)\nUrinary tract infection 2 (6.1)\nAbdominal infection 14 (42.4)\n8. Is it necessary to assess the administration of a broad-spectrum antimicrobial in patients with severe comorbidity?\nYes, because they are high-risk patients 30 (90.9)\nNot only for that reason 1 (3)\nNo, but I would consider the potency 2 (6.1)\n9. Can noradrenaline be administered peripherally?\nYes 26 (78.8)\nNo 7 (21.2)\n10. What do you use to monitor hemodynamic response to therapy?\n Arterial pressure 22 (66.7)\nLactate 9 (27.3)\nUltrasound 2 (6.1)\nBlock III. Infection Management\n1. Should different circuits be established for the care of infected patients?\nYes 18 (54.5)\nNo 15 (45.5)\n2. Do you think it is necessary for the isolation circuit to have a separate entrance to the centre?\nYes 31 (93.9)\nNo 2 (6.1)\n3. Is it necessary to have a 24-hour on-site microbiologist present in the hospital?\nYes 17 (51.5)\nNo 16 (48.5)Key issues in the infected patient care in the Emergency Department F. Chiarella, et al.\nRev Esp Quimioter 2016;29(6): 318-327 3234. Which element leads to increased spending in the process of an infection?\nHospitalization 18 (54.5)\nTreatment failure 15 (45.5)\n5. Do you believe that short-stay units and/or home care units are useful in the management of infected patients?\nNot very useful 1 (3)\nSomewhat useful 2 (6.1)\nVery useful 30 (90.9)\nhalf-life that can be administered in a single dose of 1500 mg. \nIt provides a dosage facility advantage that would potentially reduce the risk of complications associated with multiple-dose parenteral therapy and facilitate outpatient management\n19,20.\nMoreover, MRDO gram-negative bacteria are a serious \nhealth problem worldwide because of the severity infections that they can cause and the dif\ufb01culties in establishing prop-er empirical treatment. ESBL production is the most impor -\ntant problem of resistance among Enterobacteriaceae, which cause nosocomial infections, but are also frequently isolated in community patients\n13. There are other therapeutic limitations \nagainst resistant gram-negative bacteria, such as carbapene -\nmase-carrying Enterobacteriaceae or glucose-nonfermenting gram-negative bacilli, such as Pseudomonas aeruginosa or Acinetobacter baumannii.\nA new beta-lactam, ceftolozane/tazobactam, has recent -\nly become available. This is a derivative of ceftazidime asso -\nciated with a beta-lactamase inhibitor with higher activity against P. aeruginosa\n21. It is indicated for the treatment of \nadults with complicated intra-abdominal and complicated uri -\nnary tract infections, including pyelonephritis. It has in vitro activity against ESBL-producing microorganisms and against multi-drug resistance P. aeruginosa.  ED physicians have con -\nsidered that it could be useful against these pathogens in en-vironments where there is a high rate of resistance of Pseu-\ndomonas to carbapenems, or where there is a high incidence of infections by carbapenemase-carrying strains, in order to reduce the use of carbapenems. In addition, there are other therapeutic alternatives against ESBL strains such as tigecy -\ncline or fosfomycin, and even the combination of penicillinase with penicillins (piperacillin/tazobactam or amoxicillin/clavula -\nnate) in the treatment of urinary sepsis with low MIC. \nThe group of experts agreed that, in order to broaden \nthe spectrum of antimicrobials and provide coverage against MDRO, the site of infection, risk factors, comorbidity and the severity of the process, as well as pharmacokinetic and phar -\nmacodynamic parameters (PK/PD), should always be consid -\nered. For the patients\u2019 severity assessment, the degree of co -\nmorbidity should be added to clinical and laboratory criteria. It has been published that patients with a Charlson index score higher than 2 have poorer short- and long-term prognosis\n22. primary biomarker for risk strati\ufb01cation of patients, due to its \nutility, accessibility and immediacy.\nBlock II. Diagnosis and Treatment\nBacterial resistance is a \ufb01rst magnitude problem. Despite \nthe number of new antibiotic molecules available, MDRO are \nincreasingly emerging. The production of extended spectrum beta-lactamases (ESBL) is currently the most important prob -\nlem of resistance among Enterobacteriaceae. These microor -\nganisms may cause nosocomial infections although they are also isolated in out-hospital patients\n13. The frequency of this \nsituation may be higher in patients with serious infections who receive inappropriate empirical treatment. Therefore, the identi\ufb01cation of the factors, which predict the presence of in -\nfections by MRDO, is important to offer early and appropriate antibiotic treatment\n14. \n ED physicians argued that methicillin-resistant Staphylo-\ncoccus aureus (MRSA) empirical coverage should only be con -\nsidered occasionally in community patients. However, it should not be forgotten that MRSA microorganisms are present in 20% of staphylococcal infections\n15. Furthermore, it has been \ndocumented gram-positive isolates, usually Staphylococcus \nspp. and Enterococcus spp., with elevated MICs to linezolid, in \nSpanish critical patients16. \nTedizolid is a new antibiotic from the family of oxazolid -\ninones, indicated for SSTI treatment in adults, including those caused by MRSA. Tedizolid could be useful in SSTI instead of linezolid in patients with thrombocytopenia or in those who are at risk of developing it during treatment. This group includes those with vitamin B12 de\ufb01ciency, myelodysplastic syndrome, expectation of prolonged duration of treatment, chronic liv -\ner disease, cancer, previous use of vancomycin, the presence of a low platelet count before the initiation of treatment, and low body mass index\n17. Another possible alternative would be \nceftaroline, a \ufb01fth-generation cephalosporin with extraor -\ndinary af\ufb01nity for PBP2a, which gives it high activity against MRSA, as well as all the safety-related advantages of being a beta-lactam\n18. Recently, dalbavancin has been launched on the \nSpanish market. This is an antibiotic also useful in SSTI, which belongs to the group of semisynthetic lipoglycopeptides struc-turally related to teicoplanin. It is an antimicrobial with a long Table 1  Survey Questions and Results (cont.)\nSIRS: Systemic Inflammatory Response Syndrome; SOFA: Sequential Organ Failure Assessment; CRP: C-Reactive Protein; PCT: ProcalcitoninKey issues in the infected patient care in the Emergency Department F. Chiarella, et al.\nRev Esp Quimioter 2016;29(6): 318-327 324to take it only if their symptoms do not improve or worsen in \nthe next days after the physician attendance. This is an admin -\nistration regimen that may reduce unwarranted use of these drugs, contributing to their responsible use\n28. The majority of \nthe participants considered appropriate this strategy, mainly in outpatient. Although information regarding the initiation of antibiotic therapy must be previously provided to the patient. \nFinally, there was a general agreement that crystalloids \nare the best choice for hemodynamic resuscitation, and fur -\nthermore, there are several studies that support their use\n29. \nAccording to current guidelines, dopamine and noradrenaline should be the \ufb01rst-line vasopressors\n30. However, there are ob -\nservational studies that have associated a higher rate of ar -\nrhythmias31 and mortality in patients treated with dopamine \nthan in those treated with norepinephrine32. Therefore, the lat -\nter is preferable as vasoactive treatment of choice. The majori -\nty ED physicians use norepinephrine through peripheral access although its peripheral administration increases the risk of ad -\nverse effects. However, the infusion through proximal periph -\neral line (antecubital fossa or external jugular vein) is unlikely to cause any problem during the \ufb01rst 4 hours in critically ill patients\n33. Subsequently, it is possible to continue its infusion \nplacing a central line. \nIn regard to monitoring the hemodynamic response \nto therapy, the majority of them said that they perform it through arterial pressure. There was little experience regarding control through non-invasive techniques such as ultrasound of the vena cava or the carotid artery, which tools that have proved to be useful in predicting response to volume overload or the need to initiate amine therapy\n34.\nBlock III: Infection Management\nEmergency care is based on the principle of giving pri -\nority to the most severely ill patients. Thus, some circuits of \npatients are de\ufb01ned in function of the risk strati\ufb01cation at ED arrival. These circuits have different diagnostic and therapeutic resources and therefore different established length of stays in the ED\n35. There was controversy among the respondents re -\ngarding the circuits that there should be established for the care of infected patients.  Most experts declared that both patients with sepsis and those with septic shock should be treated in a shock room, which would allow immediate and ef\ufb01cient care in EDs\n36.\nAccording to the need to establish isolation circuits dif -\nferentiated from the rest of them, triage had a special rele -\nvance due to the infections transmitted by respiratory route. The entrance to this circuit should be separated from others, especially in cases of epidemics of serious infections\n37.\nCurrently, few Spanish hospitals have a microbiologist \nand/or consultant for infectious diseases, either on-site or lo -\ncally available, for 24 hours a day. The majority of the partici -\npants believed that a 24-hour on-call microbiologist is neces -\nsary, whereas only a minority believed it is necessary to have a 24-hour on-call infectious diseases consultant.\nAnother important aspect is the increase in healthcare Therefore, an empirical treatment error in these patients could \nfurther worsen clinical outcomes. Most experts agreed that it would be necessary to assess and extend the antimicrobial \nspectrum or to use more powerful antibiotics in patients with \nsigni\ufb01cant comorbidity. This may be useful to achieve a great -\ner log reduction in the shortest possible time and therefore an early defervescence of the episode, reducing the period in which the patient comorbidities are destabilized, and decreas-ing the risk of revisit to the ED\n23. This is the main justi\ufb01cation \nfor using combination therapy in severe infections. This leads to reach antibiotic synergy, a greater spectrum, an early log reduction and prevention of MDRO emergence.\nIt is widespread that the best antibiotic prescription strat -\negy is the obtainment of adequate samples for culture, espe -\ncially when is necessary to use broad-spectrum antibiotics, and then the early deescalation in accordance with the results of the cultures taken in EDs. This attitude may protect both the patient and the community preserving the ecological niche. \nThe development of rapid microbiological tests could pro -\nvide information in the \ufb01rst hours of attendance to help in de -\ncision-making\n24. Currently, few centres have these techniques \nfor rapid etiologic diagnosis available to determine the aeti -\nology of the infection. The rapid \ufb02u test and urinary antigens against Legionella pneumophila and Streptococcus pneumoni-\nae are the most widespread tests in EDs. The implementation of rapid diagnostic techniques will always take into account the cost-bene\ufb01t factors. Also, it will be necessary to estab -\nlish a protocol for the previously selected patients through an epidemiological survey, in order to reduce antibiotic se -\nlective pressure and unnecessary testing costs. As for taking blood cultures, the majority of the respondents answered that the extraction depends on the site of infection but above all they serve to determine the diagnostic and therapeutic deci -\nsions, especially in sepsis and septic shock patients. Therefore, the need to draw blood cultures in all sites of infection was considered, although it was recognized that probably a higher number of blood cultures than necessary are taken in the EDs.\nIt is well known the dif\ufb01culty of \ufb01nding a biomarker that \nallows early diagnosis of sepsis due to the complexity of the pathophysiology of this process\n25,26. Sepsis diagnosis remains \na challenge, mainly in special groups of patients. The major -\nity of the participants stated that the most useful diagnostic biomarker is PCT because it is more sensitive than CRP, espe -\ncially in bacterial infections. They considered it to be especially useful in patients with uncertain diagnosis, and for the moni -\ntoring of therapeutic response in critically ill patients. Some of the professionals supported the use of CRP and lactate due to the diagnostic limitations of their workplace.\nThere was a total agreement regarding the need to ad -\nminister the \ufb01rst dose of antibiotics prior to discharge from ED, although this need will depend on the site of infection. Consequently, this was required in community-acquired pneu -\nmonia, where the guidelines clearly recognize this need\n27. \nDelayed antibiotic prescription entails providing a pre -\nscription for an antibiotic agent and instructing the patients Key issues in the infected patient care in the Emergency Department F. Chiarella, et al.\nRev Esp Quimioter 2016;29(6): 318-327 325costs in Western countries, which is a concern in terms of eco-\nnomic and health policy. Several studies describe the relation -\nship between healthcare costs and their determinants such as the aging population, the adoption of new technologies and therapeutic improvements, among others\n38,39. Most studies \nhave argued that hospitalization is the main element asso -\nciated with the costs related to infection treatment, because length of hospital stay, especially if prolonged, generating negative effects on the healthcare system. However, the ma -\njority agreed to take into account also the costs in the process of selecting antibiotics to treat a particular infection, but never to place the costs factor above their ef\ufb01cacy and bene\ufb01ts for the patient.\nFinally, it should be pointed out that hospital EDs have \ndemonstrated signi\ufb01cant progress in the adoption of man -\nagement measures to alleviate the problems of overcrowding, especially in relation to lack of available hospital beds. In this sense, alternatives have been developed to conventional hos -\npital units, including short-stay units (SSUs) and home care units\n40. The majority found that such units are very useful for \nthe management of infected patients, taking into account that these patients will be rapid discharged with a specialized med-ical team.\nCONCLUSIONS\nThe importance of correct knowledge and management of \npatients with suspected infection, sepsis or septic shock lies in the high morbidity and mortality associated with these condi-\ntions. For this reason, a monitoring system and proper training of the entire healthcare team are required, as well as extensive knowledge on these issues to ensure adequate and effective care for patients. Finally, it is essential to educate and train all health staff, especially in the ED, because it is the initial point of contact for most patients with an infection. The experts es -\ntablished proposals based on survey questions and the discus -\nsion showing in the table 2.\n*ADDENDUM\nOthers members of the Infectious Disease Group of the \nSpanish Emergency Medicine Society (INFURG-SEMES): Iria Gonzalvez Marques (C.S. Aldea Moret), Eva Muro Fern\u00e1ndez de Pinedo (Hospital 12 de Octubre), Luis Perez Ordo\u00f1o (Hos -\npital 12 de Octubre), Virginia \u00c1lvarez Rodr\u00edguez (Hospital de Getafe), Mar\u00eda Ang\u00e9lica Rivera N\u00fa\u00f1ez (Hospital La Paz), \u00c1n -\ngel Jos\u00e9 Mac\u00edas L\u00f3pez (Hospital Ntra. Sra. de Sonsoles), Marta Taverner Aparicio (Hospital Arnau de Vilanova), Noemi Ruiz de Lobera Mart\u00ednez (Complejo Hospitario San Mill\u00e1n-San Pedro), Roberto Rodr\u00edguez Alonso (Hospital del Bierzo), Jorge Garc\u00eda Criado (Hospital de Salamanca), Eva Rodr\u00edguez Gorriz (Hospital de Valencia), Marta Berned Sabater (Hospital Joan XXIII), Mar\u00eda del Mar Portillo Cano (Hospital Virgen de la Macarena), Anto -\nnio Javier Garc\u00eda Buigues (Hospital de la Marina Baixa), Iciar Huarte Sanz (Hospital de Donostia), Ainhoa Gonz\u00e1lez Querejeta (Hospital de Donostia), Julio Javier Gamazo del Rio (Hospital de Galdakao), Jos\u00e9 Luis Omiste Mart\u00ednez (Hospital Miguel Servet), 1Special care should be taken in the care of elderly patients with severe comorbidity, since both are factors associated with an increased risk of poor \nresults due to the difficulty of stratifying the risk for patients with this profile.\n2The new defining criteria of sepsis should be incorporated into routine clinical practice, but without eliminating the previously existing detection criteria. It is essential to develop a sepsis code as it has been shown to be a useful tool in improving the healthcare outcomes of patients with sepsis.\n3There is a growing problem of multidrug-resistant microorganisms infecting patients from the community, so the risk of infection by them should always be assessed when deciding on the initial empirical treatment.\n4In order to broaden the spectrum of antimicrobials, one should take into account the site of infection, risk factors, comorbidity and severity of the process, as well as pharmacokinetic and pharmacodynamic parameters of the antibiotic.\n5It would be advisable to implement microbiological techniques for rapid diagnosis with regard to proper selection of the initial antibiotic. Given the current limited availability of these, the best strategy is obtaining adequate samples for culture, especially in patients with whom it is necessary to use broad-spectrum antibiotics, for then proceeding to early deescalation.\n6The most widely used biomarker in emergencies is lactate, which is considered the best for prognostic stratification of patients. PCT is the best bio-marker from the diagnostic point of view.\n7 The perfusion of norepinephrine may initially be administered peripherally, but for no more than 4 hours.\n8Hospitalization is the element that generates the most spending in the treatment of an infection, thus strategies should be established to reduce \nhospital stay.\n9 Having isolation circuits differentiated from the rest of the emergency care circuits is essential.\n10Both Short-Stay Units and Home Care Units are alternatives to conventional hospitalization that are useful in managing infected patients and do \nnot increase the risk of poor results.Table 2  Recommendations of the Working Group.Key issues in the infected patient care in the Emergency Department F. Chiarella, et al.\nRev Esp Quimioter 2016;29(6): 318-327 326Juan Antonio Rivero Guerrero (Hospital Virgen de la Victoria), \nMarco Bustamante Araujo (Hospital de Granollers), Ferran Llopis Roca (Hospital de Bellvitge), Jos\u00e9 Manuel Pavon Monzo (Hospital de Gran Canaria), Sandra Bacca Camacho (Hospital de Matar\u00f3), Fernando Lamelo Alfonsin (Complejo Hospitalar-io de A Coru\u00f1a), Mar\u00eda Concepci\u00f3n Mart\u00ed Navarro (Hospital de Son Espases), Esteban Gonzalo Llavador Ros (Complejo Hospi -\ntalario La Fe), Jos\u00e9 Mar\u00eda Ferreras Amez (Hospital Royo Villano -\nva), Esther Maldonado P\u00e9rez (Hospital Juan Ram\u00f3n Jim\u00e9nez).\nACKNOWLEDGMENTS\nThe authors wish to thank Silvia Borr\u00e1s Carbajo for help -\ning us with English text correction.\nCONFLICTS OF INTEREST\nNone\nREFERENCES\n1. Mart\u00ednez Ortiz de Z\u00e1rate M, Gonz\u00e1lez Del Castillo J, Juli\u00e1n Jim\u00e9n -\nez A, Pi\u00f1era Salmer\u00f3n P, Llopis Roca F, Guardiola Tey JM,  et al. \nEpidemiology of infections treated in hospital emergency depart -\nments and changes since 12 years earlier: the INFURG study of the Spanish Society of Emergency Medicine (SEMES). Emergencias. 2013;25:368-78.\n2. Rodr\u00edguez A, Mart\u00edn-Loeches I, Y\u00e9benes JC. New de\ufb01nition of sep-sis and septic shock: What does it give us? Med Intensiva 2016. doi: \n10.1016/j.medin.2016.03.008. PMID:27255771.\n3. Ferrer R, Martin-Loeches I, Phillips G, Osborn TM, Townsend S, Del -\nlinger RP, et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the \ufb01rst hour: results from a guideline-based performance improvement program. Crit Care Med. 2014;42:1749-55.\n4. Almela Quilis A, Mill\u00e1n Soria J, Alonso \u00cd\u00f1igo JM, Garc\u00eda Bermejo P. Monitorizaci\u00f3n hemodin\u00e1mica no invasiva o m\u00ednimamente invasi -\nva en el paciente cr\u00edtico en los servicios de urgencias y emergencias. Emergencias. 2015;27:386-95.\n5. Zilberberg MD, Shorr AF, Micek ST, Vazquez-Guillamet C, Kollef MH. Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retro -\nspective cohort study. Crit Care. 2014;18:596. \n6. Gonz\u00e1lez-Del Castillo J, Dom\u00ednguez-Bernal C, Guti\u00e9rrez-Mart\u00edn MC, N\u00fa\u00f1ez-Orantos MJ, Candel FJ, Mart\u00edn-S\u00e1nchez FJ. Effect of the in -\nadequacy of antibiotic therapy in the Emergency Department on hospital stays. Enferm Infecc Microbiol Clin. 2015. doi: 10.1016/j.eimc.2015.10.005.\n7. Mart\u00edn-S\u00e1nchez FJ, Gonz\u00e1lez del Castillo J. Sepsis en el anciano: \u00bfest\u00e1n preparados los servicios de urgencias hospitalarios?. Emer -\ngencias 2015;27:73-4.\n8. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane \nD, Bauer M, et al. The Third International Consensus De\ufb01nitions \nfor Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315:801-10. 9. Borges M, Candel FJ, Ferrer R, Vidal P, Zaragoza R. Documento de Consenso C\u00f3digo Sepsis. Recomendaciones. IMC, 2014. \n10. Almela Quilis A, Mill\u00e1n Soria J, Sorando Serra R, Cano Cano MJ, Llorens Soriano P, Beltr\u00e1n S\u00e1nchez A. Consensus-based recommen-dations and proposals for improving the management of elderly emergency patients with suspected infection in the Spanish au -\ntonomous community of Valencia: the PIPA project. Emergencias. 2015; 27:87-94.\n11. Fern\u00e1ndez Alonso C, Gonz\u00e1lez Armengol JJ, Perdigones J, Fuentes Ferrer ME, Gonz\u00e1lez Del Castillo J, Mart\u00edn-S\u00e1nchez FJ. La utilidad de la escala Identi\ufb01cation of Seniors at Risk (ISAR) para prede -\ncir los eventos adversos a corto plazo en los pacientes ancianos dados de alta desde una unidad de corta estancia. Emergencias. 2015;27:181-4.\n12. Hausfater P. Biomarkers and infection in the emergency unit. Med \nMal Infect. 2014;44:139-45.\n13. Fari\u00f1as MC, Mart\u00ednez-Mart\u00ednez L. Fundamentos y actuaci\u00f3n cl\u00edni -\nca Infecciones causadas por bacterias gramnegativas multirresist -\nentes: enterobacterias, Pseudomonas aeruginosa, Acinetobacter \nbaumannii y otros bacilos gramnegativos no fermentadores. En -\nferm Infecc Microbiol Clin. 2013; 31:402-9. \n14. Vella V, Moore LS, Robotham JV, Davies F, Birgand GJ, Otter JA, et \nal. Isolation demand from carbapenemase-producing Enterobac-\nteriaceae screening strategies based on a West London hospital \nnetwork. J Hosp Infect. 2016. doi: 10.1016/j.jhin.2016.04.011.\n15. Cercenado E, de Gopeguib ER. Staphylococcus aureus resistente a la meticilina de origen comunitario. Enferm Infecc Microbiol Clin 2008;26:S19-24. \n16. Pe\u00f1uelas M, Candel FJ, Lejarraga C, L\u00f3pez-Gonz\u00e1lez L, Vi\u00f1uela-Pri -\neto JM, L\u00f3pez de Mendoza D. Activity of linezolid and tedizolid against clinical isolates of methicillin-resistant and methicillin and linezolid resistant Staphylococcus aureus: an in vitro comparison. Rev Esp Quimioter. 2016. pii: penuelas30jun2016. \n17. Fala L. Sivextro (Tedizolid Phosphate) Approved for the Treatment \nof Adults with Acute Bacterial Skin and Skin-Structure Infections. Am Health Drug Bene\ufb01ts. 2015; 8:S111-115.\n18. Garrison, M.W., N.M. Kawamura, and M.M. Wen, Ceftaroline fos-amil: a new cephalosporin active against resistant Gram-positive organisms including MRSA. Expert Rev Anti Infect Ther. 2012; 10:1087-103.  \n19. Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014; 370:2169-79.\n20. Tom\u00e1s Vecina S, Mozota Duarte J, Ortega Marcos M, Ruiz Navarro MG, Borillo V, San Juan Gago L,  et al. Estudio sobre la reducci\u00f3n de eventos adversos en pacientes y problemas de bioseguridad de los profesionales derivados de la aplicaci\u00f3n de cat\u00e9teres vasculares en urgencias. Emergencias. 2016;28:89-96.\n21. Scott LJ. Ceftolozane/Tazobactam: A Review in Complicated In -\ntra-Abdominal and Urinary Tract Infections. Drugs. 2016;76: 231-\n42. \n22. Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Up -\ndating and validating the Charlson comorbidity index and score for Key issues in the infected patient care in the Emergency Department F. Chiarella, et al.\nRev Esp Quimioter 2016;29(6): 318-327 327risk adjustment in hospital discharge abstracts using data from 6 \ncountries. Am J Epidemiol. 2011; 173:676-82. \n23. Jim\u00e9nez-Puente A, Del R\u00edo-Mata J, Arjona-Huertas JL, Mora-Or-d\u00f3\u00f1ez B, Nieto-de Haro L, Lara-Blanquer A,  et al. Causas de los retornos durante las 72 horas siguientes al alta de urgencias. Emer -\ngencias. 2015;27:287-93.\n24. Llor C, Hern\u00e1ndez S, Mar\u00eda Cots JM, Bjerrum L, Gonz\u00e1lez B, Garc\u00eda G, et al. Los m\u00e9dicos que disponen de pruebas r\u00e1pidas disminuyen signi\ufb01cativamente la prescripci\u00f3n de antibi\u00f3ticos en el resfriado com\u00fan. Rev Esp Quimioter 2013; 26:12-20.\n25. Wiwatcharagoses K, Kingnakom A. Procalcitonin under Investiga -\ntion as a Means of Detecting Severe Sepsis, Septic Shock and Bac -\nteremia at Emergency Department, Rajavithi Hospital. Med Assoc Thai. 2016; 99:S63-68. \n26. Calvo-Rodr\u00edguez R, Gallardo-Valverde JM, Montero-P\u00e9rez FJ, Bae -\nna-Delgado E, Jim\u00e9nez-Murillo L. Utilidad de los biomarcadores en el manejo del dolor abdominal. Emergencias. 2016;28:185-92.\n27. Torres A, Barber\u00e1n J, Falguera M, Men\u00e9ndez R, Molina J, Olaechea P, et al. Multidisciplinary guidelines for the management of commu -\nnity-acquired pneumonia. Med Clin (Barc). 2013; 140:223.e1-223.e19.\n28. Murphy M, Bradley CP, Byrne S. Antibiotic prescribing in primary \ncare, adherence to guidelines and unnecessary prescribing an Irish perspective. BMC Fam Pract. 2012; 13:43. doi: 10.1186/1471-2296-\n13-43.\n29. Perel P, Roberts I, Ker K. Colloids versus crystalloids for \ufb02uid re -\nsuscitation in critically ill patients. Cochrane Database Syst Rev. 2013;(2):CD000567. doi: 10.1002/14651858.CD000567.pub6.\n30. Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. Cec -\nconi M, De Backer D, Antonelli M, Beale R, Bakker J, Hofer C, et al. Intensive Care Med 2014;40: 1795-815.\n31. De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, et al; SOAP II Investigators. Comparison of dopamine and norepi -\nnephrine in the treatment of shock. N Engl J Med. 2010; 362:779-89. \n32. Boulain T, Runge I, Bercault N, Benzekri-Lefevre D, Wolf M, Fleury C. Dopamine therapy in septic shock: detrimental effect on survival? J Crit Care. 2009; 24:575-82. \n33. Loubani OM, Green RS. A systematic review of extravasation and local tissue injury from administration of vasopressors through pe -\nripheral intravenous catheters and central venous catheters. J Crit Care. 2015; 30:653.e9-17. doi: 10.1016/j.jcrc.2015.01.014. \n34. Stolz LA, Mosier JM, Gross AM, Douglas MJ, Blaivas M, Adhikari S. Can emergency physicians perform common carotid Doppler \ufb02ow measurements to assess volume responsiveness? West J Emerg Med. 2015; 16:255-9. \n35. A\ufb01lal M, Yalaoui F, Dugardin F, Amodeo L, Laplanche D, Blua P. \nForecasting the Emergency Department Patients Flow. J Med \nSyst. 2016; 40:175. doi: 10.1007/s10916-016-0527-0. \n36. Holder AL, Gupta N, Lulaj E, Furgiuele M, Hidalgo I, Jones MP, et \nal. Predictors of early progression to severe sepsis or shock among emergency department patients with nonsevere sepsis. Int J Emerg Med. 2016; 9:10. doi: 10.1186/s12245-016-0106-7. 37. Ortega M, Mensa J. Precauciones de aislamiento en el \u00e1rea de urgencias Hospital Cl\u00ednic, Barcelona, Espa\u00f1a. Emergencias 2009; 21:36-41.\n38. Urbanos-Garrido RM, L\u00f3pez-Valc\u00e1rcel BG. Sostenibilidad del siste -\nma sanitario y contribuci\u00f3n de los servicios de urgencias. Emergen -\ncias. 2015; 27:197-202.\n39. Tudela P, M\u00f2dol JM. La saturaci\u00f3n en los servicios de urgencias hos -\npitalarios. Emergencias. 2015;27:113-20.\n40. Moncl\u00fas Cols E, Capdevila Reniu A, Roedberg Ramos D, Pujol Fon -\ntrodona G, Ortega Romero M. Manejo de la sepsis grave y el shock s\u00e9ptico en un servicio de urgencias de un hospital urbano de tercer nivel. Oportunidades de mejora. Emergencias. 2016; 28:229-34.The new prototype was compared to direct plating of vagi -\nnal-rectal swabs onto Granada solid media plates. Direct plat -\ning method detected 124 positive samples out of 600 (20.6%) \nwhereas the new device detected 10 additional positive sam-ples (134/600, 22.3%). This new device (patent-protected) could be considered for routine GBS screening.\nKeywords: Group B Streptococcus ; pregnant woman; screening.\nINTRODUCCI\u00d3N\nEl estreptococo del grupo B (EGB) est\u00e1 considerado como \nuna de las bacterias principales causantes de sepsis neonatal1-3. \nAunque la incidencia es relativamente baja, su alta mortalidad hace que se considere necesario consensuar estrategias de prevenci\u00f3n para evitar graves o fatales episodios. Actualmente, para la profilaxis de la sepsis neonatal causada por el EGB se recomienda realizar un cribado en mujeres embarazadas entre la semana 35-37 de gestaci\u00f3n para actuar con efectividad en la prevenci\u00f3n intraparto, seg\u00fan las recomendaciones interna -\ncionales de los Centers for Diseases Control and Prevention  \n(CDC)\n4. La muestra \u00f3ptima sobre las cuales se debe realizar el \ncribado son frotis vagino-rectales obtenidos con torunda, pri -\nmero por introducci\u00f3n vaginal, seguido de introducci\u00f3n anal con ligera rotaci\u00f3n para mejorar el rendimiento. La torunda debe inocularse en medio de transporte Stuart-Amies hasta su procesamiento. La detecci\u00f3n de laboratorio del EGB se puede realizar mediante m\u00e9todo de cultivo o mediante t\u00e9cnicas mo -\nleculares. Los CDC recomiendan para la recuperaci\u00f3n del EGB de las muestras, la utilizaci\u00f3n de caldos de enriquecimiento como el Todd Hewitt o el Lim, con o sin antibi\u00f3ticos que supri -\nman parte de la flora acompa\u00f1ante, para posteriormente sub -\ncultivarlo en placas de agar sangre para detectar la beta he -\nm\u00f3lisis. Tambi\u00e9n se utilizan con buen rendimiento medios cro -\nm\u00f3genos y medios con nutrientes que favorecen la producci\u00f3n de pigmentos de color naranja por los EGB como es el medio Granada. En el \u00faltimo documento consenso espa\u00f1ol\n5, tambi\u00e9n \nse contempla la posibilidad de inocular de forma directa la to -RESUMEN\nSe ha dise\u00f1ado un dispositivo de nueva invenci\u00f3n que \ncombina recogida, transporte, cultivo y detecci\u00f3n del estrep -\ntococo del grupo B (EGB) sin necesidad de procesamiento ni manipulaciones intermedias, de manera que simplifique todo el proceso. El objetivo ha sido evaluar el rendimiento y utili -\ndad de dicho dispositivo en la detecci\u00f3n del EGB en mujeres embarazadas. Se compar\u00f3 el nuevo prototipo en paralelo con la siembra directa de las muestras vagino-rectales en el medio s\u00f3lido Granada en placas tradicionales. Mediante la siembra directa se detectaron 124 muestras positivas de 600 (20,6%). Mediante el nuevo dispositivo se detectaron las mismas que en siembra directa y adem\u00e1s 10 adicionales 134/600 (22,3%). La utilizaci\u00f3n del nuevo dispositivo podr\u00eda ser considerada en la pr\u00e1ctica cl\u00ednica asistencial de rutina para el cribado del EGB mediante previo acuerdo de comercializaci\u00f3n.\nPalabras clave: Estreptococo del Grupo B; mujer embarazada; cribado.\nEvaluation of a new device for sample \ncollection, transport and detection of Group B \nStreptococcus  in pregnant women\nABSTRACT\nWe have designed a new device that combines sample \ncollection, transportation, culture and detection of Group B \nStreptococcus (GBS), requiring no additional processing in the clinical laboratory. The objective was to evaluate the perfor-mance of this device for GBS detection in pregnant women. Evaluaci\u00f3n de un nuevo dispositivo para la \nrecogida de la muestra, transporte y detecci\u00f3n del estreptococo del grupo B en mujeres embarazadas\n1UGC Microbiolog\u00eda Complejo Hospitalario Universitario de Huelva.\n2Unidad de Microbiolog\u00eda Hospital Rafael M\u00e9ndez, Lorca.\n3UGC Farmacia Hospitalaria Complejo Hospitalario Universitario de Huelva.Alberto Tenorio-Abreu1\nJos\u00e9 Antonio G\u00f3mez-\nFern\u00e1ndez1\nLuis Arroyo-Pedrero2\nEsmeralda Rodr\u00edguez-Molins\n3\nCorrespondencia:\nDr. Alberto Tenorio Abreu. Hospital Juan Ram\u00f3n Jim\u00e9nez, Ronda Exterior Norte s/n 21005 HuelvaTfno: 657929483E-mail: albeteno@hotmail.comOriginal breve\nRev Esp Quimioter 2016;29(6): 328-331 328Evaluaci\u00f3n de un nuevo dispositivo para la recogida de la muestra, transporte y detecci\u00f3n del estreptococo \ndel grupo B en mujeres embarazadasA. Tenorio-Abreu, et al.\nRev Esp Quimioter 2016;29(6): 328-331 329coccus aureus ATCC 25923, Bacteroides fragilis  ATCC 25285, \nProteus mirabilis ATCC 43071 y Escherichia coli ATCC 25922. \nTodas las cepas control se probaron en dispositivos a los tres \nmeses de su fabricaci\u00f3n casera para verificar la estabilidad del producto.\nRESULTADOS\nEl l\u00edmite de detecci\u00f3n del nuevo dispositivo fue de 1 UFC \nde EGB obteni\u00e9ndose resultados positivos en todas las inocu -\nlaciones seriadas por triplicado. Para el estudio piloto se inclu -\nyeron un total de 600 muestras vagino-rectales. Mediante la siembra directa se detectaron 124 muestras positivas de 600 (20,6%). Mediante el nuevo dispositivo se detectaron, adem\u00e1s de las mismas que en siembra directa, 10 adicionales con un resultados global de 134 muestras positivas de 600 (22,3%). Todas las muestras consideradas positivas de cualquier inten -\nsidad (fuerte, media o tenue) fueron confirmadas mediante el sistema de identificaci\u00f3n API Rapid Strep (Biomerieux). Los resultados con las cepas control fueron los siguientes: Strep-\ntococcus agalactiae ATCC 12386: crecimiento de colonias de runda en el medio s\u00f3lido Granada sin necesidad de utilizar cal-\ndo de enriquecimiento previo. En cualquier caso, se necesita un dispositivo de toma y transporte de muestra y posteriormente un procesamiento en el laboratorio de microbiolog\u00eda que re-quieren de manipulaci\u00f3n para la inoculaci\u00f3n en caldo, en placa directa o ambas combinadas en secuencia temporal tras incu -\nbaciones anaerobias entre 24-48 horas. En el presente estudio, se ha dise\u00f1ado un dispositivo prototipo casero de nueva inven -\nci\u00f3n que combina inoculaci\u00f3n del medio, transporte, cultivo y detecci\u00f3n del EGB sin necesidad de procesamiento ni mani -\npulaciones intermedias, de forma que simplifique el proceso y elimine errores de etiquetado de muestra y manipulaci\u00f3n. El objetivo ha sido evaluar el rendimiento y utilidad de dicho pro -\ntotipo en la detecci\u00f3n del EGB en mujeres embarazadas.\nMATERIAL Y M\u00c9TODOS\nSe dise\u00f1\u00f3 y patent\u00f3 por los autores del presente estudio, \nun dispositivo casero a modo de prototipo consistente en un tubo cil\u00edndrico de pl\u00e1stico con un lateral cubierto en leng\u00fce -\nta por medio s\u00f3lido Granada (Becton Dickinson, USA) y con -\nteniendo en el fondo 800 \u00b5l de caldo Todd Hewitt con anti -\nbi\u00f3ticos (BectonDickinson, USA), respetando las condiciones de almacenaje y tiempo de caducidad del fabricante de ambos componentes (figura 1). El tap\u00f3n del dispositivo dispon\u00eda de rosca debidamente aflojada para permitir la entrada de la at -\nm\u00f3sfera anaerobia durante la incubaci\u00f3n. Se dise\u00f1\u00f3 para que en un solo dispositivo se pudiese inocular la muestra, transpor -\ntar, enriquecer y detectar el EGB sin necesidad de manipula -\nci\u00f3n y pasos intermedios. Se realiz\u00f3 un estudio piloto en el que se compar\u00f3 la siembra directa de las muestras vagino-rectales en el medio s\u00f3lido Granada en placas tradicionales (Becton Dickinson, USA), con la posterior inoculaci\u00f3n del nuevo tubo con las mismas torundas usadas del paciente. El nuevo dispo-sitivo fue sembrado del siguiente modo: primero se sembr\u00f3 la leng\u00fceta y posteriormente se sumergi\u00f3 la torunda en el medio de enriquecimiento. Las placas y tubos se incubaron en  ver -\ntical a 37\u00baC durante 48 horas en atm\u00f3sfera anaerobia (con el tap\u00f3n ligeramente desenroscado). A las 24 horas se realiz\u00f3 una primera lectura y el nuevo dispositivo se inclin\u00f3 lo suficiente como para ba\u00f1ar la superficie del agar de la leng\u00fceta con el medio l\u00edquido enriquecido. El crecimiento de colonias de co -\nlor naranja (de cualquier tonalidad: intensa, media o tenue) se consider\u00f3 positivo seg\u00fan las instrucciones del fabricante (Becton Dickinson, USA), tanto en las placas como en el nuevo dispositivo. El l\u00edmite de detecci\u00f3n del nuevo dispositivo se de-termin\u00f3 por inoculaci\u00f3n en triplicado de diluciones seriadas de concentraci\u00f3n conocida seg\u00fan la escala de MacFarland. Se rea -\nlizaron inoculaciones seriadas por triplicado, de 1000, 100, 10 y 1 Unidades Formadoras de Colonia (UFC). La especificidad de las muestras consideradas positivas se determin\u00f3 mediante la identificaci\u00f3n de las colonias naranjas con el sistema de iden -\ntificaci\u00f3n API Rapid Strep (Biomerieux). As\u00ed mismo, tambi\u00e9n se prob\u00f3 con siembras de cepas control de la colecci\u00f3n ATCC: Streptococcus agalactiae ATCC 12386, Streptococcus pyoge-\nnes ATCC 19615, Enterococcus faecalis ATCC 29212, Staphylo-Figura 1  Dispositivo para transporte, cultivo y \ndetecci\u00f3n del EBG. Tubo de la izquierda: muestra positiva. Tubo de la derecha: muestra negativa.\nEvaluaci\u00f3n de un nuevo dispositivo para la recogida de la muestra, transporte y detecci\u00f3n del estreptococo \ndel grupo B en mujeres embarazadasA. Tenorio-Abreu, et al.\nRev Esp Quimioter 2016;29(6): 328-331 330preliminares,  no solo mantiene, sino que mejora el rendimien -\nto diagn\u00f3stico frente a la siembra directa. Este hecho, es espe -\ncialmente relevante cuando en este ensayo se ha inoculado el \nnuevo dispositivo con las torundas previamente sembradas en placas de medio s\u00f3lido Granada, con la consiguiente disminu -\nci\u00f3n del in\u00f3culo sembrado en el nuevo dispositivo. Por tanto, esta nueva combinaci\u00f3n de medio s\u00f3lido y de enriquecimiento en un solo dispositivo podr\u00eda contribuir a disminuir la tasa de incidencia de sepsis neonatal causada por el EGB. De cualquier modo, ser\u00eda necesario confirmar dichos resultados con  estu-dios m\u00e1s extensos que permitan validar la t\u00e9cnica en centros externos, imprescindible para su posible comercializaci\u00f3n.\nEn conclusi\u00f3n, el nuevo dispositivo, adem\u00e1s de recuperar \nm\u00e1s muestras positivas que la siembra directa, podr\u00eda ahorrar costes en medios de transporte y manipulaciones interme -\ndias, haciendo m\u00e1s sencillo todo el proceso desde la toma de muestra hasta la lectura e interpretaci\u00f3n. Su utilizaci\u00f3n en un futuro pr\u00f3ximo podr\u00eda ser considerada en la pr\u00e1ctica cl\u00ednica asistencial de rutina para el cribado del EGB mediante previo acuerdo de comercializaci\u00f3n y validaci\u00f3n externa.\nBIBLIOGRAF\u00cdA\n1. Ballard MS, Sch\u00f8nheyder HC, Knudsen JD, Lyytik\u00e4inen O, Dryden M \net al. The changing epidemiology of group B Streptococcus bloods-\ntream infection: A multi-national population-based assessment. Infect Dis (Lond). 2016;12:1-6.\n2. Musilova I, Pliskova L, Kutova R, Jacobsson B, Paterova P, Kacero -\nvsky M. Streptococcus agalactiae in pregnancies complicated by preterm prelabor rupture of membranes. J Matern Fetal Neonatal Med. 2016;29(7):1036-40.\n3. Shah BA, Padbury JF. Neonatal sepsis: an old problem with new insights. Virulence. 2014;5(1):170-8.\n4. Verani JR, McGee L, Schrag SJ; Division of Bacterial Diseases, Na-tional Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC). Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010. MMWR Recomm Rep 2010;59(RR-10):1-36.\n5. Al\u00f3s Cort\u00e9s JI, Andreu Domingo A, Arribas Mir L, Cabero Roura L, Cueto Lopez M, L\u00f3pez Sastre J, et al. Prevention of perinatal group B Streptococcal disease. Updated Spanish recommendations 2012. Rev Esp Quimioter 2012; 25(1):79-88.\n6. Tenorio-Abreu A, Gil-Tom\u00e1s JJ. Diagnostic yield of instant liquid biphasic Granada medium for group B Streptococcus detection in \npregnant women. Enferm Infecc Microbiol Clin. 2012;30(6):354-5.\n7. Martinho F, Prieto E, Pinto D, Castro RM, Morais AM, Salgado L, et al. Evaluation of liquid biphasic Granada medium and instant liquid biphasic Granada medium for group B Streptococcus detec-tion. Enferm Infecc Microbiol Clin. 2008;26(2):69-71.\n8. Tenorio-Abreu A, Arroyo LA, G\u00f3mez-Alonso B. Enhanced recovery of group B Streptoccocus in pregnant women screening. Rev Esp Quimioter. 2015;28(6):328-9.\n9. Romanik M, Nowosielski K, Martirosian G, Por\u0119ba R, Sioma-Markowska U. Identification of pregnant women at risk of color naranja; Streptococcus pyogenes ATCC 19615: creci -\nmiento de colonias peque\u00f1as de color ligeramente gris\u00e1ceo; \nEnterococcus faecalis ATCC 29212: crecimiento de colonias de tama\u00f1o mediano de color gris; Staphylococcus aureus ATCC \n25923: sin crecimiento; Bacteroides fragilis ATCC 25285: sin crecimiento; Proteus mirabilis ATCC 43071: sin crecimiento; \nEscherichia coli ATCC 25922: sin crecimiento. Los resultados de las cepas control testados en dispositivos a los tres meses de su fabricaci\u00f3n fueron id\u00e9nticos a los de reciente fabricaci\u00f3n.\nDISCUSI\u00d3N\nTras revisi\u00f3n de la bibliograf\u00eda relacionada, no se encontr\u00f3 \nning\u00fan estudio que utilizara dispositivo similar ni para el transpor-te y detecci\u00f3n del EGB ni para otros microorganismos, por lo que se decidi\u00f3 proteger la invenci\u00f3n mediante patente con propiedad titular del Servicio Andaluz de Salud cuyo n\u00famero de solicitud es P201530810. S\u00ed existe un medio Granada bif\u00e1sico comercial con una utilidad similar al presente estudio pero con dise\u00f1o y mate -\nriales diferentes, consistente en un tubo con un caldo y un fondo de medio s\u00f3lido en polvo que pigmenta con la presencia de EGB tras 48 horas de incubaci\u00f3n, pero con rendimientos que no han demostrado ser suficientemente aceptables\n6,7. Aunque la siembra \ndirecta en medio granada aporta buenos resultados8 y est\u00e1 acep -\ntada como m\u00e9todo de cribado5, existen numerosos estudios que \ndemuestran un mejor rendimiento para la detecci\u00f3n del EGB con la utilizaci\u00f3n de un medio de enriquecimiento seguido de pase a medio s\u00f3lido\n9-11, bien agar sangre para observar la beta hem\u00f3lisis \no bien un medio crom\u00f3geno o medio granada para observar la pigmentaci\u00f3n producida por la bacteria. Por eso se decidi\u00f3 unir ambos componentes, enriquecimiento y cultivo en medio grana -\nda en un mismo dispositivo, de manera que permitiera simplifi -\ncar el proceso, evitando errores inherentes a la manipulaci\u00f3n, y adecuarse a los mejores rendimientos reportados en la bibliograf\u00eda para la recuperaci\u00f3n del EGB en mujeres embarazadas y as\u00ed evitar o prevenir en lo m\u00e1ximo posible la transmisi\u00f3n vertical y la apari-ci\u00f3n de sepsis neonatal por dicha bacteria pat\u00f3gena. Por tanto, el dispositivo realiza las funciones de transporte de muestra, cultivo y detecci\u00f3n en un solo paso, evitando procesos y manipulaciones intermedias, simplificando de esta forma la detecci\u00f3n de EGB y posibles errores en procesamiento, seguimiento y recepci\u00f3n de la muestra.\nLa sensibilidad del dispositivo determinada por el l\u00edmite de \ndetecci\u00f3n por in\u00f3culo se ha mostrado con un nivel de recupe-raci\u00f3n excelente, detect\u00e1ndose in\u00f3culos de solo 1 UFC de EGB en las series realizadas en triplicado. Por otra parte, la especi -\nficidad de la detecci\u00f3n mediante la pigmentaci\u00f3n de cualquier intensidad del color naranja, tambi\u00e9n se mostr\u00f3 excelente, con un 100% de especificidad seg\u00fan la confirmaci\u00f3n con la iden -\ntificaci\u00f3n mediante el sistema API Rapid Strep y con las cepas control de la colecci\u00f3n ATCC probadas.\nEl estudio piloto realizado en comparaci\u00f3n a la siembra \ndirecta, muestra resultados prometedores a favor del dispo -\nsitivo prototipo de nueva invenci\u00f3n, detect\u00e1ndose todos los positivos diagnosticados por siembra directa, adem\u00e1s de de -\ntectar casi un 2% m\u00e1s de muestras positivas. Los resultados Evaluaci\u00f3n de un nuevo dispositivo para la recogida de la muestra, transporte y detecci\u00f3n del estreptococo \ndel grupo B en mujeres embarazadasA. Tenorio-Abreu, et al.\nRev Esp Quimioter 2016;29(6): 328-331 331Streptococcus group B colonisation. Neuro Endocrinol Lett 2011;32(3):308-12.\n10. El Aila NA, Tency I, Claeys G, Saerens B, Cools P, Verstraelen H, et al. Comparison of different sampling techniques and of different culture methods for detection of group B Streptococcus carriage \nin pregnant women. BMC Infect Dis 2010;10:285.\n11. Pruss A, Galant K, Giedrys-Kalemba S. Analysis of screening tests for Streptococcus agalactiae in pregnant women from the West \nPomeranian region.Ginekol Pol. 2015;86(8):616-21.Rev Esp Quimioter 2016;29(6): 332-335 332Tipi\ufb01caci\u00f3n mediante secuencias multilocus \nde cepas humanas de Campylobacter coli  en \nGranada (Espa\u00f1a) \nRESUMEN\nIntroducci\u00f3n. Diferentes subtipos de Campylobacter spp. \nse han asociado con diarrea y la t\u00e9cnica de tipado mediante \nan\u00e1lisis de secuencias de m\u00faltiples locus (MLST) se ha emplea-do para la tipi\ufb01caci\u00f3n gen\u00e9tica. En el presente trabajo, la t\u00e9cni -\nca MLST se utiliz\u00f3 para analizar la diversidad gen\u00e9tica de ocho cepas de Campylobacter coli.\nMaterial y m\u00e9todos. 19 marcadores gen\u00e9ticos fueron \nampli\ufb01cados mediante el an\u00e1lisis MLST: AnsB, DmsA, ggt, \nCj1585c, CJJ81176-1367/1371, Tlp7, cj1321-cj1326, fucP, \ncj0178, cj0755/cfrA, ceuE, pldA, cstII, cstIII. Despu\u00e9s de com -\nparar las secuencias obtenidas con la base de datos MLST para Campylobacter, se asignaron el n\u00famero de los alelos, los se -\ncuenciotipos (STs) y los complejos clonales (CCs).\nResultados. Las 8 cepas de C. coli aisladas mostraron  4 \nSTs diferentes pertenecientes a 2 CCs. Siete aislamientos per -\ntenecieron al complejo clonal ST-828 y s\u00f3lo un aislado perte -\nneci\u00f3 al ST-21. Dos aislados pertenecieron al mismo paciente, pero fueron obtenidos en diferentes periodos de tiempo.\nConclusiones. La t\u00e9cnica MLST puede ser \u00fatil para la ca -\nracterizaci\u00f3n taxon\u00f3mica de aislados de C. coli. \nPalabras clave: Campylobacter coli ; m\u00e9todos de tipi\ufb01caci\u00f3n; an\u00e1lisis de se -\ncuencias; MLST; diarrea. \nINTRODUCTION\nThe Gram-negative bacterium Campylobacter spp. is a zo -\nonotic pathogen which may be part of the gut microbiota of a range of wild and domesticated mammal and bird species\n1. This \nbacterium is able to colonize the intestines of chicken, turkey and waterfowl and to be transmitted to human by faecal-oral ABSTRACT\nIntroduction. Different subtypes of Campylobacter spp. \nhave been associated with diarrhoea and a Multilocus Se-quence Typing (MLST) method has been performed for subtyp -\ning. In the present work, MLST was used to analyse the genetic diversity of eight strains of Campylobacter coli.\nMaterial and methods. Nineteen genetic markers \nwere ampli\ufb01ed for MLST analysis: AnsB, DmsA, ggt, Cj1585c, \nCJJ81176-1367/1371, Tlp7, cj1321-cj1326, fucP, cj0178, \ncj0755/cfrA, ceuE, pldA, cstII, cstIII. After comparing the ob-\ntained sequences with the Campylobacter MLST database, the \nallele numbers, sequence types (STs) and clonal complexes (CCs) were assigned.\nResults. The 8 C. coli isolates yielded 4 different STs be -\nlonging to 2 CCs. Seven isolates belong to ST-828 clonal com -\nplex and only one isolate belong to ST-21. Two samples came from the same patient, but were isolated in two different pe-riods of time.\nConclusions. MLST can be useful for taxonomic charac-\nterization of C. coli isolates.\nKey words: Campylobacter coli ; typing methods; Sequence Typing; MLST; \ndiarrhoea Multilocus Sequence Typing analysis of human \nCampylobacter coli in Granada (Spain)\n1Biobanco del Sistema Sanitario P\u00fablico Andaluz (BBSSPA). Granada.\n2Departamento de Microbiolog\u00eda. Facultad de Medicina. Universidad de Granada.\n3Laboratorio de Microbiolog\u00eda Complejo Hospitalario Universitario de Granada (Hospital Virgen de las Nieves).Jos\u00e9 Antonio Carrillo-\u00c1vila1\nAntonio Sorl\u00f3zano-Puerto2\nMercedes P\u00e9rez-Ruiz3\nJos\u00e9 Guti\u00e9rrez-Fern\u00e1ndez2,3\nCorrespondencia:\n Jos\u00e9 Guti\u00e9rrez-Fern\u00e1ndezDepartamento de Microbiolog\u00eda. Facultad de Medicina. Avenida de la Investigaci\u00f3n 11. E-18016 Granada, Spain. E-mail: josegf@go.ugr.esBrief reportMultilocus Sequence Typing analysis of human Campylobacter coli in Granada (Spain) J. A. Carrillo-\u00c1vila, et al.\nRev Esp Quimioter 2016;29(6): 332-335 333DNA extraction and quanti\ufb01cation. DNA was extract-\ned from chocolate agar plates cultures. One ml. of PBS pH 7.5 \nwas added to each plate. Campylobacter were resuspended \nwith an inoculating loop. Resuspended bacteria in PBS were recovered and added to a 1.5 ml Eppendorf tube. The Eppen -\ndorf tubes were centrifuged for 10 min at 5000 g. Pellet were resuspended in 180 \u00b5l Buffer ATL (Qiagen, CA, USA) and DNA was extracted using QiAamp DNA Mini kit (Qiagen, CA, USA) following manufacturer instructions. DNA concentration and purity (A\n260/A280) were measured using a Nanodrop (Thermo \nScienti\ufb01c, USA).\nMLST. Nineteen genetic markers were ampli\ufb01ed for MLST \nanalysis following Zautner et al. recommendation8: AnsB, Dm-\nsA, ggt (g-glutamil transpeptidase), Cj1585c (oxidoreductase), \nCJJ81176-1367/1371 (serin protease), Tlp7, cj1321-cj1326, \nfucP, cj0178, cj0755/cfrA, ceuE, pldA, cstII, cstIII. PCR prod -\nucts were puri\ufb01ed using StrataPrep PCR Puri\ufb01cation Kit (cat n\u00ba 400771, Agilent Technologies, CA, USA) and sequenciation was carried out in an ABI PRISM 3100 genetic Analyzer (Aplied Biosystem, CA, USA). After comparing the obtained sequences with the Campylobacter MLST database (http://pubmlst.org/\ncampylobacter), the allele numbers, sequence types (STs) and clonal complexes (CCs) were assigned\n9.\nRESULTS\nThe 8 C. coli isolates yielded 4 different STs belonging to \n2 CCs. Seven isolates belonged to ST-828 clonal complex and only one isolate belonged to ST-21. Two samples came from the same patient, but were isolated 23 days apart (table 1).\nDISCUSSION \nCurrently, phylogenetic methods like MLST are considered \nto be the standard typing methods for Campylobacter spp. iso-lates\n5. Many different host-adapted clonal complexes never or route. Based on its frequency, Campylobacter jejuni  is the most \nimportant causing diarrhoea in humans whereas Campylobacter \ncoli is the most resistant to antibiotics, although is much less fre -\nquent causing disease in humans2. Campylobacter infection in \nhumans tends to be sporadic, and rarely manifests as outbreaks \nexcept when a single point source results in direct transmission to many people, for example, via contaminated drinking water\n3. \nDifferent subtypes of Campylobacter spp. have been associated \nwith different manifestations of disease such as diarrhoea, and several subtyping methods have been established during the past years\n4. In the last years sequence-based methods, such as \nMultilocus Sequence Typing (MLST)5 and the sequencing of the \nshort variable region of the \ufb02agellin A gene are widely used4. \nMLST has shown some advantages over other molecular meth -\nods because includes transferability, standardized nomenclature, free access to the database and direct comparability of results between different studies\n6. In the present work, MLST was per -\nformed to analyse the genetic diversity of eight strains of C. coli  \nisolated in Granada (Spain) in a short period of time.\nMATERIAL AND METHODS\nClinical samples. Eight faeces samples isolated in Grana -\nda (Spain) from seven patients with ages between 5 months and 38 years old were analysed for the pres -\nence of Campylobacter spp. All samples were \ncultured at the Microbiology Department of Virgen de las Nieves Hospital Complex, Gra -\nnada, between August 19\nth, 2013 and Oc -\ntober 21th, 2013. Samples were gathered in \nsterile containers with no transport media and delivered to our laboratory under re -\nfrigeration (4 \u00b0C), with a maximum delay of 2 hours before their processing. They were processed for coproculture immediately on their reception by culture in CampyBAP\u00ae medium with 10% blood (Becton Dickinson, BD, Franklin Lakes, NJ, USA) using a 30-\u00b5g cefoxitin disk (BD BBL\u00ae) and incubated for 48h at 42\u00b0C in microaerophilic atmosphere (Campygen\u00ae, Oxoid, Basingstoke, UK). Suspi -\ncious colonies were identi\ufb01ed by means of oxidase cytochrome tests (Difco, Detroit, MI, USA), Gram staining, and mass spectrometry using the Biotyper\u00ae system (Bruker Daltonics, Coventry, UK). The samples were also seeded in the usual culture media for enteropathogens for 48 h (XLD\u00ae agar [BD] at 37\u00b0C for recovery of Salmonella, Shigella, and Plesiomonas, and CIN\u00ae agar [BD] \nat 30\u00b0C for recovery of Yersinia and Aeromonas) or 24h (Sel -\nenito\u00ae broth [Difco] for recovery of Salmonella, followed by a \nsubculture in Hektoen\u00ae agar [BD] at 37 \u00b0C). Colonies suspect -\ned of being enteropathogenic were identi\ufb01ed by means of the Biotyper\u00ae system (Bruker Daltonics) and the usual biochemi -\ncal tests (MicroScan; Siemens Healthcare, Rockville, MD, USA). Colonies identi\ufb01ed as Salmonella were subjected to the agglu -\ntination test to determine the serogroup (Difco)\n7.Table 1  Results for the eight samples analysed. Clonal complex \nand sequence type for the eight strains analysed are indicated. The samples with *, 56758 and 64611, were isolated from the same patient 23 days apart. Age of patients is indicated in the table.\nSAMPLE CODE PATIENT AGE CLONAL COMPLEX SEQUENCE TYPE\n56602 10 months ST-21 1526\n56628 10 years ST-828 825\n56758* 38 years ST-828 825\n57554 6 years ST-828 825\n64611* 38 years ST-828 825\n66537 2 years ST-828 825\n64642 5 months ST-828 5755\n70069 7 years ST-828 464Multilocus Sequence Typing analysis of human Campylobacter coli in Granada (Spain) J. A. Carrillo-\u00c1vila, et al.\nRev Esp Quimioter 2016;29(6): 332-335 334Infectious etiology of diarrheas studied in a third-level hospital \nduring a \ufb01ve-year period. Rev Esp Enferm Dig 2015;107:89-97. \n3. Ragimbeau C, Schneider F, Losch S, Even J, Mossong J. Multi -\nlocus sequence typing, pulsed-\ufb01eld gel electrophoresis, and \ufb02a short variable region typing of clonal complexes of Campylo-\nbacter jejuni strains of human, bovine, and poultry origins in Luxembourg. Appl Envir Microbiol 2008;74:7715-22. \n4. Zautner AE, Masanta WO, Tareen AM, Weig M, Lugert R, Gross U, et al. Discrimination of multilocus sequence typing-based Campylobacter jejuni subgroups by MALDI-TOF mass spectrome -\ntry. BMC Microbiol 2013;13:247.\n5. Dingle KE, Colles FM, Wareing DR, Ure R, Fox AJ, Bolton FE, et al. Multilocus sequence typing system for Campylobacter jejuni. \nJ Clin Microbiol 2001;39:14-23. \n6. Karenlampi R, Rautelin H, Schonberg-Norio D, Paulin L, Hanni-nen ML. Longitudinal study of Finnish Campylobacter jejuni and C. coli isolates from humans, using multilocus sequence typing, including comparison with epidemiological data and isolates from poultry and cattle. Appl Environ Microbiol 2007;73:148-55. \n7. Gomez-Camarasa C, Gutierrez-Fernandez J, Rodriguez-Grang -\ner JM, Sampedro-Martinez A, Sorlozano-Puerto A, Navar -\nro-Mari JM. Evaluation of the rapid RIDAQUICK Campylobac -\nter(R) test in a general hospital. Diag Microbiol Infect Disease. 2014;78(2):101-4.\n8. Zautner AE, Ohk C, Tareen AM, Lugert R, Gross U. Epidemiologi -\ncal association of Campylobacter jejuni groups with pathogenic-\nity-associated genetic markers. BMC Microbiol. 2012;12:171.\n9. Jolley KA, Chan MS, Maiden MC. mlstdbNet - distributed mul -\nti-locus sequence typing (MLST) databases. BMC Bioinformatics. 2004;5:86.\n10. Vidal AB, Colles FM, Rodgers JD, McCarthy ND, Davies RH, Maid-en MC, et al. Genetic diversity of Campylobacter jejuni and Cam-\npylobacter coli isolates from conventional broiler \ufb02ocks and the impact of sampling strategy and laboratory method. Appl Envi -\nron Microbiol 2016; 82(8):2347-55.\n11. Jorgensen F, Ellis-Iversen J, Rushton S, Bull SA, Harris SA, Bryan SJ, et al. In\ufb02uence of season and geography on Campylobac-\nter jejuni and C. coli subtypes in housed broiler \ufb02ocks reared in Great Britain. Appl Environ Microbiol 2011;77:3741-8. \n12. Rotariu O, Dallas JF, Ogden ID, MacRae M, Sheppard SK, Maid -\nen MC, et al. Spatiotemporal homogeneity of Campylobacter \nsubtypes from cattle and sheep across northeastern and south -\nwestern Scotland. Appl Environ Microbiol 2009;75:6275-81. \n13. Miller RS, Miller WG, Behringer M, Hariharan H, Matthew V, Oyarzabal OA. DNA identi\ufb01cation and characterization of Campylobacter jejuni and Campylobacter coli isolated from caecal samples of chickens in Grenada. J Applied Microbiol 2010;108:1041-9. \n14. Quintana-Hayashi MP, Thakur S. Phylogenetic analysis reveals common antimicrobial resistant Campylobacter coli population \nin antimicrobial-free (ABF) and commercial swine systems. PloS one 2012;7:e44662. only rarely cause disease in humans whereas others may be \ncommon human pathogens with different foodborne sourc -\nes. In the present study one of the isolates belong to ST-21 and seven isolates to ST-828. This is consistent with previous reports by other authors as the ST-21, ST-45 and ST-828 are the most frequent CCs found in humans\n1. These CCs, together \nwith ST-35310, and ST-443, ST-57411 are the most frequent -\nly isolated in poultry and cattle.  A seasonal and geographical \nin\ufb02uence distribution for different STs have been described. In this sense, ST-828 is the most common CC found in sheep in Scotland although, it also has been found in swine production \nsystem\n12. In USA, this ST-828 CC has been extensively found in \nchickens13 and pigs14. A different study has shown that ST-21, \nST-45 and ST828 CCs were the most prevalent CCs in ducks from South Korea\n15.  The different CCs described above are \ncommonly isolated in multiple animal species and shown ex-traordinarily rapid rates of zoonotic transfer leading to little or no phylogenetic association with speci\ufb01c host species\n1. Clonal \ncomplex shown differences in stress responses; this is proba -\nble the main reason for the presence of certain Campylobacter \nspp. subgroups in de\ufb01ned hosts, environments, and the spread over different transmission routes\n4. \nRisk factors for Campylobacter infection, include eating \nor preparing raw or undercooked meat, especially chicken meat, drinking unpasteurized milk or untreated water, contact with domestic animals, foreign travel and swimming in natural bodies of water\n16. Molecular epidemiological investigations are \ncritical to understand the sources and routes of transmission. More than 95% of human infections are attributable to ani -\nmals farmed for meat and poultry. In a study investigating 291 broiler farms in Andalusia, the prevalence of Campylobacter \nspp. in individual animals was 38.1% and the \ufb02ock prevalence was 62.9%\n17. One of the limitations of our study is that we \ndo not have information regarding the source of transmission of the isolates to the patients of our study. One possibility is that they could have been infected with C. coli isolates derived \nfrom cattle or poultry as these reservoirs are the most frequent in the geographical area of the patients\n17 .\nIn this study, seven from eight isolates belong to the same \nclonal complex (ST-828), and \ufb01ve from those seven isolates be-long to the same Sequence Type (825). This fact together with the short period of time when the samples were collected in Granada, allow us to think of a high probability of a common origin of this outbreak, at least for these 5 samples. In conclu -\nsion, this method based on nineteen genes MLST analysis, can be useful for taxonomic characterization of C. coli isolates. \nREFERENCES\n1. Dearlove BL, Cody AJ, Pascoe B, Meric G, Wilson DJ, Shep-\npard SK. Rapid host switching in generalist Campylobacter \nstrains erodes the signal for tracing human infections. ISME J.  2016;10:721-9. .\n2. Sanchez-Capilla AD, Sorlozano-Puerto A, Rodriguez-Granger J, Martinez-Brocal A, Navarro-Mari JM, Gutierrez-Fernandez J. Multilocus Sequence Typing analysis of human Campylobacter coli in Granada (Spain) J. A. Carrillo-\u00c1vila, et al.\nRev Esp Quimioter 2016;29(6): 332-335 33515. Wei B, Cha SY, Kang M, Roh JH, Seo HS, Yoon RH, et al. Anti -\nmicrobial susceptibility pro\ufb01les and molecular typing of Cam-\npylobacter jejuni and Campylobacter coli isolates from ducks in \nSouth Korea. Appl Environ Microbiol. 2014;80:7604-10. \n16. Wingstrand A, Neimann J, Engberg J, Nielsen EM, Gerner-Smidt P, Wegener HC, et al. Fresh chicken as main risk factor for cam -\npylobacteriosis, Denmark. Emerging Infect Dis. 2006;12:280-5. \n17. Torralbo A, Borge C, Allepuz A, Garcia-Bocanegra I, Sheppard SK, Perea A, et al. Prevalence and risk factors of Campylobacter \ninfection in broiler \ufb02ocks from southern Spain. Preventive Vet Med. 2014;114:106-13.Rev Esp Quimioter 2016;29(6): 336-337 336extensamente empleada en los laboratorios de Microbiolog\u00eda \nCl\u00ednica debido a su buena correlaci\u00f3n con la microdiluci\u00f3n en caldo\n1 (t\u00e9cnica de referencia recomendada por los comit\u00e9s del \nCLSI o el EUCAST), siendo adem\u00e1s, m\u00e1s f\u00e1cil y r\u00e1pida de realizar que \u00e9sta. En nuestro laboratorio empleamos el E-test tanto para veri\ufb01car una CMI obtenida por un sistema automatizado como para testar antibi\u00f3ticos que no aparecen en los paneles de dichos sistemas. Al tratarse de una t\u00e9cnica manual es susceptible de incurrir en errores aleatorios, dif\u00edciles de evitar. Sin embargo, resulta de capital inter\u00e9s intentar detectar y evitar el error sistem\u00e1tico en su realizaci\u00f3n, pues podr\u00eda repercutir en el manejo cl\u00ednico y el pron\u00f3stico del paciente frente a microorganismos multirresistentes (aquellos con las CMI m\u00e1s elevadas a varios f\u00e1rmacos), al limitar alternativas terap\u00e9uticas. Esto, por ejemplo, resulta decisivo en el contexto de las infecciones causadas por enterobacterias portadoras de carbapenemasas (EPC), en las que es importante que la realizaci\u00f3n de la t\u00e9cnica de E-test sea \ufb01able y reproducible.\nLa implantaci\u00f3n de los programas de calidad en los \nlaboratorios de bacteriolog\u00eda cuenta con trabas como la heterogeneidad y variabilidad de las muestras empleadas, el habitual empleo de t\u00e9cnicas manuales dif\u00edciles de controlar y el hecho de trabajar con organismos vivos, por ello susceptibles a cambios durante su manipulaci\u00f3n. Sin embargo constituyen una herramienta necesaria cuyo objetivo es el de estandarizar y homogeneizar sistemas de trabajo para hacerlos reproducibles y seguros.\nEn octubre de 2015 participamos en un \u201cEstudio \nmultic\u00e9ntrico para determinar la capacidad de los laboratorios espa\u00f1oles de identi\ufb01car fenotipos de resistencia a los beta-lact\u00e1micos en enterobacterias\u201d organizado por la Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica (SEIMC). Participando en el mismo, tuvimos la oportunidad de descubrir un error sistem\u00e1tico en la realizaci\u00f3n de E-test que sobrevaloraba la CMI a los carbapenemes. Los resultados hac\u00edan dif\u00edcil o imposible el empleo de esta familia de antimicrobianos frente a las EPC.Sr. Editor: la concentraci\u00f3n m\u00ednima inhibitoria o CMI\n90 \nse de\ufb01ne como la concentraci\u00f3n m\u00ednima de antimicrobiano necesaria para inhibir el crecimiento del 90% de una poblaci\u00f3n bacteriana en un medio de cultivo despu\u00e9s de su incubaci\u00f3n. Se establece en el laboratorio aplicando concentraciones conocidas crecientes de un determinado antimicrobiano a una diluci\u00f3n tambi\u00e9n conocida de poblaci\u00f3n bacteriana ajustada a un coe\ufb01ciente de turbidez, que denominamos \u00edndice de McFarland, y que se correlaciona con la cantidad de bacteria en ese medio de cultivo. Este coe\ufb01ciente de turbidez se mide con aparatos denominados nefel\u00f3metros en un proceso \u00e1gil y rutinario en todos los laboratorios de Microbiolog\u00eda. Para poder extrapolar y reproducir de manera global los resultados sobre sensibilidad o resistencia a los antibi\u00f3ticos de los microorganismos, as\u00ed como las circunstancias en que esto sucede, se necesitan est\u00e1ndares internacionales tanto de la especie bacteriana (cepas ATCC) como en la concentraci\u00f3n en el medio (\u00edndice de McFarland). A partir de estos est\u00e1ndares, se marcan internacionalmente los puntos de corte de sensibilidad o resistencia, que se correlacionar\u00e1n con el \u00e9xito o fracaso al emplear determinado antimicrobiano e incluso la dosis a la que \u00e9ste se podr\u00eda emplear. Estos puntos de corte se actualizan continuamente en funci\u00f3n de par\u00e1metros farmacol\u00f3gicos, epidemiol\u00f3gicos y de respuesta cl\u00ednica en comit\u00e9s internacionales, como el Clinical Laboratory Standars Institute (CLSI) o el European Committee for Antimicrobial Susceptibility Testing (EUCAST), que todos los laboratorios siguen, garantizando la calidad y reproducibilidad de los resultados microbiol\u00f3gicos y cl\u00ednicos.\nLa determinaci\u00f3n de la CMI a antimicrobianos por \nmedio de la difusi\u00f3n en gradiente, E-test, es una t\u00e9cnica Controles interlaboratorio: algo m\u00e1s que un examen \nde conocimientos\nServicio de Microbiolog\u00eda Cl\u00ednica. Hospital Cl\u00ednico San Carlos. Universidad Complutense. Madrid. Spain.Marina Pe\u00f1uelas\nFrancisco Javier CandelAvelina Su\u00e1rez Moya\nCorrespondencia:\nMarina Pe\u00f1uelasServicio de Microbiolog\u00eda Cl\u00ednica. Hospital Cl\u00ednico San Carlos. Universidad ComplutenseAvda Dr Mart\u00edn Lagos s/n28040. Madrid. Spain.Tel\u00e9fono: +34 91 330 3486E-mail: marinapenuelas03@gmail.comCarta al DirectorControles interlaboratorio: algo m\u00e1s que un examen de conocimientos M. Pe\u00f1uelas, et al.\nRev Esp Quimioter 2016;29(6): 336-337 337detectados. 3) Introducci\u00f3n de un control interno mensual en \ncada laboratorio en los que se realiza dicha t\u00e9cnica con una cepa ATCC. \nDe esta experiencia quisi\u00e9ramos destacar el papel \nrelevante de la participaci\u00f3n en ensayos de aptitud o pruebas de intercomparaci\u00f3n en el establecimiento de pol\u00edticas y procedimientos robustos que garanticen la \ufb01abilidad de los resultados emitidos. Del mismo modo, quisi\u00e9ramos remarcar la utilidad de los programas de calidad en los centros sanitarios, que nos permiten detectar errores e iniciar las acciones correctivas con objeto de mejorar la e\ufb01cacia de nuestros laboratorios y la mejor asistencia a nuestros pacientes. \nBIBLIOGRAF\u00cdA\n1. G\u00f3mez-Garc\u00e9s JL, L\u00f3pez-Faba lF, Burillo A, Yolanda Gil A. \n\u201cEstudio comparativo de Wider, E-test y microdiluci\u00f3n para la determinaci\u00f3n de la sensibilidad a daptomicina y otros tres antimicrobianos de aislamientos cl\u00ednicos de Staphylococcus spp. resistentes a meticilina y Enterococcus spp\u201d. Rev Esp Quimioter \n2010; 23: 87-92.\n2. Garc\u00eda-Rodr\u00edguez JA, Cant\u00f3n R, Garc\u00eda S\u00e1nchez JE, G\u00f3mez-Lus ML, Mart\u00ednez-Mart\u00ednez L, Rodr\u00edguez-Avial C, Vila J. 11. \u201cM\u00e9todos b\u00e1sicos para el estudio de la sensibilidad a los antimicrobianos\u201d en Picazo JJ, \u201cProcedimientos en Microbiolog\u00eda Cl\u00ednica\u201d. (http://www.seimc.org/) 1\u00aa edici\u00f3n. 2000.En esta situaci\u00f3n se llev\u00f3 a cabo un an\u00e1lisis de las posibles \ncausas que comenz\u00f3 por veri\ufb01car la realizaci\u00f3n de todas las \ncalibraciones de nefel\u00f3metros programadas desde antes de la realizaci\u00f3n de la prueba. A continuaci\u00f3n se revis\u00f3 la manera de \nrealizar los E-test por parte del personal t\u00e9cnico descubriendo \nuna falta de homogeneidad. En este punto y para eliminar variables interindividuales, una \u00fanica persona repiti\u00f3 la t\u00e9cnica de E-test con 10 de las cepas de la prueba, empleando otro nefel\u00f3metro (denominado nefel\u00f3metro control) y siguiendo las indicaciones publicadas para la realizaci\u00f3n del McFarland seg\u00fan los protocolos de la SEIMC\n2. Se consideraron aceptables \nlos resultados dentro de un rango de dos diluciones por ambos \nextremos respecto a las enviadas por el grupo organizador \ndel estudio. De esta manera se obtuvieron 9/10 resultados aceptables. A continuaci\u00f3n se repiti\u00f3 la determinaci\u00f3n con el mismo nefel\u00f3metro empleado en la realizaci\u00f3n de la prueba (denominado nefel\u00f3metro HC) y a\u00f1adiendo a las \ncepas probadas una cepa ATCC de referencia (E. coli 25922), \nobteniendo tambi\u00e9n 9/10 resultados aceptables m\u00e1s el correspondiente a la cepa ATCC. Se consider\u00f3 que las cepas que se sal\u00edan de los criterios de aceptabilidad eran fruto de un error aleatorio no grave (tabla 1).\nCon estos resultados se tomaron las siguientes medidas: \n1) Implantaci\u00f3n de una instrucci\u00f3n t\u00e9cnica de c\u00f3mo realizar un E-test; 2) Introducci\u00f3n en el plan de formaci\u00f3n continuada del personal t\u00e9cnico del laboratorio una sesi\u00f3n sobre dicha instrucci\u00f3n t\u00e9cnica haciendo especial hincapi\u00e9 en los fallos Tabla 1  CMI a meropenem determinada por E-test frente a cepas de EPC remitidas del \nprograma SEIMC y n\u00famero de diluciones de diferencia respecto a la referencia. \nDatos del estudio intercomparativo y de las comprobaciones realizadas con distintos nefel\u00f3metros siguiendo las normas de realizaci\u00f3n de E-test publicadas. \naLos dos casos en los que se obtuvieron valores de CMI con una diferencia superior \na dos diluciones respecto a la referencia correspond\u00edan a pruebas realizadas sobre cepas distintas con nefel\u00f3metros diferentes  siendo en un caso un error por exceso y en otro por defecto, por lo que se consideraron errores aleatorios.      Nefel\u00f3metro control       Nefel\u00f3metro HC\nCEPACMI Referencia \n(SEIMC)Resultados obtenidos en \nnuestro laboratorioCMI N\u00ba diluciones CMI N\u00ba diluciones\nE. coli 0,5 >32 8 4a0,75 1\nE. cloacae 4 >32 1,5 -1 0,38 -3a\nK. pneumoniae 8 >32 3 -1 3 -1\nK. pneumoniae >32 >32 >32 0 >32 0\nK. pneumoniae 0,125 0,25 0,047 -1 0,094 0\nK. oxytoca 1 1 0,5 -1 1 0\nK. pneumoniae 2 >32 1,5 0 1,5 0\nR. ornithinolylica 0,5 4 0,75 1 0,38 0\nE. coli 0,25 16 0,75 2 0,25 0\nE. aerogenes 0,125 3 0,125 0 0,125 0Rev Esp Quimioter 2016;29(6): 338-339 338nuestro hospital una t\u00e9cnica de diagn\u00f3stico molecular, el en -\nsayo Genotype MTBC (Hain Lifescience, Nehren, Germany). Esta \nt\u00e9cnica consiste en una ampli\ufb01caci\u00f3n de \u00e1cido nucleico por \nPCR y posteriormente en una hibridaci\u00f3n en fase s\u00f3lida que diferencia las siguientes especies pertenecientes a Mycobac-\nterium tuberculosis complex: M. tuberculosis/M. canettii, M. \nafricanum, M. microti, M. bovis subsp. bovis, M. bovis subsp. \ncaprae, y M. bovis BCG.La utilizaci\u00f3n de este ensayo permiti\u00f3 \nidenti\ufb01car el aislamiento de Mycobacterium tuberculosis com-plex como M. tuberculosis y M. africanum. A la vista de estos resultados, se descart\u00f3 la contaminaci\u00f3n cruzada. \nDurante este periodo la paciente continu\u00f3 con el mismo \ntratamiento antirretroviral.\nPosteriormente, en el a\u00f1o 2011, nuestra paciente fue in -\ngresada de nuevo en el hospital por presentar un cuadro febril de 3 semanas de evoluci\u00f3n. Hab\u00eda sido diagnosticada de amig -\ndalitis y se paut\u00f3 amoxicilina/\u00e1cido clavul\u00e1nico, sin mejor\u00eda. Se palpaba una adenopat\u00eda laterocervical izquierda y refer\u00eda tos productiva con expectoraci\u00f3n parduzca y malestar general. Presentaba una carga viral de VIH inferior a 20 copias y cifra de CD4 de 499. La TAC de t\u00f3rax no mostr\u00f3 datos de afectaci\u00f3n pulmonar. Las muestras para estudio de micobacterias fueron: una punci\u00f3n de la adenopat\u00eda cervical que fue negativa, dos hemocultivos para micobacterias que fueron negativos y tres esputos todos ellos con baciloscopia negativa. En todos los es -\nputos se aisl\u00f3 M. avium y en dos de ellos adem\u00e1s M. africanum. \nLa prueba de sensibilidad a f\u00e1rmacos de primera l\u00ednea (isonia -\nzida, rifampicina, pirazinamida, etambutol y estreptomicina) a la cepa de M. africanum realizada por el sistema BACTEC\nTM \nMGIT 960 system (Becton Dickinson, Maryland USA) mostr\u00f3 sensibilidad a todos los f\u00e1rmacos.\n En la biopsia ganglionar realizada se aisl\u00f3 M. avium y M. \nafricanum, se objetiv\u00f3 linfadenitis granulomatosa con granu -\nlomas necrotizantes y la tinci\u00f3n de Kinyoun fue positiva.\nInicialmente se paut\u00f3 tratamiento con isoniazida, rifam -\npicina, pirazinamida y etambutol pero la paciente desarroll\u00f3 Sr. Editor: las micobacterias no tuberculosas (MNT) son \nmicroorganismos de distribuci\u00f3n ubicua en el medio ambiente que tradicionalmente han sido consideradas pat\u00f3genos opor-tunistas. En la actualidad existe una preocupaci\u00f3n creciente por el aislamiento de MNT en muestras cl\u00ednicas. En pacientes inmunodeprimidos, tanto las micobacterias tuberculosas (MTC) como las MNT son pat\u00f3genos oportunistas frecuentes. Un reto importante es la interpretaci\u00f3n del signi\ufb01cado cl\u00ednico de los aislamientos mixtos de MTC y MNT. \nPresentamos el caso de una paciente con aislamiento mix -\nto de MTC y MNT. \nSe trata de una mujer de 34 a\u00f1os de edad, natural de \nNigeria que reside en Espa\u00f1a desde el a\u00f1o 2003. En el a\u00f1o 2005 es diagnosticada de infecci\u00f3n por VIH con carga viral de 106.000 copias y cifra de linfocitos CD4 de 432, con un nadir a \ufb01nales de ese mismo a\u00f1o de 187. Presentaba un  Sarcoma de Kaposi de afectaci\u00f3n cut\u00e1nea que remiti\u00f3 tras tratamiento an -\ntirretroviral con efavirenz, emtricitabina y tenofovir. Posterior -\nmente, en ese mismo a\u00f1o present\u00f3 sepsis de origen urinario por Escherichia coli. Durante este episodio se recogieron dos \nmuestras de esputo y se realiz\u00f3 una punci\u00f3n medular. Las baci -\nloscopias de ambos esputos fueron negativas y en uno de ellos se aisl\u00f3 Mycobacterium tuberculosis complex, hallazgo consi-derado como una posible  contaminaci\u00f3n cruzada. La paciente no presentaba s\u00edntomas, la radiograf\u00eda de t\u00f3rax era normal y no recibi\u00f3 tratamiento tuberculost\u00e1tico.\nLa paciente present\u00f3 buena tolerabilidad al tratamiento \nantirretroviral, manteniendo e\ufb01cacia virol\u00f3gica, carga viral en plasma indetectable,  y recuperaci\u00f3n inmunol\u00f3gica, concentra -\nciones de CD4 superiores a 800 hasta 2010.\nEn 2010 se introdujo en el Servicio de Microbiolog\u00eda de Coinfecci\u00f3n por Mycobacterium africanum y \nMycobacterium avium en una paciente con SIDA\n1Facultad de Ciencias Biom\u00e9dicas y Salud. Universidad Europea de Madrid. Villaviciosa de Od\u00f3n (Madrid).\n2Servicio de Microbiolog\u00eda. Hospital Universitario de Getafe (Madrid).\n3Servicio de Medicina Interna. Hospital Universitario de Getafe (Madrid).Ana Garc\u00eda-Ca\u00f1as1\nJuana Cacho-Calvo2\nGabriel Gaspar Alonso-\nVega3\nF. Javier Esteban-Fern\u00e1ndez3\nSergio Julio Rodriguez-\u00c1lvarez\n3\nGloria P\u00e9rez-Caballero3\nEmilia Cond\u00e9s-Moreno1\nCorrespondencia:\nAna Garc\u00eda Ca\u00f1as Facultad de Ciencias Biom\u00e9dicas y Salud. Universidad Europea de Madrid. Villaviciosa de Od\u00f3n (Madrid).Tfno.: 912115309. E-mail: ana.garcia4@universidadeuropea.esCarta al DirectorCoinfecci\u00f3n por Mycobacterium africanum y Mycobacterium avium en una paciente con SIDA A. Garc\u00eda-Ca\u00f1as, et al.\nRev Esp Quimioter 2016;29(6): 338-339 339culosis in Ontario, Canada. Int J Tuberc Lung Dis 2013; 17: 676-681. \n4. Sharma K, Sharma A, Modi M, Singh G, Kaur H, Varma S, et al. PCR \ndetection of co-infection with Mycobacterium tuberculosis and \nMycobacterium avium in AIDS patients with meningitis. J Med Mi -\ncrobiol 2012; 61: 1789-91. \n5. Sharma K, Mewara A, Gupta N, Sharma A, Varma S. Multiplex PCR in diagnosis of M. tuberculosis and M. avium co-infection from lymph node in an AIDS patient. Indian J Med Microbiol 2015; 33 Suppl: 151-153. hepatitis, eosino\ufb01lia, anemia hemol\u00edtica y toxicidad cut\u00e1nea \nque hicieron sospechar de un cuadro de toxicidad por rifam -\npicina. Se cambi\u00f3 el tratamiento a isoniazida, pirazinamida, etambutol y claritromicina durante 2 meses, seguido de isonia-zida, etambutol y claritromicina 16 meses m\u00e1s para cubrir a los dos pat\u00f3genos ante la sospecha de coinfecci\u00f3n por M. avium y \nM. africanum. La evoluci\u00f3n posterior fue buena considerando criterios cl\u00ednicos y microbiol\u00f3gicos (el cultivo y la tinci\u00f3n para micobacterias de un exudado ganglionar que dren\u00f3 espont\u00e1 -\nneamente fueron negativos).\nEl aislamiento de MNT en muestras respiratorias no es \nsu\ufb01ciente para establecer el diagn\u00f3stico de enfermedad, son necesarios criterios cl\u00ednicos, microbiol\u00f3gicos y radiol\u00f3gicos\n1. \nLa interpretaci\u00f3n de los aislamientos mixtos de MTC y MNT en muestras respiratorias plantea di\ufb01cultades ya que puede tratarse de una colonizaci\u00f3n, o de una contaminaci\u00f3n de la muestra, por parte de la MNT, o de una aut\u00e9ntica coinfecci\u00f3n. En los \u00faltimos a\u00f1os son varios los estudios que resaltan la im -\nportancia de no ignorar la posible signi\ufb01caci\u00f3n cl\u00ednica de las MNT halladas en aislamientos mixtos en muestras respirato -\nrias\n2, y de realizar un seguimiento de  los pacientes con tuber -\nculosis pulmonar y aislamientos mixtos3.\nEl desarrollo de las t\u00e9cnicas moleculares para la identi -\n\ufb01caci\u00f3n de micobacterias nos permite detectar cultivos con aislamientos m\u00faltiples con mayor facilidad y rapidez. Esto es esencial para poder establecer un diagn\u00f3stico y tratamiento adecuado en el caso de pacientes con SIDA\n4,5. En el caso des -\ncrito, el aislamiento de M. avium y M. africanum se produjo en \nmuestras respiratorias y ganglionares. Se interpret\u00f3 como una coinfecci\u00f3n y se realiz\u00f3 tratamiento para cubrir los dos pat\u00f3 -\ngenos. La evoluci\u00f3n de la paciente fue favorable.\nFINANCIACI\u00d3N\nLos autores declaran no haber recibido \ufb01nanciaci\u00f3n para \nla realizaci\u00f3n de este estudio.\nCONFLICTO DE INTERESES\nLos autores declaran no tener ning\u00fan con\ufb02icto de inte-\nreses.\nBIBLIOGRAF\u00cdA\n1. Grif\ufb01th DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gor -\ndin F, et al. An of\ufb01cial ATS/IDSA statement: diagnosis, treatment, \nand prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416. \n2. Hwang SM, Lim MS, Hong YJ, Kim TS, Park KU, Song J, et al. Si-multaneous detection of Mycobacterium tuberculosis complex  and \nnontuberculous mycobacteria in respiratory specimens. Tuberculo -\nsis 2013; 93: 642-646. \n3. Damaraju D, Jamieson F, Chedore P, Marras T. Isolation of non-tuberculous mycobacteria among patients with pulmonary tuber -Rev Esp Quimioter 2016;29(6): 340-341 340is slightly higher than that documented for us. The differen -\nce between their studies and ours is that we have studied all \nranks and not only those over 14 years as by Uematsu et al.7 or \nover 50 years in the case of Gil Prieto et al.8 . In our experien-\nce, 75% of patients admitted for pneumonia at age 62 HCUV years.\nThe present contribution seeks to establish a single mes -\nsage: the burden of hospitalization for pneumonia from the eighth decade of life is very important in our environment. Concomitantly it should be noted that a strategy of vacci -\nnation against the agents mainly involved in the etiology of pneumonia, Streptococcus pneumoniae or Haemophilus in-\n\ufb02uenza, can be highly ef\ufb01cient in our environment. In this sen -\nse, the greater understanding of the epidemiology of pneumo -\ncoccal disease is the key for setting public health policies. Our results are presented as a preliminary step to an economic as -\nsessment of the vaccination strategy against S. pneumoniae in our old population and determining risk conditions that provi -\nde more useful. These analyzes of ef\ufb01ciency are already being made recently by other authors in other contexts, presenting vaccination as a highly ef\ufb01cient tool\n9,10.\nREFERENCES\n1. Vila-C\u00f3rcoles A, Aguirre-Chavarr\u00eda C, Ochoa-Gondar O, de Diego C, \nRodr\u00edguez-Blanco T, G\u00f3mez F et al. In\ufb02uence of chronic illnesses and underlying risk conditions on the incidence of pneumococcal pneumonia in older adults. Infection 2015; 43: 699-706.\n2. Gil-Prieto R, Pascual-Garcia R, Walter S, \u00c1lvaro-Meca A, Gil-De-Miguel \u00c1. Risk of hospitalization due to pneumococcal disease in adults in Spain. The CORIENNE study. Hum Vaccin Immunother 2016; 12: 1900-5.\n3. Calder\u00f3n C, Dennis R. Economic cost of Streptococcus pneumoniae \ncommunity-acquired pneumonia, meningitis and bacteremia in an adult population that required hospitalization in Bogot\u00e1, Colom -\nbia. Biomedica 2014; 34: 92-101.Sir,\nThe importance of determining disease burden for pneu -\nmonia is suf\ufb01ciently proven. A large number of articles have \nbeen published in our country1-3 and outside4-7 in this sense.\nAware of this, our group has set up a retrospective study \nin which have been revised 5,758 episodes of pneumonia ad -\nmitted to the University Hospital of Valladolid, that  serving a population of 275,000, for the period 2009-2014.  The annual income range for this cause ranged from 1,029 (in 2009) and 907 (2014), with \ufb01gures of 925, 979, 1002 and 916 for inter-mediate consecutive years. Hospitalization for pneumonia was higher in men than in women with a ratio of 1.78. The mean age of patients admitted for this reason was at 67.86 years with a standard deviation of 23.28 years. The age range in which more episodes documented was the 76-85 years with 1,844 patients (32.04% of total); the fewest episodes was de -\ntected in the range under 15 with 294 patients (5.10% of to-tal). The rate of hospitalization for pneumonia in our study was 3.54 people per 1,000 population hospitalized; being to 23.66 per thousand inhabitants in those over 86 years. The hospitali-zation rate that we obtained in our study indicates that 38.88 per thousand incomes is a type of pneumonia. As for seasonal analysis in the \ufb01rst \ufb01ve weeks of the onset of winter in our la -\ntitude (end of year two and three of the beginning of the next) maximum input values   are reached.\nThe female-male ratio of 0.58 published by Uematsu et \nal.\n7 in a multicenter study of 289 hospitals is particularly mat -\nched to that obtained in our work of 0.59 as is also the avera-ge age of both series. The burden of hospitalization for acute pneumonia Community described in a series published in 2011 by Gil-Prieto et al.\n8 increases to advance the age range and Pneumonia: burden of disease\nHospital Cl\u00ednico Universitario y Facultad de Medicina de Valladolid, SpainMiguel L\u00f3pez GobernadoAlberto P\u00e9rez-RubioAgust\u00edn MayoJos\u00e9 M\u00aa Eiros\nCorrespondence:\nJos\u00e9 M\u00aa Eiros BouzaMicrobiolog\u00eda, 6\u00aa Planta. Facultad de Medicina. Avda Ram\u00f3n y Cajal, 7. 47005 Valladolid. Tfno.: 983-423063Fax: 983-423022E-mail: eiros@med.uva.esCarta al DirectorPneumonia: burden of disease M. L\u00f3pez  Gobernado, et al.\nRev Esp Quimioter 2016;29(6): 340-341 3414. Grif\ufb01n MR, Zhu Y, Moore MR, Whitney CG, Grijalva CG. U.S. hospi -\ntalizations for pneumonia after a decade of pneumococcal vacci -\nnation. N Engl J Med. 2013 ; 369: 155-63.\n5. Wu DB, Roberts CS, Huang YC, Chien L, Fang CH, Chang CJ. A re -\ntrospective study to assess the epidemiological and economic bur -\nden of pneumococcal diseases in adults aged 50 years and older in \nTaiwan. J Med Econ 2014; 17: 312-9.\n6. Amodio E, Costantino C, Boccalini S, Tramuto F, Maida CM, Vitale F. Estimating the burden of hospitalization for pneumococcal pneu -\nmonia in a general population aged 50 years or older and impli-cations for vaccination strategies. Hum Vaccin Immunother 2014; 10: 1337-42.\n7. Uematsu H, Kunisawa S, Yamashita K, Imanaka Y. The Impact of Patient Pro\ufb01les and Procedures on Hospitalization Costs through Length of Stay in Community-Acquired Pneumonia Patients Ba-sed on a Japanese Administrative Database. PLoS One 2015; 10: e0125284\n8. Gil-Prieto R, Garc\u00eda-Garc\u00eda L, Alvaro-Meca A, M\u00e9ndez C, Garc\u00eda A, de Miguel AG. The burden of hospitalizations for community-acquired pneumonia (CAP) and pneumococcal pneumonia in adults in Spain (2003-2007). Vaccine 2011; 29: 412-6.\n9. Lorente-Anto\u00f1anzas R, Varona Malumbres JL, Anto\u00f1anzas F, Re -\njas J. La vacunaci\u00f3n anti-neumoc\u00f3cica con la vacuna conjugada 13-valente en poblaci\u00f3n inmunocompetente de 65 a\u00f1os: an\u00e1lisis del impacto presupuestario en Espa\u00f1a implicando un modelo de transmisi\u00f3n din\u00e1mica. Rev Esp Salud P\u00fablica.2016; 90: 1-12.\n10. Werkhoven C, Hollingsworth R, Huijts S, Bolkenbaas M, Webber C, Patterson S, Sanders E, Bonten M. Pneumococcal conjugate va -\nccine herd effects on non-invasive pneumococcal pneumonia in elderly. Vaccine. 2016; 34 :3275-82.Rev Esp Quimioter 2016;29(6): 342-344 342ban recibiendo corticoides durante el periodo de incubaci\u00f3n de \nla varicela10.\nPresentamos un caso de afectaci\u00f3n visceral generalizada, \nque evolucion\u00f3 r\u00e1pidamente a fallo multiorg\u00e1nico fulminante y muerte por varicela z\u00f3ster, en un adulto que hab\u00eda recibido dosis altas de corticoides.\nMujer de 27 a\u00f1os, entre los antecedentes de inter\u00e9s des -\ntaca que tres semanas antes de su ingreso en UCI, la paciente estuvo ingresada en el Servicio de Neurolog\u00eda por cansancio, p\u00e9rdida de fuerza y hormigueos en extremidades superiores, acompa\u00f1ada de alteraciones de la visi\u00f3n en forma de diplop\u00eda. Fue diagnosticada de esclerosis m\u00faltiple y tratada con corticoi -\ndes recibiendo  inicialmente una dosis de choque de 5,75 g in -\ntravenosos de metilprednisolona, continuando posteriormente con el tratamiento corticoideo en pauta descendente. Ante la buena evoluci\u00f3n fue dada de alta a domicilio. \nA las tres semanas de ser dada de alta, reingresa  en el \nServicio de Digestivo por fallo hep\u00e1tico y lesiones cut\u00e1neas de etiolog\u00eda no \ufb01liada. En las siguientes 48 horas presenta mala evoluci\u00f3n cl\u00ednica, con importante deterioro del nivel de con -\nciencia secundario a encefalopat\u00eda hep\u00e1tica, e insu\ufb01ciencia respiratoria, motivo por el que se solicita consulta a UCI proce -\ndi\u00e9ndose a ingreso urgente,  intubaci\u00f3n traqueal y ventilaci\u00f3n mec\u00e1nica. En la exploraci\u00f3n, llamaba la atenci\u00f3n la presencia de m\u00faltiples lesiones cut\u00e1neas vesiculares de contenido he-morr\u00e1gico que se encontraban diseminadas por todo el cuerpo (\ufb01gura 1 A y B). En la anal\u00edtica destacaba una elevaci\u00f3n im -\nportante de las transaminasas con aspartato aminotransferasa de 6.204 U/L, y alaninoaminotransferasa de 5.357 U/L. En el estudio de coagulaci\u00f3n exist\u00edan importantes alteraciones, con un tiempo de tromboplastina parcial muy alargado, superior a 250 segundos, tiempo de protrombina superior a 150 segun -\ndos, tasa de protrombina del 16% y d\u00edmero D de 5.881 ng/mL. La paciente presentaba una plaquetopenia de 59.000 y en el hemograma destacaba una leucocitosis de 28.000 con impor -\ntante desviaci\u00f3n izquierda. Sr. Editor: la varicela es una enfermedad aguda extremada-\nmente contagiosa, producida por el virus varicela-z\u00f3ster (VVZ), que afecta fundamentalmente a ni\u00f1os y produce \ufb01ebre, s\u00ednto-mas generales y una erupci\u00f3n d\u00e9rmica t\u00edpica. El herpes z\u00f3ster es la manifestaci\u00f3n local de la reactivaci\u00f3n de una infecci\u00f3n latente por el VVZ, en los ganglios de las ra\u00edces dorsales o del trig\u00e9mino, y que puede aparecer por estr\u00e9s o  en pacientes con disminuci\u00f3n de la inmunidad celular de distinto origen. La va -\nricela es generalmente una enfermedad benigna en la infancia y deja inmunidad duradera\n1. En pa\u00edses desarrollados la presen -\ntaci\u00f3n en adultos es rara, ya que supone menos del 5% de los casos de varicela, pero en los adultos es una enfermedad gra -\nve con un mayor n\u00famero de complicaciones, pudiendo llegar a ser mortal debido a la aparici\u00f3n de neumon\u00eda, pericarditis, miocarditis, meningitis o encefalitis\n2-4. Las formas m\u00e1s graves \ncon desenlace fatal se producen en pacientes severamente in -\nmunodeprimidos5,6 por lo que en pacientes oncol\u00f3gicos, y con \ntrasplantes tanto de \u00f3rganos s\u00f3lidos como de progenitores hematopoy\u00e9ticos, se recomienda una vigilancia extrema y en ocasiones realizar tratamiento pro\ufb01l\u00e1ctico. La complicaci\u00f3n m\u00e1s frecuente y grave de la varicela en los adultos es la neu -\nmon\u00eda, que ocasiona fallo respiratorio severo precisando ingre -\nso en la Unidad de Cuidados Intensivos (UCI) y tratamiento con ventilaci\u00f3n mec\u00e1nica incluso en pacientes inmunocompeten-tes\n7. La afectaci\u00f3n visceral masiva por el virus de la varicela \nz\u00f3ster, acompa\u00f1ado o no de afectaci\u00f3n cut\u00e1nea, es una pre-sentaci\u00f3n poco habitual de la varicela en pacientes que no es -\nt\u00e1n gravemente inmunocomprometidos pero que han recibido alg\u00fan tipo de f\u00e1rmaco inmunosupresor\n8,9. \nIgualmente se ha descrito un aumento de la gravedad de \nla varicela en ni\u00f1os con leucemia linfobl\u00e1stica aguda que esta -Varicela z\u00f3ster con fallo multiorg\u00e1nico fulminante \ntras altas dosis de corticoides \n1Servicio de Medicina Intensiva, Hospital Universitario Central de Asturias, Oviedo. Espa\u00f1a.\n2Servicio de Microbiolog\u00eda, Hospital Universitario Central de Asturias, Oviedo. Espa\u00f1a.Dolores Escudero1\nSantiago Mel\u00f3n2\nRaquel Rodr\u00edguez-Garc\u00eda1\nLuc\u00eda Vi\u00f1a1\nIv\u00e1n Astola1\nFernando V\u00e1zquez2\nCorrespondencia:\nDolores EscuderoServicio de Medicina Intensiva. Hospital Universitario Central de Asturias.Av. Roma s/n 33011 OviedoTfno: 985108000 Extensi\u00f3n 38162.Fax 985108777 E-mail: dolores.escudero@sespa.princast.esCarta al DirectorVaricela z\u00f3ster con fallo multiorg\u00e1nico fulminante tras altas dosis de corticoides D. Escudero, et al.\nRev Esp Quimioter 2016;29(6): 342-344 343El cuadro cl\u00ednico progres\u00f3 r\u00e1pidamente y de forma fulminante, \nsiendo exitus a las 28 horas de su ingreso en UCI. \nSe le realiz\u00f3 estudio necr\u00f3psico que con\ufb01rm\u00f3 el diagn\u00f3s -\ntico cl\u00ednico con importante afectaci\u00f3n del es\u00f3fago, pulmones, h\u00edgado y bazo, destacando entre todos los hallazgos una ne -\ncrosis hep\u00e1tica masiva. Desde el punto de vista microbiol\u00f3gi -\nco se con\ufb01rm\u00f3 el diagn\u00f3stico de varicela-z\u00f3ster mediante un cultivo r\u00e1pido (Shell-vial, IF) a los 3 d\u00edas del fallecimiento. El cultivo tras 15 d\u00edas sobre monocapas celulares con \ufb01broblastos de pulm\u00f3n fetal humano (\ufb01gura 2B), con\ufb01rm\u00f3 nuevamente el diagn\u00f3stico de varicela-z\u00f3ster. \nEste caso cl\u00ednico nos recuerda, que la infecci\u00f3n grave vis -\nceral por el virus de la varicela z\u00f3ster, es una posibilidad que debe ser tenida en cuenta en pacientes que hayan recibido re-cientemente altas dosis de corticoides u otro tipo de f\u00e1rmacos inmunosupresores.  En estos casos se podr\u00eda  considerar la pro-\ufb01laxis con gammaglobulinas. Como dato adicional a tener en Con la sospecha cl\u00ednica de varicela hemorr\u00e1gica, por el \naspecto de las lesiones cut\u00e1neas, y el fallo hep\u00e1tico masivo \nacompa\u00f1ante, se obtuvo mediante punci\u00f3n con aguja \ufb01na, l\u00ed -\nquido de las lesiones vesiculares cut\u00e1neas que se envi\u00f3 en fres-\nco al Servicio de Microbiolog\u00eda. Tres horas despu\u00e9s, Microbiolo -\ng\u00eda  con\ufb01rm\u00f3 el diagn\u00f3stico de varicela mediante la realizaci\u00f3n de inmuno\ufb02uorescencia directa con anticuerpos monoclonales sobre el l\u00edquido obtenido de las ves\u00edculas (\ufb01gura 2A). Rehisto -\nriada la familia, con\ufb01rman que una ni\u00f1a del entorno familiar, hab\u00eda tenido la varicela aproximadamente unos diez d\u00edas antes.\nA pesar del tratamiento con aciclovir intravenoso y todo \nel tratamiento de sost\u00e9n habitual de un paciente cr\u00edtico, la paciente desarroll\u00f3 un fallo multiorg\u00e1nico con fallo hemo -\ndin\u00e1mico, respiratorio, renal y hep\u00e1tico acompa\u00f1ado de una importante hemorragia alveolar y m\u00faltiples hemorragias por mucosas, orina, tubo digestivo y lugares de inserci\u00f3n de cat\u00e9 -\nteres, secundarias a la coagulaci\u00f3n intravascular diseminada. Figura 1  Lesiones cut\u00e1neas vesiculares hemorr\u00e1gicas\nFigura 2  Lesiones A: Inmunofluorescencia directa de varicela-z\u00f3ster sobre c\u00e9lulas \nde ves\u00edculas. Se observan las c\u00e9lulas verdes infectadas con el virus y \nte\u00f1idas con un anticuerpo monoclonal espec\u00edfico (flechas). B: Foco de infecci\u00f3n del virus varicela z\u00f3ster (tinci\u00f3n verde brillante) sobre monocapa celular de fibroblastos de pulm\u00f3n fetal humano (MRC-5) \nVaricela z\u00f3ster con fallo multiorg\u00e1nico fulminante tras altas dosis de corticoides D. Escudero, et al.\nRev Esp Quimioter 2016;29(6): 342-344 344cuenta, recientemente, algunos autores, encuentran una alta \nprevalencia de varicela z\u00f3ster en pacientes diagnosticados de esclerosis m\u00faltiple como era el caso aqu\u00ed presentado\n11.  \nCONFLICTO DE INTERESES\nLos autores declaran no tener ning\u00fan con\ufb02icto de intereses\nBIBLIOGRAF\u00cdA\n1. Sauerbrei A. Diagnosis, antiviral therapy, and prophylaxis of vari -\ncella-zoster virus infections. Eur J Clin Microbiol Infect Dis. 2016; \n35:723-34.  \n2. Blanquer J. Sole- Viol\u00e1n J, Carvajal J, Lucena F. Infecciones comuni-tarias que requieren ingreso en UCI. Med Intensiva 2010;34:388-96\n3. G\u00f3mez R, Gonz\u00e1lez A, Bustillo M, Soto I, Fern\u00e1ndez R. Miocarditis por virus varicela-zoster en el adulto. An Med Interna.  2007;24:307-8\n4. Chamizo FJ, Gilarranz R, Hern\u00e1ndez M, Ramos D, Pena MJ. Central \nnervous system infections caused by varicella-zoster virus. J Neu -\nrovirol. 2016; 22:529-32.\n5. Ladri\u00e8re M, Bibes B, Rabaud C, Delaby P, May T, Canton P. Varice-lla zoster virus infection after bone marrow transplant. Unusual presentation and importance of prevention.  Presse Med. 2001; 30:1151-4.\n6. Salavert M, Granada R, D\u00edaz A, Zaragoza R. Papel de las infec -\nciones v\u00edricas en pacientes inmunodeprimidos.  Med Intensiva. \n2011;35:117-25\n7. D\u00edaz A, Zaragoza R, Granada R, Salavert M. Infecciones virales graves en pacientes inmunocompetentes. Med Intensiva. 2011;35:179-85\n8. Akiyama M, Yoshifuji K, Fukuda T, Tohda S, Miki T, Miura O, et al. Fulminant visceral disseminated varicella-zoster virus infection without skin involvement in a patient with autoimmune hemolytic anemia on prednisolone therapy. Rinsho Ketsueki. 2016; 57: 467-71.\n9. Tsuji H, Yoshifuji H, Fujii T, Matsuo T, Nakashima R, Imura Y, et al. Visceral disseminated varicella zoster virus infection after rituximab treatment for granulomatosis with polyangiitis. Mod Rheumatol. 2014; 27:1-7. \n10. Hill G, Chauvenet AR, Lovato J, McLean TW. Recent steroid ther -\napy increases severity of varicella infections in children with acute lymphoblastic leukemia. Pediatrics. 2005; 116: e525-9.\n11. Naja\ufb01 S, Ghane M, Yousefzadeh-Chabok S, Amiri M. The high pre -\nvalence of the varicella zoster virus in patients with relapsing-re -\nmitting multiple sclerosis: a case-control study in the north of Iran. Jundishapur. J Microbiol. 2016 12; 9: e34158. ", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}